AUTHOR INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Abdul-Karim, R., and **Assali, N. S.** Antidiuretic action of oxytocin *969
Abelmann, Walter H. See Stein, Abelmann, Lieber, Leevy and Cherrick *1032
Acra, D. J. See Perkins, Acra and Rolfs *1016
Adams, Reuben. See Madison, Combes, Adams and Strickland 507
—. See Madison, Combes and Adams *1009
Adatto, Irving J. See Baratz, Doig and Adatto 1539
Aggeler, Paul M. See Hoag, Aggeler and Fowell 554
Ahrens, E. H., Jr. See Farquhar, Hirsch and Ahrens *984
Albrink, Margaret J., and **Neuwirth, Robert S.** Effect of previous starvation on the response of plasma lipids and free fatty acids to a fat meal 441
Alkjaersig, Norma. See Sawyer, Fletcher, Alkjaersig and Sherry 426
Allan, Mary B. See Sackner, Schnabel, Allan and Lewis *1023
Allen, David W. See Jandl and Allen *1000
—, and **Jandl, James H.** Factors influencing relative rates of synthesis of adult and fetal hemoglobin *in vitro* 1107
—. See Jandl, Engle and Allen 1818
Almy, Thomas P. See Lipkin, Almy and Quastler *1007
Ambrus, Clara M. See Lowe, Ambrus, Ambrus, Mosovich, Mink and Sokal *1007
Ambrus, Julian L. See Lowe, Ambrus, Ambrus, Mosovich, Mink and Sokal *1007
Anderson, Helen M., and **Turner, Joseph C.** Relation of hemoglobin to the red cell membrane 1
Andrus, Margaret H. See Robin, Vester, Wilson and Andrus *1022
Arimura, Akira. See Dingman, Gaitan, Staub, Arimura and Peterson *981
Ashenbrucker, Helen. See Mauer, Athens, Ashenbrucker, Cartwright and Wintrobe 1481
Ashton, Doris. See Howell, Ashton and Wyngaarden *997
Ashworth, W. D. See Harris, Ashworth and Ingelfinger 1744
Assali, N. S. See Abdul-Karim and Assali *969
Aster, Richard H. See Shulman, Aster, Leitner and Hiller *1028
Athens, John W., Mauer, Alvin M., Raab, Spencer O., Haab, Otto P., and **Cartwright, George E.** Studies of granulocyte kinetics *969
—. See Mauer, Athens, Ashenbrucker, Cartwright and Wintrobe 1481
Atkins, Elisha, and **Freedman, Lawrence R.** Studies on the mechanism of fever following intravenous inoculation of staphylococci *969
Au, William Y. W., and **Raisz, Lawrence G.** Studies on the renal concentrating mechanism. V. Effect of diuretic agents 1302
Avigan, Joel. See Steinberg, Avigan and Feigelson *1032
Aygen, Maurice. See Braunwald, Frye, Gilbert and Aygen *974
—. See Braunwald, Frye, Aygen and Gilbert 1874

B

Baggett, Billy. See Savard, Dorfman, Baggett, Fielding, Engel, McPherson, Lister, Johnson, Hamblen and Engel 534
Bahn, Robert C. See Davis, Yankopoulos, Lieberman, Holman and Bahn 765
Baker, Faith A. See Smith and Baker 15
Baker, Herman. See Leevy, George, Ziffer and Baker *1005
Baker, Katharine J. See Javitt, Wheeler, Baker, Ramos and Bradley 1570
Baker, Orland. See Chapman, Bruce, Baker and Fisher *976
Baldini, Mario, and **Ebbe, Shirley.** Preservation of platelet viability at 4° C *970
Baldwin, David S. See Hulet, Baldwin, Biggs, Gombos and Chasis 389
—, **Hulet, William H., Biggs, Albert W., Gombos, Ervin A.**, and **Chasis, Herbert.** Renal function in the separate kidneys of man. II. Hemodynamics and excretion of solute and water in essential hypertension 395
Ball, C. Edwin. See Stanley, Ball and Jaegers *1031
Ballard, Fred B., Danforth, William H., Naegle, Siegfried, and **Bing, Richard J.** Myocardial metabolism of fatty acids 717
Bank, Norman, and **Schwartz, William B.** The influence of anion mobility on urinary acidification and the excretion of titratable acid *970
—, and **Schwartz, William B.** The influence of anion penetrating ability on urinary acidification and the excretion of titrable acid 1516
Banks, Julia. See Marks and Banks *1010
Baratz, Robert A., Doig, Andrew, and **Adatto, Irving J.** Plasma antidiuretic activity and free water clearance following osmoreceptor and neurohypophyseal stimulation in human subjects 1539
Barclay, William R. See Burrows, Niden, Harper and Barclay 795
—. See Burrows, Niden, Mittman, Talley, and Barclay 943
Barker, S. B. See Hill, Barker, McNeil, Tingley and Hibbett 523
Barnes, Mildred W. See Wallmark and Barnes *1038
Barnet, Harry N. See Bartlett and Barnet 56
Barnett, Eugene V., and **Baron, Samuel.** An alternate schedule for poliomyelitis immunization *970
Barnett, G. Octo, Fox, Samuel M., 3rd, Mallos, Alexander J., Greenfield, Joseph C., Jr., and **Fry, Donald L.** The significance of the instantaneous aortic blood ejection velocity *971
Barnett, H. L. See Edelmann, Barnett and Troupkou 1062

Baron, Samuel. See BARNETT and BARON *970
Bartlett, Grant R., and **Barnet, Harry N.** Changes in the phosphate compounds of the human red blood cell during blood bank storage 56
—, and **Shafer, A. William.** Phosphate compounds of the rabbit red blood cell during storage in acid citrate dextrose (ACD) and ACD-inosine 62
—. See SHAFER and BARTLETT 69
Bartter, Frederic C. See SCHEDL and BARTTER 248
—, **Mills, Ivor H.,** and **Gann, Donald S.** Increase in aldosterone secretion by carotid artery constriction in the dog and its prevention by thyrocarotid arterial junction denervation 1330
Bass, David E. See WOOD and BASS 825
Bates, D. V., Varvis, C. J., Donevan, R. E., and **Christie, R. V.** Variations in the pulmonary capillary blood volume and membrane diffusion component in health and disease 1401
Baxter, James H., Goodman, Howard C., and **Havel, Richard J.** Serum lipid and lipoprotein alterations in nephrosis 455
Bearn, Alexander G. See GERMAN and BEARN *989
Beck, J. C. See LEZNOFF, FISHMAN, GOODFRIEND, MCGARRY, ROSE and BECK *1006
Beck, William S. See BERTLES, WILTZ and BECK *972
Becker, E. Lovell, Heinemann, Henry O., Igarashi, Kietsu, Hodler, Jurg E., and **Gershberg, Herbert.** Renal mechanisms for the excretion of inorganic sulfate in man 1909
Bedell, George N. See WILSON and BEDELL 42
Beisel, William R. See GANGAROSA, BEISEL, BENYAJATI and SPRINZ *988
Belsky, Joseph L. See PAPPER, BELSKY and BLEIFER 876
Bennett, T. E. See TARAIL and BENNETT *1035
Benyajati, Chanyo. See GANGAROSA, BEISEL, BENYAJATI and SPRINZ *988
Berger, Eugene Y., Pecikyan, Rene, and **Kanzaki, Grace.** A pattern of sodium excretion in patients with decompensated cirrhosis of the liver who recover from their edematous state *971
Berkeley, B. J. See BERNFELD, BONNER and BERKELEY 1864
Berkson, David M. See STAMLER, LINDBERG, BERKSON, HALL and MILLER *1030
Berlin, Nathaniel I., and **Watkin, Donald M.** Changes in gross body composition during controlled weight loss *971
Berliner, Robert W. See JAENIKE and BERLINER 481
Berman, M. L. See GOODALL and BERMAN 1533
Berman, Mones. See SEGAL, BERMAN and BLAIR *1027
Bernfeld, Peter, Bonner, C. D., and **Berkeley, B. J.** Serum β-lipoprotein levels in health and disease, as determined by the nephelometric method with amylopectin sulfate as reagent 1864
Bernhard, Gerson C., and **Talmage, David W.** The demonstration of three types of inhibitors and one type of stabilizer of the latex fixation test for rheumatoid arthritis *972
Berry, J. Norman. See OWEN, TYOR, FLANAGAN and BERRY 288
Berson, Solomon A. See YALOW and BERSON *1041
—. See YALOW and BERSON 1157
Bertinchamps, Albert J. See COTZIAS and BERTINCHAMPS *979
Bertles, John F., Wiltz, Charles J., and **Beck, William S.** Metabolic turnover of the ribonucleic acid of mammalian reticulocytes during maturation *in vitro* *972
Bessman, Alice N. Oral glutamate therapy in ammonemia due to blood in the gastrointestinal tract *972
Bierman, H. R., and **Marshall, G. J.** Variability of response of human tumor cells to chemotherapeutic agents *973
Biggs, Albert W. See HULET, BALDWIN, BIGGS, GOMBOS and CHASIS 389
—. See BALDWIN, HULET, BIGGS, GOMBOS and CHASIS 395
Bing, Richard J. See BALLARD, DANFORTH, NAEGLE and BING 717
Blair, Alberta. See SEGAL, BERMAN and BLAIR *1027
Blakemore, W. S. See COOPER, ROSENTHAL and BLAKEMORE *979
Bleifer, Kenneth H. See PAPPER, BELSKY and BLEIFER 876
Bloch, Hubert. See FARR and BLOCH *985
Block, Matthew H. See HAIBY, WASI and BLOCK *994
Blomstrand, Rolf, and **Dahlbäck, Olle.** The fatty acid composition of human thoracic duct lymph lipids 1185
Bloom, Jaime. See DEMING, DALY, BLOOM, BRÚN and KAPLAN *980
Blount, S. Gibert, Jr. See REEVES, GROVER, FILLEY and BLOUNT *1020
Bogdonoff, Morton D., Weissler, Arnold M., and **Merritt, Frank L.** The effect of autonomic ganglionic blockade upon serum free fatty acid levels in man 959
—. See FRIEDBERG, KLEIN, BOGDONOFF, ESTES and TROUT *987
—. See FRIEDBERG, KLEIN, TROUT, BOGDONOFF and ESTES 1511
Bojarski, Tadeusz B. See HIATT and BOJARSKI *996
Bollet, Alfred Jay. Effects of antirheumatic agents on connective tissue metabolism *973
—, and **Shuster, Allen.** Metabolism of mucopolysaccharides in connective tissue. II. Synthesis of glucosamine-6-phosphate 1114
Bollman, Jesse L. See HOFFMAN, WHITCOMB, BUTT and BOLLMAN 132
Bond, Victor P. See RUBINI, CRONKITE, BOND and FLIEDNER 909
Bondurant, Stuart. The alveolar lining: A method of extraction; the surface tension lowering effect of cigarette smoke *973
Bonner, C. D. See BERNFELD, BONNER and BERKELEY 1864
Bonting, Sjoerd L. See POLLAK, BONTING and MUEHRCKE *1018
—, **Pollak, Victor E., Muehrcke, Robert C.,** and **Kark, Robert M.** Quantitative histochemistry of the nephron. II. Alkaline phosphatase activity in man and other species 1372
—, **Pollak, Victor E., Muehrcke, Robert C.,** and **Kark, Robert M.** Quantitative histochemistry of the nephron. III. Lactic dehydrogenase activity in man and other species 1381
—. See POLLAK, BONTING, MUEHRCKE and KARK 1386
—. See POLLAK, BONTING, MUEHRCKE and KARK 1394
Borgström, Bengt. Studies on intestinal cholesterol absorption in the human 809

Bradley, Stanley E. See Wheeler, Meltzer and Bradley 1131
—. See Javitt, Wheeler, Baker, Ramos and Bradley 1570
Brady, Roscoe O. See Trams and Brady 1546
Bragdon, Joseph. See Kayden, Karmen, Dumont and Bragdon *1001
Brandborg, Lloyd L. See Rubin, Brandborg, Flick, Parmentier, Phelps and van Niel *1023
Braude, Abraham I. See Mologne and Braude *1013
—, **McConnell, J.**, and **Douglas, H.** Fever from pathogenic fungi 1266
Braunwald, Eugene, and **Kelly, Eugene R.** The effects of exercise on central blood volume in man 413
—. See Ross, Waldhausen and Braunwald 930
—. See Ross, Braunwald and Waldhausen 937
—, **Frye, Robert L., Gilbert, Joseph W.**, and **Aygen, Maurice.** Observations on the operation of Starling's law of the heart in man *974
—. See Frye and Braunwald 1043
—, **Frye, Robert L., Aygen, Maurice M.**, and **Gilbert, Joseph W., Jr.** Studies on Starling's law of the heart. III. Observations in patients with mitral stenosis and atrial fibrillation on the relationships between left ventricular end-diastolic segment length, filling pressure, and the characteristics of ventricular contraction 1874
Brecher, George. See Stohlman, Brecher and MacKinney *1032
Bresler, Emanuel H., and **Gilmartin, Jerry N.** The effect of hyperglycemia without glycosuria on salt and water excretion *974
Bricker, Neal S., Kime, S. Wesley, Jr., Morrin, Peter A. F., and **Orlowski, Tadeusz.** The influence of glomerular filtration rate, solute excretion and hydration on the concentrating mechanism of the experimentally diseased kidney in the dog 864
—. See Morrin, Bricker and Kime *1013
—, **Orlowski, Tadeusz, Kime, S. Wesley, Jr.**, and **Morrin, Peter A. F.** Observations on the functional homogeneity of the nephron population in the chronically diseased kidney of the dog 1771
Brigham, M. Prince, Stein, William H., and **Moore, Stanford.** The concentrations of cysteine and cystine in human blood plasma 1633
Briscoe, W. A. See Gurtner, Briscoe and Cournand 1080
Brodovsky, D., Macdonell, J. A., and **Cherniack, R. M.** The respiratory response to carbon dioxide in health and in emphysema 724
Brodsky, William A., and **Schilb, Theodore P.** Electrical and osmotic characteristics of the isolated turtle bladder *974
Brody, Jacob. See Shelokov, Craighead and Brody *1028
Brody, Jerome I., and **Finch, Stuart C.** Serum factors in acquired hemolytic anemia in patients with lymphoma and leukemia *975
Bromberg, Philip A., Robin, Eugene D., and **Forkner, Claude E., Jr.** The existence of ammonia in blood *in vivo* with observations on the significance of the $NH_4^+ - NH_3$ system 332
Brown, C. Harmon, Saffan, Benjamin D., and **Preedy, John R. K.** Renal handling of estrogens in late pregnancy *975
Brown, Rose. See MacLeod, Brown and Lynn *1008
Browne, Harry G. See Louria, Fallon and Browne 1435
Bruce, Tom A. See Chapman, Bruce, Baker and Fisher *976
Brun, Lili. See Deming, Daly, Bloom, Brun and Kaplan *980
Buckalew, Vardaman M., Jr. See Morrison, Buckalew, Miller and Lewis *1014
Buri, Rachit. See Scribner, Buri and Caner *1027
Burrows, Belton A., Slingerland, D. Ward, Liuzzi, Anthony, Dell, Elizabeth S., and **Graham, Dorothy E.** Thyroidal iodide secretion *975
Burrows, Benjamin, Niden, Albert H., Harper, Paul V., Jr., and **Barclay, William R.** Non-uniform pulmonary diffusion as demonstrated by the carbon monoxide equilibration technique: Mathematical considerations 795
—, **Niden, Albert H., Mittman, Charles, Talley, Robert C.**, and **Barclay, William R.** Non-uniform pulmonary diffusion as demonstrated by the carbon monoxide equilibration technique: Experimental results in man 943
Butt, Hugh R. See Hoffman, Whitcomb, Butt and Bollman 132
Byers, Sanford O. See Friedman, St. George, Byers and Rosenman 758
—. See Gunn, Friedman and Byers 1963

C

Cahill, George F., Jr., Wood, Francis C., Jr., Leboeuf, Bernard, and **Renold, Albert E.** Mannose metabolism, an index of glucose utilization *976
Calabresi, Paul, and **Greenberg, Mortimer.** Circulating antinuclear globulins in patients with chronic liver disease *976
Caner, John E. Z. See Scribner, Buri and Caner *1027
Carroll, Evelyn L. See Pechet and Carroll *1015
—. See Henneman, Forbes, Moldawer, Dempsey and Carroll 1223
Carroll, John. See Reeves, Hefner, Jones, Coghlan, Prieto and Carroll *1020
Carroll, William R. See Davis, Carroll, Trapasso and Yankopoulos 1463
Carter, Anne C. See Sandberg, Slaunwhite and Carter 1914
Cartwright, George E. See Athens, Mauer, Raab, Haab and Cartwright *969
—. See Mauer, Athens, Ashenbrucker, Cartwright and Wintrobe 1481
Castenfors, Hans, Hultman, Eric, and **Josephson, Bertil.** Effect of intravenous infusions of ethyl alcohol on estimated hepatic blood flow in man 776
Castillo, C. A. See Rowe, Castillo, Maxwell and Crumpton *1022
Castle, William B. See Cooper and Castle 199
Chaffee, William. See Chodos, Chaffee and Wells *977
Chalmers, Thomas C. See Greenberg, Wong, Miller, Scarlata and Chalmers *992
Chapman, Carleton B., Bruce, Tom A., Baker, Orland, and **Fisher, Joseph N.** The effect of partial and total denervation of the heart on left ventricular function *976

—, **Fisher, Joseph N.**, and **Sproule, Brian J.** Behavior of stroke volume at rest and during exercise in human beings 1208
Chasis, Herbert. See HULET, BALDWIN, BIGGS, GOMBOS and CHASIS 389
—. See BALDWIN, HULET, BIGGS, GOMBOS and CHASIS 395
Chegoriansky, Julio. See LOSPALLUTO, CHEGORIANSKY, LEWIS and ZIFF 473
Chen, Philip S., Jr. See TEREPKA and CHEN *1035
Cherniack, Neil S. See WATSON, CHERNIACK and ZECHMAN 1737
Cherniack, R. M. See BRODOVSKY, MACDONELL and CHERNIACK 724
Cherrick, Gilbert R. See STEIN, ABELMANN, LIEBER, LEEVY and CHERRICK *1032
Chodos, Robert B., Chaffee, William, and **Wells, Raymond, Jr.** Erythropoiesis and blood destruction in congestive heart failure *977
Choppin, Purnell W. See PHILIPSON and CHOPPIN *1017
Christie, R. V. See BATES, VARVIS, DONEVAN and CHRISTIE 1401
Clatanoff, Dallas V. Correction by heparin of coagulation abnormalities due to intravascular clotting *977
Clifford, George O. See SCHMIDT and CLIFFORD *1026
Clifford, P. P. See SULLIVAN, MILLER, WOOD, CLIFFORD and DUFF *1034
Clowdus, Bernard F., Higgins, John A., Orvis, A. L., and **Summerskill, W. H. J.** Serial changes in body water, exchangeable sodium, exchangeable potassium and serum electrolyte concentrations during the treatment of ascites *977
Cobau, C. D. See KORST, JOHNSON, COBAU, RENNIE and FRENKEL *1003
Cobb, Leonard A., Kramer, Robert J., and **Finch, Clement A.** Circulatory effects of chronic hypervolemia in polycythemia vera 1722
Coghlan, Cecil. See REEVES, HEFNER, JONES, COGHLAN, PRIETO and CARROLL *1020
Cohen, Burton D. See SPRITZ, COHEN and RUBIN *1030
Cohen, Gerald. See GITLOW, MENDLOWITZ, KHASSIS, COHEN and SHA 221
Cohn, George L., and **Hume, Michael.** The *in vivo* glucuronide conjugation of radioactive steroids by the dog kidney *978
—, and **Hume, Michael.** The *in vivo* glucuronide conjugation of radioactive etiocholanolone and androsterone by the dog kidney 1584
Coleman, Solon L. See RITZMANN, COLEMAN and LEVIN 1320
Combes, Burton. See MADISON, COMBES, ADAMS and STRICKLAND 507
—, and **Stakelum, Geneva Sue.** Conjugation of sulfobromophthalein sodium (BSP) with glutathione by an enzyme in the supernatant fraction of liver *978
—. See MADISON, COMBES and ADAMS. *1009
—, and **Stakelum, Geneva Sue.** Conjugation of sulfobromophthalein sodium with glutathione in thioether linkage by the rat 1214
Comstock, John. See ELIEL, HAWRYLKO and COMSTOCK *982
Conn, Hadley L., Jr., and **Luchi, Robert J.** Some studies on the nature of quinidine-albumin interaction *978
Conrad, Marcel E. See CROSBY and CONRAD *979
Converse, J. M. See LAWRENCE, RAPAPORT, CONVERSE and TILLETT 185
Cooper, Bernard A., and **Castle, William B.** Sequential mechanisms in the enhanced absorption of vitamin B_{12} by intrinsic factor in the rat 199
Cooper, D. Y., Rosenthal, Otto, and **Blakemore, W. S.** Stimulation of steroid formation of adrenocortical homogenates by medulla and catechloamines *979
Cooperman, Jack M. See LUHBY and COOPERMAN *1008
Cotzias, George C., and **Bertinchamps, Albert J.** Transmanganin, the specific manganese-carrying protein of human plasma *979
Cournand A. See GURTNER, BRISCOE and COURNAND 1080
—. See FRITTS, HARDEWIG, ROCHESTER, DURAND and COURNAND 1841
Craighead, John. See SHELOKOV, CRAIGHEAD and BRODY *1028
Cronkite, Eugene P. See RUBINI, CRONKITE, BOND and FLIEDNER 909
Crosby, William H., and **Conrad, Marcel E.** Red cell shape and red cell life span in hereditary spherohomogenates by medulla and catecholamines *979
Crout, J. Richard. See OATES, GILLESPIE, CROUT and SJOERDSMA *1015
Crumpton, C. W. See ROWE, CASTILLO, MAXWELL and Crumpton *1022
Cummings, Richard M. See LEVINSON and CUMMINGS *1005
Cushing, Ivan E. See MILLER, CUSHING and WU *1012
Cutler, Ralph, Kleeman, Charles R., Dowling, J. Thomas, and **Maxwell, Morton H.** Physiological studies in a family with nephrogenic (vasopressin-resistant) diabetes insipidus (N.D.I.) *980
—. See KLEEMAN, KOPLOWITZ, MAXWELL, CUTLER and DOWLING 1472

D

Dagenais, Yves M. See RENOLD, MARTIN, DAGENAIS, STEINKE, NICKERSON and SHEPS 1487
—. See SHEPS, NICKERSON, DAGENAIS, STEINKE, MARTIN and RENOLD 1499
Dahl, Lewis K. See SILVER, ROBERTSON and DAHL 420
Dahlbäck, Olle. See BLOMSTRAND and DAHLBÄCK 1185
Daly, Marie M. See DEMING, DALY, BLOOM, BRUN and KAPLAN *980
Dameshek, William. See SCHWARTZ and DAMESHEK 952
Danforth, William H. See BALLARD, DANFORTH, NAEGLE and BING 717
Darrow, Daniel C. See HELLERSTEIN, KAISER, DARROW and DARROW 282
Darrow, Daniel DeS. See HELLERSTEIN, KAISER, DARROW and DARROW 282
Daughaday, William H., and **Kozak Mariz, Ida.** Hormonal control of collagen synthesis by cartilage studies *in vitro* *980
Davie, Earl W. See RATNOFF, MALLETT and DAVIE *1019
Davis, Bernard B. See LATHEM, DAVIS, ZWEIG and DEW 840
—. See LATHEM, DAVIS and RODNAN *1004
Davis, James O., Yankopoulos, Nicholas A., Lieberman, Ferol, Holman, John, and **Bahn, Robert C.** The role of the anterior pituitary in the control of

aldosterone secretion in experimental secondary hyperaldosteronism 765
—, **Carroll, William R., Trapasso, Mary,** and **Yankopoulos, Nicholas A.** Chemical characterization of cardiac myosin from normal dogs and from dogs with chronic congestive heart failure 1463
Dawson, Anthony M., and **Isselbacher, Kurt J.** The esterification of palmitate-1-C^{14} by homogenates of intestinal mucosa 150
—, and **Isselbacher, Kurt J.** Studies on lipid metabolism in the small intestine with observations on the role of bile salts 730
Dawson, Chandler. See JAWETZ, THYGESON, HANNA, DAWSON and MITSUI *1000
Dayton, Ann L. See FINLAYSON, SUCHINSKY and DAYTON 1837
De Backer, W. See DE MOOR, DE BACKER, HENDRIKX, HINNEKENS and DE BOCK 816
De Bock, A. See DE MOOR, DE BACKER, HENDRIKX, HINNEKENS and DE BOCK 816
DeCarli, Leonore M. See LIEBER, DECARLI and SCHMID *1007
Delchamps, E. See HOWELL, DELCHAMPS, RIEMER and KIEM 919
Dell, Elizabeth S. See BURROWS, SLINGERLAND, LIUZZI, DELL and GRAHAM *975
Deming, Quentin B., Daly, Marie M., Bloom, Jaime, Brun, Lili, and **Kaplan, Ruth.** Effect of antihypertensive treatment in the rat on the potentiation of atherogenesis by experimental hypertension *980
—. See LARAGH, ULICH, JANUSZEWICZ, DEMING, KELLY and LIEBERMAN 1091
De Moor, P., De Backer, W., Hendrikx, A., Hinnekens, M., and **De Bock, A.** Analysis by means of an analog computer of plasma corticoid values during adrenocorticotropic hormone infusion 816
Dempsey, Eleanor F. See HENNEMAN, FORBES, MOLDAWER, DEMPSEY and CARROLL 1223
Despointes, Rene H. See DINGMAN and DESPOINTES 1851
Dew, Robert. See LATHEM, DAVIS, ZWEIG and DEW 840
Deykin, Daniel, Wessler, Stanford, and **Reimer, Stanley M.** Serum thrombotic accelerator (STA) activity as a measure of the antithrombotic effect of Dicumarol *981
Di Girolamo, Mario. See RUDMAN, DI GIROLAMO, SEIDMAN and REID *1023
Dingman, Joseph F., Gaitan, Eduardo, Staub, Max C., Arimura, Akira, and **Peterson, Ralph E.** Hypoaldosteronism in panhypopituitarism *981
—, and **Despointes, Rene H.** Adrenal steroid inhibition of vasopressin release from the neurohypophysis of normal subjects and patients with Addison's disease 1851
Doherty, Dorothy J. See LANE, MENGEL and DOHERTY *1004
Doig, Andrew. See BARATZ, DOIG and ADATTO 1539
Dölle, W. See IBER, KERR, DÖLLE and SHERLOCK 1201
Donevan, R. E. See BATES, VARVIS, DONEVAN and CHRISTIE 1401
Dorfman, Ralph I. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Douglas, H. See BRAUDE, MCCONNELL and DOUGLAS 1266
Dow, Elias, C., and **Stanbury, John B.** Strontium and calcium metabolism in metabolic bone diseases 885
Dowdle, Eugene B. See SCHACHTER, DOWDLE, SCHENKER and KIMBERG *1025
Dowling, J. Thomas. See CUTLER, KLEEMAN, DOWLING and MAXWELL *980
—, **Freinkel, Norbert,** and **Ingbar, Sidney H.** The effect of estrogens upon the peripheral metabolism of thyroxine 1119
—. See KLEEMAN, KOPLOWITZ, MAXWELL, CUTLER and DOWLING 1472
Dreiling, D. A. See JANOWITZ and DREILING *1000
Dreyfus, Jean-Claude. See KRUH, DREYFUS, SCHAPIRA and GEY 1180
Dubach, Ulrich C., and **Recant, Lillian.** Enzymatic activity of isolated kidney glomeruli in two types of experimental nephrosis *981
—, and **Recant, Lillian.** Enzymatic activity of the isolated glomerulus in normal and nephrotic rats 1364
Dubin, Alvin. See KUSHNER, SZANTO and DUBIN *1003
Duff, John. See SULLIVAN, MILLER, WOOD, CLIFFORD and DUFF *1034
Dumont, Allan E. See KAYDEN, KARMEN, DUMONT and BRAGDON *1001
Durand, J. See FRITTS, HARDEWIG, ROCHESTER, DURAND and COURNAND 1841

E

Ebbe, Shirley. See BALDINI and EBBE *970
Eckstein, John W. See HORSLEY and ECKSTEIN *997
Edelman, I. S., Ts'o, P. O. P., and **Vinograd, J.** Binding of magnesium to microsomal nucleoprotein (RNAP) and ribonucleic acid (RNA) *982
Edelmann, C. M., Jr., Barnett, H. L., and **Troupkou, V.** Renal concentrating mechanisms in newborn infants. Effect of dietary protein and water content, role of urea, and responsiveness to antidiuretic hormone 1062
Efron, Mary L. See GERALD, EFRON and PEASE *989
Egdahl, Richard H. Studies suggesting the presence of an extrahypothalamic ACTH-releasing center in the dog *982
Eisentraut, A. M. See UNGER, EISENTRAUT, MCCALL and MADISON *1036
Eitzman, Donald V. See SMITH, EITZMAN and MILLER *1029
Elder, T. David, and **Wyngaarden, James B.** The biosynthesis and turnover of oxalate in normal and hyperoxaluric subjects 1337
Eliasson, Sven G. See HUGHES and ELIASSON 111
Eliel, Leonard P., Hawrylko, Josephine, and **Comstock, John.** Bone magnesium, calcium and citrate interrelationships *982
Elsbach, Peter. Preferential and active transport of linoleic acid by polymorphonuclear leukocytes *983
Engbring, Norman H., Lennon, Edward J., and **Engstrom, William W.** Studies on the equilibration of thyroxine between the intravascular and extravascular spaces *983
Engel, Frank L. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Engel, Lewis L. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Engle, Louise K. See JANDL, ENGLE and ALLEN 1818
Engstrom, William W. See ENGBRING, LENNON and ENGSTROM *983

Epstein, Franklin H. See FERRIS, LEVITIN and EPSTEIN *985
Epstein, Robert M. See WHEELER, EPSTEIN, ROBINSON and SNELL 236
Estes, E. H., Jr. See FRIEDBERG, HARLAN, TROUT and ESTES 215
——. See FRIEDBERG, KLEIN, BOGDONOFF, ESTES and TROUT *987
—. See FRIEDBERG, KLEIN, TROUT, BOGDONOFF and ESTES 1511

F

Fahey, John L., and **Goodman, Howard C.** Characterization of anti-thyroglobulin factors in human serum 1259
—. See GOODMAN, FAHEY and MALMGREN 1595
Falcone, A. B., Mao, R. L., and **Shrago, E.** Inhibition of incorporation of orthophosphate into ATP by fatty acids *984
Fallon, Nancy. See LOURIA, FALLON and BROWNE 1435
Faloon, William W., Taylor, Frederic F., Hellman, Samuel, and **Ohanessian, Simon.** The effect of sodium and potassium intake upon the natriuretic response to spirolactones *984
Farquhar, John W., Hirsch, Robert L., and **Ahrens, E. H., Jr.** Evidence that atheroma fatty acids are in flux *984
Farr, Richard S., and **Bloch, Hubert.** The binding capacity of tuberculous and nontuberculous human serum for I^{131}-labeled extracts from tubercle bacilli *985
Farrar, John T. See GROISSER and FARRAR 1607
Feigelson, Eugene B. See STEINBERG, AVIGAN and FEIGELSON *1032
Feigl, Eric O. See PETERSON, FEIGL and GOURAS *1017
Feinberg, I. See LASSEN, FEINBERG and LANE 491
Ferguson, John H., Wilson, Ella Gray, Iatridis, Sotirios G., Rierson, Herman A., and **Johnston, Betty R.** Enzymes and blood clotting. I. Trypsin as an accessory factor 1942
Ferris, Benjamin G., Jr., and **Pollard, David S.** Effect of deep and quiet breathing on pulmonary compliance in man 143
Ferris, Thomas F., Levitin, Howard, and **Epstein, Franklin H.** The effect of hypercalcemia on renal tubular function *985
Field, James B., Pastan, Ira, Johnson, Phyllis, and **Herring, Betty.** *In vitro* stimulation of glucose oxidation in thyroid slices by thyroid stimulating hormone *986
Field, Morton H., and **Reiss, Eric.** Vitamin D-resistant rickets: The effect of calcium infusion on phosphate reabsorption 1807
Fielding, Linda L. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Filley, Giles F. See REEVES, GROVER, FILLEY and BLOUNT *1020
Filmanowicz, Edward. See GURNEY and FILMANOWICZ *994
Finch, Clement A. See COBB, KRAMER and FINCH 1722
Finch, Stuart C. See BRODY and FINCH *975
—. See PERILLIE and FINCH 1353
Finlayson, J. S., Suchinsky, Richard T., and **Dayton, Ann L.** Effects of long-term storage on human serum albumin. I. Chromatographic and ultracentrifugal aspects 1837
Finlayson, James K. See STANFIELD, LURIA, FINLAYSON, LOVEJOY and YU *1031
Fisch, Charles, Martz, B. L., and **Priebe, Fred H.** Enhancement of potassium-induced atrioventricular block by toxic doses of digitalis drugs 1885
Fisher, Joseph N. See CHAPMAN, BRUCE, BAKER and FISHER *976
—. See CHAPMAN, FISHER and SPROULE 1208
Fishman, Alfred P. See RIGATTO, TURINO and FISHMAN *1021
—. See RIGATTO and FISHMAN 1626
Fishman, J. See LEZNOFF, FISHMAN, GOODFRIEND, MCGARRY, ROSE and BECK *1006
Flanagan, John F. See OWEN, TYOR, FLANAGAN and BERRY 288
Fletcher, Anthony P. See SAWYER, FLETCHER, ALKJAERSIG and SHERRY 426
Flick, Arnold L. See RUBIN, BRANDBORG, FLICK, PARMENTIER, PHELPS and VAN NIEL *1023
Fliedner, T. M. See RUBINI, CRONKITE, BOND and FLIEDNER 909
Fong, Conrad T. O. See SCHWARTZ, RASMUSSEN, SCHOESSLER, FONG and SILVER *1026
Forbes, Anne P. See HENNEMAN, FORBES, MOLDAWER, DEMPSEY and CARROLL 1223
Forkner, Claude E., Jr. See BROMBERG, ROBIN and FORKNER 332
—. See STEIN, FORKNER, SPENCER, ROBIN and KURLAND *1031
Foster, Daniel W., and **Siperstein, Marvin D.** The Krebs cycle and diabetic ketosis *986
Fowell, Alfred H. See HOAG, AGGELER and FOWELL 554
Fox, Samuel M., 3rd. See BARNETT, FOX, MALLOS, GREENFIELD and FRY *971
Frank, Martin J. See REGAN, TIMMIS, FRANK, MCGINTY and HELLEMS *1020
Franklin, E. C. Some properties of the breakdown products of human 7S gamma globulin and antibodies *986
—. Structural units of human 7S gamma globulin 1953
Frantz, Andrew G., Holub, Donald A., and **Jailer, Joseph W.** Further evidence of a relative lack of C-21 hydroxylation in congenital adrenal hyperplasia 904
Frazell, E. L. See HELLMAN, FRAZELL and ROSENFELD 1288
Fredricks, Robert E. See TANAKA, VALENTINE and FREDRICKS *1034
—, **Tanaka, Kouichi R.,** and **Valentine, William N.** Zinc in human blood cells: Normal values and abnormalities associated with liver disease 1651
Freedman, Lawrence R. See ATKINS and FREEDMAN *969
Freinkel, Norbert, and **Goodner, Charles J.** Carbohydrate metabolism in pregnancy. 1. The metabolism of insulin by human placental tissue 116
—. See GOODNER and FREINKEL *991
—. See DOWLING, FREINKEL and INGBAR 1119
Freis, Edward D., Wanko, Annemarie, Schnaper, Harold W., and **Frohlich, Edward D.** Mechanism of the altered blood pressure responsiveness produced by chlorothiazide 1277
Frenkel, E. P. See KORST, JOHNSON, COBAU, RENNIE and FRENKEL *1003
Friedberg S. J., Harlan, W. R., Jr., Trout, D. L., and **Estes, E. H., Jr.** The effect of exercise on the

concentration and turnover of plasma nonesterified fatty acids 215
—, **Klein, Robert F., Bogdonoff, Morton D., Estes, E. Harvey, Jr.,** and **Trout, David L.** The effect of insulin upon the peripheral uptake of plasma free fatty acids in man *987
—, **Klein, R. F., Trout, D. L., Bogdonoff, M. D.,** and **Estes, E. H., Jr.** The characteristics of the peripheral transport of C^{14}-labeled palmitic acid 1511
Friedman, Emanuel A., Gray, Mary Jane, Grynfogel, Maurice, Hutchinson, Donald L., Kelly, William Thomas, and **Plentl, Albert A.** The distribution and metabolism of C^{14}-labeled lactic acid and bicarbonate in pregnant primates 227
Friedman, Meyer, St. George, Shirley, Byers, Sanford, O., and **Rosenman, Ray H.** Excretion of catecholamines, 17-ketosteroids, 17-hydroxycorticoids and 5-hydroxyindole in men exhibiting a particular behavior pattern (A) associated with high incidence of clinical coronary artery disease 758
—. See GUNN, FRIEDMAN and BYERS 1963
Frimpter, George W., and **Thompson, David D.** Conjugated amino acids in deproteinized plasma of patients with renal failure *987
Fritts, H. W., Jr., Hardewig, A., Rochester, D. F., Durand J., and **Cournand, A.** Estimation of pulmonary arteriovenous shunt-flow using intravenous injections of T-1824 dye and KR^{85} 1841
Frohlich, Edward D. See FREIS, WANKO, SCHNAPER and FROHLICH 1277
Fry, Donald L. See BARNETT, FOX, MALLOS, GREENFIELD and FRY *971
Frye Robert L. See BRAUNWALD, FRYE, GILBERT and AYGEN *974
—, and **Braunwald, Eugene.** Studies on Starling's law of the heart. I. The circulatory response to acute hypervolemia and its modification by ganglionic blockade 1043
—. See BRAUNWALD, FRYE, AYGEN and GILBERT 1874
Fudenberg, Hugh, German, James L., III, and **Kunkel, Henry G.** The occurrence of rheumatoid factor and other gamma globulin abnormalities in the families of patients with agammaglobulinemia *987
Furman, Robert H., Lakshmi, K., Norcia, Leonard N., and **Howard, R. Palmer.** Effect of *in vitro* sonic oscillation on distribution of serum lipoproteins in idiopathic "essential" hyperlipemia and other hyperlipidemic states *988
Furusho, Akio. See LEWIS, REED, FURUSHO and SNIDER *1006

G

Gaitan, Eduardo. See DINGMAN, GAITAN, STAUB, ARIMURA and PETERSON *981
Gandy, Hortense M., Keutmann, E. Henry, and **Izzo, Anthony J.** Characterization of urinary steroids in adrenal hyperplasia: Isolation of metabolites of cortisol, compound S, and desoxycorticosterone from a normotensive patient with adrenogenital syndrome 364
Gangarosa, Eugene J., Beisel, William R., Benyajati, Chanyo, and **Sprinz, Helmuth.** Studies of gastrointestinal pathophysiology in acute Asiatic cholera *988
Gann, Donald S. See BARTTER, MILLS and GANN 1330
Gardner, Edward, Jr., Wright, Claude-Starr, and **Williams, Bettie Z.** An evaluation of the urine hydrolysis test for primitive white blood cell differentiation *988
Gardner, Frank H. See YACHNIN and GARDNER *1040
Gardner, Lytt I. See GREENBERG and GARDNER 1729
Geller, Herman M. See REYNOLDS, GELLER and REDEKER *1021
Genest, Jacques, Nowaczynski, Wojciech, Koiw, Erich, and **Sandor, Thomas.** Pregnanetriol excretion and urinary pregnanetriol/aldosterone ratio in normal subjects and patients with arterial hypertension *989
George, William S. See LEEVY, GEORGE, ZIFFER and BAKER *1005
Gerald, Park S., Efron, Mary L., and **Pease, Margaret J.** Presence of an altered amino acid sequence in Hgb M (Boston type) *989
German, James L., III. See FUDENBERG, GERMAN and KUNKEL *987
—, and **Bearn, Alexander G.** Family studies on the chromosomal complement of mongols *989
Gershberg, Herbert. See BECKER, HEINEMANN, IGARASHI, HODLER and GERSHBERG 1909
Gey, George O. See KRUH, DREYFUS, SCHAPIRA and GEY 1180
Gilbert, Joseph W. See BRAUNWALD, FRYE, GILBERT and AYGEN *974
—. See BRAUNWALD, FRYE, AYGEN and GILBERT 1874
Gillespie, Louis, Jr. See OATES, GILLESPIE, CROUT and SJOERDSMA *1015
Gilmartin, Jerry N. See BRESLER and GILMARTIN *974
Gilmore, Joseph P. See SARNOFF, MITCHELL and GILMORE *1025
Giordano, Carmelo, Weinstok, Herman, and **Merrill, John P.** Effect of acute uremia on arterial blood pressure in rabbits *990
Gitlow, Stanley E., Mendlowitz, Milton, Khassis, Sarah, Cohen, Gerald, and **Sha, Joanne.** The diagnosis of pheochromocytoma by determination of urinary 3-methoxy,4-hydroxymandelic acid 221
—, and **Kruk, Elizabeth.** A rapid urine test for pheochromocytoma *990
Glenchur, Harry, Zinneman, Horace H., and **Hall, Wendell H.** Blocking antibodies after Brucella hyperimmunization and infection in rabbits and mice *990
Goetz, F. C., Hartmann, J. F., and **Lazarow, A.** Electron microscopy of the human glomerulus in early diabetes *991
Goldberg, Martin. See HANDLER, WOJTCZAK and GOLDBERG *994
Goldstein, Marvin, Hauser, A. Daniel, and **Levitt, Marvin F.** Meralluride-induced solute and water diuresis in hydrated man *991
Gombos, Ervin A. See HULET, BALDWIN, BIGGS, GOMBOS and CHASIS 389
—. See BALDWIN, HULET, BIGGS, GOMBOS and CHASIS 395
Gonzalez, Luis F., and **Layne, Ennis C.** Studies of tritium-labeled digoxin: Tissue, blood and urine determinations 1578
Goodall, McC., and **Berman, M. L.** Urinary output of adrenaline, noradrenaline and 3-methoxy-4-hydroxymandelic acid following centrifugation and anticipation of centrifugation 1533
—, and **Haynes, B. W., Jr.** Adrenal medullary insufficiency in severe thermal burn 1927
Goodfriend, L. See LEZNOFF, FISHMAN, GOODFRIEND, MCGARRY, ROSE and BECK *1006

Goodman, Howard C. See BAXTER, GOODMAN and HAVEL 455
—. See FAHEY and GOODMAN 1259
—, **Fahey, John L.,** and **Malmgren, Richard A.** Serum factors in lupus erythematosus and other diseases reacting with cell nuclei and nucleoprotein extracts: Electrophoretic, ultracentrifugal and chromatographic studies 1595
Goodner, Charles J. See FREINKEL and GOODNER 116
—, and **Freinkel, Norbert.** The "diabetic" pituitary: Observations on the carbohydrate metabolism of pituitary tissue *991
Gordon, Hymie. Studies on the origin of the fecal fat *992
Gordon, Robert S., Jr. See HAVEL and GORDON 1777
Gordy, Edwin. See SANDBERG, HAUSCHKA, GORDY and KOEPF *1024
Gorlin, R. See MESSER, WAGMAN, LEVINE, NEILL and GORLIN *1011
Gottschalk, Carl W. See LASSITER, GOTTSCHALK and MYLLE *1004
Gouras, Peter. See PETERSON, FEIGL and GOURAS *1017
Graham, Dorothy E. See BURROWS, SLINGERLAND, LIUZZI, DELL and GRAHAM *975
Gray, Mary Jane. See FRIEDMAN, GRAY, GRYNFOGEL, HUTCHINSON, KELLY and PLENTL 227
Grayzel, Arthur I., Seegmiller, J. E., and **Love, Ethel.** Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine 447
Greenberg, Mortimer. See CALABRESI and GREENBERG *976
Greenberg Mortimer S., Wong, Helena, Miller, Stephen A., Scarlata, Robert W., and **Chalmers, Thomas C.** Iron absorption and turnover in hypoxia *992
Greenberg, Robert E., and **Gardner, Lytt I.** Catecholamine metabolism in a functional neural tumor 1729
Greenfield, Joseph C., Jr. See BARNETT, FOX, MALLOS, GREENFIELD and FRY *971
Gribetz, H. Joel. See ZIFF, GRIBETZ and LOSPALLUTO 405
Griggs, Robert C., Weisman, Russell, Jr., and **Harris, John W.** Alterations in osmotic and mechanical fragility related to *in vitro* erythrocyte aging and splenic sequestration in hereditary spherocytosis 89
Grob, David, and **Johns, Richard J.** Mechanism of neuromuscular block in myasthenia gravis *992
Groisser, Victor W., and **Farrar, John T.** Absorption of radioactive sodium from the intestinal tract of man. I. Effect of intestinal motility. II. Effect of an organomercurial 1607
Grossman, Jacob, Rosenblum, Robert, Lau, Sun Hing, and **Wolfman, Morris.** Cardiac and renal responses to acute volume loading in patients with heart disease *993
Grover, Robert F. See REEVES, GROVER, FILLEY and BLOUNT *1020
Grumbach, Melvin M., and **Kaplan, Selna L.** Amino acid and α-keto acid-induced hyperinsulinism in the leucine-sensitive type of idiopathic hypoglycemia *993
Grynfogel, Maurice. See FRIEDMAN, GRAY, GRYNFOGEL, HUTCHINSON, KELLY and PLENTL 227
Gunn, C. G. Intensification of rabbit atherosclerosis by chronic hypothalamic stimulation *993
—, **Friedman, Meyer,** and **Byers, Sanford. O.** Effect of chronic hypothalamic stimulation upon cholesterol-induced atherosclerosis in the rabbit 1963
Gurney, Clifford W., and **Filmanowicz, Edward.** The kinetics of erythropoiesis *994
Gurtner, H. P., Briscoe, W. A., and **Cournand, A.** Studies of the ventilation-perfusion relationships in the lungs of subjects with chronic pulmonary emphysema, following a single intravenous injection of radioactive krypton (Kr^{85}). I. Presentation and validation of a theoretical model 1080

H

Haab, Otto P. See ATHENS, MAUER, RAAB, HAAB and CARTWRIGHT *969
Haddad, Heskel M. Rates of I^{131}-labeled thyroxine metabolism in euthyroid children 1590
Haiby, Gabriel, Wasi, Prawase, and **Block, Matthew H.** Significance of the distribution and cytology of iron in primary hemochromatosis during treatment with phlebotomies *994
Hall, Charles A. The plasma disappearance of intravenously administered cobalt^{58} vitamin B_{12} 1312
Hall, Philip W., III, and **Relman, Arnold S.** Acid excretion in rubidium- and cesium-substituted rats 171
Hall, Wendell H. See GLENCHUR, ZINNEMAN and HALL *990
Hall, Yolanda. See STAMLER, LINDBERG, BERKSON, HALL and MILLER *1030
Hallgren, Bo, Stenhagen, Stina, Svanborg, Alvar, and **Svennerholm, Lars.** Gas chromatographic analysis of the fatty acid composition of the plasma lipids in normal and diabetic subjects 1424
Hamblen, Edwin C. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Hamerman, David. See SANDSON and HAMERMAN 782
Handler, Joseph S., Wojtczak, Andrezej, and **Goldberg, Martin.** Maximum rates of excretion of titratable acid *994
—. The role of lactic acid in the reduced excretion of uric acid in toxemia of pregnancy 1526
Hanna, Lavelle. See JAWETZ, THYGESON, HANNA, DAWSON and MITSUI *1000
Hardewig, A. See FRITTS, HARDEWIG, ROCHESTER, DURAND and COURNAND 1841
Harlan, W. R., Jr. See FRIEDBERG, HARLAN, TROUT and ESTES 215
Harper, Harold A. See KOLB and HARPER *1002
Harper, Paul V., Jr. See BURROWS, NIDEN, HARPER and BARCLAY 795
Harris, Jean, and **Vaughan, John.** Penicillin antibody in disease *995
Harris, John W. See GRIGGS, WEISMAN and HARRIS 89
Harris, Lauran D., Ashworth, W. D., and **Ingelfinger, Franz J.** Esophageal aperistalsis and achalasia produced in dogs by prolonged cholinesterase inhibition 1744
Hartmann J. F. See GOETZ, HARTMANN and LAZAROW *991
Hauschka, Theodore S. See SANDBERG, HAUSCHKA, GORDY and KOEPF *1024
Hauser, A. Daniel. See GOLDSTEIN, HAUSER and LEVITT *991

Havel, Richard J. See Baxter, Goodman and Havel 455
—, and **Gordon, Robert S., Jr.** Idiopathic hyperlipemia: Metabolic studies in an affected family 1777
Hawk, William A. See Scherbel, McKittrick and Hawk *1025
Hawrylko, Josephine. See Eliel, Hawrylko and Comstock *982
Hayford-Welsing, Ernest J. See Lewis, McElroy, Hayford-Welsing and Samberg 1345
Haynes, B. W., Jr. See Goodall and Haynes 1927
Hays, Richard M., and **Leaf, Alexander.** Inadequacy of the "pore theory" to account for the action of neurohypophyseal hormones on water and solute movement across a living membrane *995
Hecht, Hans H. See Lange, Smith and Hecht 1413
Hefner, Lloyd L. See Reeves, Hefner, Jones, Coghlan, Prieto and Carroll *1020
Heinemann, Henry O. See Zeffren and Heinemann *1042
—. See Becker, Heinemann, Igarashi, Hodler and Gershberg 1909
Hellems, Harper K. See Regan, Timmis, Frank, McGinty and Hellems *1020
Hellerstein, Stanley, Kaiser, Carolyn, Darrow, Daniel DeS, and **Darrow, Daniel C.** The distribution of bromide and chloride in the body 282
Hellman, Leon, Frazell, E. L., and **Rosenfeld, R. S.** Direct measurement of cholesterol absorption via the thoracic duct in man 1288
Hellman, Samuel. See Faloon, Taylor, Hellman and Ohanessian *984
Hellriegel, Kurt O. See Hultgren, Spickard and Hellriegel *998
Hendrikx, A. See De Moor, De Backer, Hendrikx, Hinnekens and De Bock 816
Henneman, Dorothy H., and **Henneman, Philip H.** Effects of human growth hormone on levels of blood and urinary carbohydrate and fat metabolites in man 1239
Henneman, Philip H., Forbes, Anne P., Moldawer, Marc, Dempsey, Eleanor F., and **Carroll, Evelyn L.** Effects of human growth hormone in man 1223
—. See Henneman and Henneman 1239
Hennes, Allen R., and **Redding, Tommy W.** Supportive effect of adrenal steroids on acetate metabolism *996
Herbert, Victor. Serum folic acid activity: Assay and nature *996
Herring, Betty. See Field, Pastan, Johnson and Herring *986
Hess, Evelyn, and **Ziff, Morris.** Reaction of rheumatoid leukocytes with fluorescent aggregated gamma globulin *996
Hiatt, Howard H., and **Bojarski, Tadeusz B.** Factors influencing deoxyribonucleic acid synthesis *in vivo* *996
Hibbett, Lester L. See Hill, Barker, McNeil, Tingley and Hibbett 523
Hibbs, Richard G. See Phillips and Hibbs *1017
Higgins, John A. See Clowdus, Higgins, Orvis and Summerskill *977
Hill, S. Richardson, Jr., Barker, S. B., McNeill, Jean H., Tingley, John O., and **Hibbett, Lester L.** The metabolic effects of the acetic and propionic acid analogs of thyroxine and triiodothyronine 523
Hiller, Merilyn C. See Shulman, Aster, Leitner and Hiller *1028
Hills, A. Gorman. See Marks and Gorman *1010
Hinnekens, M. See De Moor, De Backer, Hendrikx, Hinnekens and De Bock 816
Hirsch, Robert L. See Farquhar, Hirsch and Ahrens *984
Hoag, M. Silvija, Aggeler, Paul M., and **Fowell, Alfred H.** Disappearance rate of concentrated proconvertin extracts in congenital and acquired hypoproconvertinemia 554
Hocott, Joe B. See Pierce and Hocott 8
Hodler, Jurg E. See Becker, Heinemann, Igarashi, Hodler and Gershberg 1909
Hoffman, Harry N., II, Whitcomb, Fred F., Jr., Butt, Hugh R., and **Bollman, Jesse L.** Bile pigments of jaundice 132
Hogan, Janet C. See Sanford, Hunter, Windom and Hogan *1024
Holford, Fred D. See Mithoefer and Holford *1012
Hollander, Walter, Jr. See Woods, Welt, Hollander and Newton 28
Hollenberg, C. H. See Raben and Hollenberg 435
—. The effect of fasting on the lipoprotein lipase activity of rat heart and diaphragm 1282
Hollifield, Guy. Hyperlipogenesis in adipose tissue of rats limited to a daily two hour feeding period *997
Holman, John. See Davis, Yankopoulos, Lieberman, Holman and Bahn 765
Holub, Donald A. See Frantz, Holub and Jailer 904
Horiuchi, Martha. See Miller and Horiuchi *1011
Horowitz, Herbert I. See Spaet, Horowitz and Zucker-Franklin *1029
Horsley, A. W., and **Eckstein, John W.** The effects of mephentermine on cardiac output in normotensive and hypotensive dogs *997
Horswell, Richard R. See Tyor, Horswell and Owen *1036
Houck, J. C., Jacob, R. A., and **Maengwyn-Davies, G. D.** The effect of Sodium Dilantin administration upon the chemistry of the skin 1758
Howard, R. Palmer. See Furman, Lakshmi, Norcia and Howard *988
Howell, D. S., Delchamps, E., Riemer, W., and **Kiem, I.** A profile of electrolytes in the cartilaginous plate of growing ribs 919
Howell, R. Rodney, Ashton, Doris, and **Wyngaarden, James B.** Lipid, carbohydrate and purine abnormalities in Von Gierke's disease *997
Hsiung, G. D., Isacson, Peter, and **McCollum, Robert W.** Serological reactions with a newly isolated myxovirus *998
Huckabee, William E. Metabolic regulation of cardiac output *998
Huebner, Robert J. See Rowe and Huebner *1023
Hughes, Ann H., and **Eliasson, Sven G.** Synthesis of cholesterol and fatty acids in fractions of peripheral nerve 111
Huguley, Charles M., Jr. See Smith and Huguley *1029
Hulet, William H., Baldwin, David S., Biggs, Albert W., Gombos, Ervin A., and **Chasis, Herbert.** Renal function in the separate kidneys of man. I. Hemodynamics and excretion of solute and water in normal subjects 389
—. See Baldwin, Hulet, Biggs, Gombos and Chasis 395

Hultgren, Herbert N., Spickard, Warren B., and **Hellriegel, Kurt O.** High altitude pulmonary edema *998
Hultman, Eric. See CASTENFORS, HULTMAN and JOSEPHSON 776
Hume, Michael. See COHN and HUME *978
—. See COHN and HUME 1584
Hunter, Betty W. See SANFORD, HUNTER, WINDOM and HOGAN *1024
Hutchinson, Donald L. See FRIEDMAN, GRAY, GRYNFOGEL, HUTCHINSON, KELLY and PLENTL 227

I

Iatridis, Sotirios, G. See FERGUSON, WILSON, IATRIDIS, RIERSON and JOHNSTON 1942
Iber, F. L., Kerr, D. N. S., Dölle, W., and **Sherlock, S.** Measurement of blood flow in the collateral vessels of the portal vein; preliminary results of a new method 1201
Igarashi, Kietsu. See BECKER, HEINEMANN, IGARASHI, HODLER and GERSHBERG 1909
Ingbar, Sidney H. Thyroxine metabolism in the absence of thyroxine-binding globulin and its implications with regard to the physiological role of hormonal binding *999
—. See DOWLING, FREINKEL and INGBAR 1119
Ingelfinger, Franz J. See HARRIS, ASHWORTH and INGELFINGER 1744
Isacson, Peter. See HSIUNG, ISACSON and MCCOLLUM *998
Island, D. P. See WILLIAMS, OLDFIELD, ISLAND and LIDDLE *1040
Isselbacher, Kurt J. See DAWSON and ISSELBACHER 150
—. See DAWSON and ISSELBACHER 730
—, and **McCarthy, Elizabeth A.** Effects of alcohol on the liver: Mechanism of the impaired galactose utilization *999
Izak, G., Wilner, T., and **Mager, J.** Amino acid activating enzymes in red blood cells of normal, anemic and polycythemic subjects 1763
Izzo, Anthony J. See GANDY, KEUTMANN and IZZO 364

J

Jacob, R. A. See HOUCK, JACOB and MAENGWYN-DAVIES 1758
Jaegers, Kenneth R. See STANLEY, BALL and JAEGERS *1031
Jaenike, John R., and **Berliner, Robert W.** A study of distal renal tubular functions by a modified stop flow technique 481
Jailer, Joseph W. See FRANTZ, HOLUB and JAILER 904
Jandl, James H., and **Allen, David W.** Oxidative hemolysis and precipitation of hemoglobin: Heinz body anemias as an accelerated form of red cell aging *1000
—. See ALLEN and JANDL 1107
—, and **Kaplan, Manuel E.** The destruction of red cells by antibodies in man. III. Quantitative factors influencing the patterns of hemolysis *in vivo* 1145
—, **Engle, Louise K.,** and **Allen, David W.** Oxidative hemolysis and precipitation of hemoglobin. I. Heinz body anemias as an acceleration of red cell aging 1818
Janowitz, H. D., and **Dreiling, D. A.** A "precursor solution" of pancreatic juice: Evidence for an exchange mechanism *1000
Januszewicz, Vlodzimierz. See LARAGH, ULICK, JANUSZEWICZ, DEMING, KELLY and LIEBERMAN 1091
Javitt, Norman B., Wheeler, Henry O., Baker, Katharine J., Ramos, Oswaldo L., and **Bradley, Stanley E.** The intrahepatic conjugation of sulfobromophthalein and glutathione in the dog 1570
Jawetz, Ernest, Thygeson, Phillips, Hanna, Lavelle, Dawson, Chandler, and **Mitsui, Yukihiko.** "Trachoma viruses" isolated in the United States *1000
Johns, Richard J. See GROB and JOHNS *992
Johnson, Alan J. Characterization and significance of inhibitors controlling the activation of fibrinolysis in man *1001
Johnson, Blanche, and **Schubert, Maxwell.** Protein-polysaccharides of human costal cartilage 1752
Johnson, David S. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534
Johnson, F. D. See KORST, JOHNSON, COBAU, RENNIE and FRENKEL *1003
Johnson, Phyllis. See FIELD, PASTAN, JOHNSON and HERRING *986
Johnston, Betty R. See FERGUSON, WILSON, IATRIDIS, RIERSON and JOHNSTON 1942
Jones, F. See MUIRHEAD, STIRMAN and JONES 266
Jones, W. B. See REEVES, HEFNER, JONES, COGHLAN, PRIETO and CARROLL *1020
Josephson, Bertil. See CASTENFORS, HULTMAN and JOSEPHSON 776

K

Kaiser, Carolyn. See HELERSTEIN, KAISER, DARROW and DARROW 282
Kaiser, E. See YOSHIDA, YAMASHITA, KAISER and METCOFF *1041
Kanzaki, Grace. See BERGER, PECIKYAN and KANZAKI *971
Kaplan, Manuel E. See JANDL and KAPLAN 1145
Kaplan, Ruth. See DEMING, DALY, BLOOM, BRUN and KAPLAN *980
Kaplan, Selna L. See GRUMBACH and KAPLAN *993
Kark, Robert M. See BONTING, POLLAK, MUEHRCKE and KARK 1372
—. See BONTING, POLLAK, MUEHRCKE and KARK 1381
—. See POLLAK, BONTING, MUEHRCKE and KARK 1386
—. See POLLAK, BONTING, MUEHRCKE and KARK 1394
Karmen, Arthur. See KAYDEN, KARMEN, DUMONT and BRAGDON *1001
Kayden, Herbert J., Karmen, Arthur, Dumont, Allan E., and **Bragdon, Joseph.** Fatty acid patterns of human lymph and serum after corn oil or coconut oil feeding *1001
Kelly, Eugene R. See BRAUNWALD and KELLY 413
Kelly, William G. See LARAGH, ULICK, JANUSZEWICZ, DEMING, KELLY and LIEBERMAN 1091
Kelly, William Thomas. See FRIEDMAN, GRAY, GRYNFOGEL, HUTCHINSON, KELLY and PLENTL 227
Kerr, D. N. S. See IBER, KERR, DÖLLE and SHERLOCK 1201
Kety, Seymour S. See LEWIS, SOKOLOFF, WECHSLER, WENTZ and KETY 707
Keutmann, E. Henry. See GANDY, KEUTMANN and IZZO 364

Khassis, Sarah. See GITLOW, MENDLOWITZ, KHASSIS, COHEN and SHA 221
Kiem, I. See HOWELL, DELCHAMPS, RIEMER and KIEM 919
Kilbourne, Edwin D. See SCHULMAN and KILBOURNE *1026
Kilburn, Kaye H., and **Sieker, Herbert O.** A comparative study of pulmonary circulatory effects of intravenous isoproterenol in pulmonary emphysema, heart failure and mitral stenosis *1001
Kimberg, Daniel V. See SCHACHTER, DOWDLE, SCHENKER and KIMBERG *1025
Kime, S. Wesley, Jr. See BRICKER, KIME, MORRIN and ORLOWSKI 864
—. See MORRIN, BRICKER and KIME *1013
—. See BRICKER, ORLOWSKI, KIME and MORRIN 1771
Kipnis, David M., and **Reiss, Eric.** The effect of cell structure and growth hormone on protein synthesis in striated muscle *1002
Kitchin, Arthur H. See SWAN and KITCHIN *1034
Kittinger, A. L. See MONROE and KITTINGER *1013
Kleeman, Charles R. See CUTLER, KLEEMAN, DOWLING and MAXWELL *980
—, **Koplowitz, Jerry, Maxwell, Morton H., Cutler, Ralph,** and **Dowling, J. Thomas.** Mechanisms of impaired water excretion in adrenal and pituitary insufficiency. II. Interrelationships of adrenal cortical steroids and antidiuretic hormone in normal subjects and in diabetes insipidus 1472
Klein, Robert F. See FRIEDBERG, KLEIN, BOGDONOFF, ESTES and TROUT *987
—. See FRIEDBERG, KLEIN, TROUT, BOGDONOFF and ESTES 1511
Klipstein, Frederick A., and **Ranney, Helen M.** Electrophoretic components of the hemoglobin of red cell membranes 1894
Koch-Weser, Dieter, and **Moses, John M.** Observations on the mechanism of tolerance to the local Shwartzman phenomenon using isotopically labeled endotoxin *1002
Koepf, George F. See SANDBERG, HAUSCHKA, GORDY and KOEPF *1024
Koiw, Erich. See GENEST, NOWACZYNSKI, KOIW and SANDOR *989
Kolb, Felix O., and **Harper, Harold A.** Modification by diet of urinary amino acid pattern in cystinuria *1002
Koplowitz, Jerry. See KLEEMAN, KOPLOWITZ, MAXWELL, CUTLER and DOWLING 1472
Korst, D. R., Johnson, F. D., Cobau, C. D., Rennie, M. H., and **Frenkel, E. P.** Studies with a cyclic phosphamide ester of nitrogen mustard: Cyclophosphamide *1003
Kozak Mariz, Ida. See DAUGHADAY and KOZAK MARIZ *980
Kramer, Robert J. See COBB, KRAMER and FINCH 1722
Kruh, Jacques, Dreyfus, Jean-Claude, Schapira, Georges, and **Gey, George O., Jr.** Abnormalities of muscle protein metabolism in mice with muscular dystrophy 1180
Kruk, Elizabeth. See GITLOW and KRUK *990
Kunkel, Henry G. See FUDENBERG, GERMAN and KUNKEL *987
Kurland, George S. See STEIN, FORKNER, SPENCER, ROBIN and KURLAND *1031
Kushner, Daniel S., Szanto, Paul B., and **Dubin, Alvin.** Acute adult glomerulonephritis: Studies of healing and progression to chronicity *1003

L

Lakshmi, K. See FURMAN, LAKSHMI, NORCIA and HOWARD *988
Landeryou, Mary Jean. See SPINK and LANDERYOU 302
Landy, Maurice, Trapani, Robert-John, and **Rosen, Fred S.** Inactivation of endotoxin by a humoral component. VI. Two separate systems required for viable and killed *Salmonella typhosa* 352
Lane, M. H. See LASSEN, FEINBERG and LANE 491
Lane, Montague, Mengel, Charles E., and **Doherty, Dorothy J.** Rapid induction of isolated riboflavin deficiency in man *1004
Lang, Daphne. See WHITBY and LANG 854
Lange, Ramon L., Smith, Carlisle, and **Hecht, Hans H.** Arterial blood flow patterns in human subjects and their effect on indicator dilution curves from various arterial sites 1413
Laragh, John H., Ulick, Stanley, Januszewicz, Vlodzimierz, Deming, Quentin B., Kelly, William G., and **Lieberman, Seymour.** Aldosterone secretion and primary and malignant hypertension 1091
Lassen, N. A., Feinberg, I., and **Lane, M. H.** Bilateral studies of cerebral oxygen uptake in young and aged normal subjects and in patients with organic dementia 491
Lassiter, William E., Gottschalk, Carl W., and **Mylle, Margaret.** Micropuncture study of net transtubular movement of water and urea in the rat kidney *1004
Lathem, Willoughby, Davis, Bernard B., Zweig, Paul H., and **Dew, Robert.** The demonstration and localization of renal tubular reabsorption of hemoglobin by stop flow analysis 840
——, **Davis, Bernard B.,** and **Rodnan, Gerald P.** Renal tubular secretion of uric acid in the mongrel dog *1004
Lau, Sun Hing. See GROSSMAN, ROSENBLUM, LAU and WOLFMAN *993
Lawrence, H. S., Rapaport, F. T., Converse, J. M., and **Tillett, W. S.** Transfer of delayed hypersensitivity to skin homografts with leukocyte extracts in man 185
Layne, Ennis C. See GONZALEZ and LAYNE 1578
Lazarow, A. See GOETZ, HARTMAN and LAZAROW *991
Leaf, Alexander. See HAYS and LEAF *995
Leboeuf, Bernard. See CAHILL, WOOD, LEBOEUF and RENOLD *976
Lee, S. L., Meiselas, L. E., Zingale, S. B., and **Richman, R.** Antibody production in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) *1005
Leevy, Carroll M., George, William S., Ziffer, Herman, and **Baker, Herman.** Pantothenic acid, fatty liver and alcoholism *1005
—. See STEIN, ABELMANN, LIEBER, LEEVY and CHERRICK *1032
Leitner, Alfred. See SHULMAN, ASTER, LEITNER and HILLER *1028
Lennon, Edward J. See ENGBRING, LENNON and ENGSTROM *983

Lesser, Gerson T., Perl, William, and **Steele, J. Murray.** Determination of total body fat by absorption of an inert gas; measurements and results in normal human subjects 1791

Levin, William C. See RITZMANN, COLEMAN and LEVIN 1320

Levine, H. J. See MESSER, WAGMAN, LEVINE, NEILL and GORLIN *1011

Levinsky, Norman G., Tyson, Ian, and **Relman, Arnold S.** The relationship between cationic amino acids and potassium in rat muscle *in vitro* *1005

Levinson, Richard A., and **Cummings, Martin M.** A study of tuberculin reactions in an Indian hospital population *1005

Levitin, Howard. See FERRIS, LEVITIN and EPSTEIN *985

Levitt, Marvin F. See GOLDSTEIN, HAUSER and LEVITT *991

Lewis, Arthur. See LOSPALLUTO, CHEGORIANSKY, LEWIS and ZIFF 473

Lewis, Benjamin M., Sokoloff, Louis, Wechsler, Richard L., Wentz, W. Budd, and **Kety, Seymour S.** A method for the continuous measurement of cerebral blood flow in man by means of radioactive krypton (Kr^{79}) 707

—, **Reed, L. C., Jr., Furusho, Akio,** and **Snider, Thomas H.** The effect of pulmonary air cysts on respiratory mechanics and pulmonary diffusing capacity *1006

—, **McElroy, William T., Hayford-Welsing, Ernest J.,** and **Samberg, L. Carl.** The effects of body position, ganglionic blockade and norepinephrine on the pulmonary capillary bed 1345

Lewis, David H. See SACKNER, SCHNABEL, ALLAN and LEWIS *1023

Lewis, John D. See MORRISON, BUCKALEW, MILLER and LEWIS *1014

Ley, Allyn B. The relation of erythropoiesis to iron absorption *1006

Leznoff, A., Fishman, J., Goodfriend, L., McGarry, E. E., Rose, B., and **Beck, J. C.** The cytological localization of human growth hormone with fluorescent antibody *1006

Liddle, G. W. See WILLIAMS, OLDFIELD, ISLAND and LIDDLE *1040

Lieber, Charles S., DeCarli, Leonore M., and **Schmid, Rudi.** Stimulation of hepatic fatty acid synthesis by ethanol *in vivo* and *in vitro* *1007

—. See STEIN, ABELMANN, LIEBER, LEEVY and CHERRICK *1032

Lieberman, Ferol. See DAVIS, YANKOPOULOS, LIEBERMAN, HOLMAN and BAHN 765

Lieberman, Seymour. See LARAGH, ULICK, JANUSZEWICZ, DEMING, KELLY and LIEBERMAN 1091

Lindberg, Howard A. See STAMLER, LINDBERG, BERKSON, HALL and MILLER *1030

Lipkin, Martin, Almy, Thomas P., and **Quastler, Henry.** Stability of protein in intestinal epithelial cells *1007

Lister, Leonard M. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534

Liuzzi, Anthony. See BURROWS, SLINGERLAND, LIUZZI, DELL and GRAHAM *975

Lospalluto, Joseph. See ZIFF, GRIBETZ and LOSPALLUTO 405

—, **Chegoriansky, Julio, Lewis, Arthur,** and **Ziff, Morris.** Chromatographic properties of gamma globulin: Behavior of serum gamma macroglobulins 473

Louria, Donald B., Fallon, Nancy, and **Browne, Harry G.** The influence of cortisone on experimental fungus infections in mice 1435

Love, Ethel. See GRAYZEL, SEEGMILLER and LOVE 447

Lovejoy, Frank W., Jr. See STANFIELD, LURIA, FINLAYSON, LOVEJOY and YU *1031

Lowe, Charles U., Ambrus, Julian L., Ambrus, Clara M., Mosovich, Luis L., Mink, Irving B., and **Sokal, Joseph E.** Bleeding diathesis in children with liver glycogen disease and in their parents *1007

Luchi, Robert J. See CONN and LUCHI *978

Ludwig, George D. Inhibition of serotonin production by isonicotinic acid hydrazide with control of symptoms in the malignant carcinoid syndrome *1008

Luhby, A. Leonard, and **Cooperman Jack M.** Formiminoglutamic acid versus serum "folic acid" as an index of folic acid deficiency *1008

Lund, Charles C. See MCMENAMY, LUND, NEVILLE and WALLACH 1675

—. See MCMENAMY, LUND and WALLACH 1688

Luria, Milton N. See STANFIELD, LURIA, FINLAYSON, LOVEJOY and YU *1031

Lynn, William S. See MACLEOD, BROWN and LYNN *1008

Mc

MacKinney, Archie A. See STOHLMAN, BRECHER and MACKINNEY *1032

MacLeod, Robert M., Brown, Rose, and **Lynn, William S.** *In vitro* stimulation of hexokinase by insulin *1008

McCall, Mary S. See UNGER, EISENTRAUT, MCCALL and MADISON *1036

McCants, Ralph S. See OWEN, MCCANTS and MCCONAHEY 790

McCarthy, Elizabeth A. See ISSELBACHER and MCCARTHY *999

McCluskey, Robert T. See WEISSMANN, POTTER, MCELLIGOTT, MELTZER and MCCLUSKEY *1039

McCollum, Robert W. See HSIUNG, ISACSON and MCCOLLUM *998

McConahey, William M. See OWEN, MCCANTS and MCCONAHEY 790

McConnell, J. See BRAUDE, MCCONNELL and DOUGLAS 1266

McCune, Robert. Delivery of antimicrobial drugs across inflammatory membrane in rabbits 846

—. The capacity of tubercle bacilli to assume a latent state *in vivo* *1009

McElligott, Frank. See WEISSMANN, POTTER, MCELLIGOTT, MELTZER and MCCLUSKEY *1039

McElroy, William T. See LEWIS, MCELROY, HAYFORD-WELSING and SAMBERG 1345

McGarry, E. E. See LEZNOFF, FISHMAN, GOODFRIEND, MCGARRY, ROSE and BECK *1006

McGinty, John D. See REGAN, TIMMIS, FRANK, MCGINTY and HELLEMS *1020

McKittrick, Roy L. See SCHERBEL, MCKITTRICK and HAWK *1025

McMenamy, Rapier H., Lund, Charles C., Neville, Gerald J., and **Wallach, Donald F. H.** Studies of unbound amino acid distributions in plasma, erythro-

cytes, leukocytes and urine of normal human subjects 1675
—, **Lund, Charles C.,** and **Wallach, Donald F. H.** Unbound amino acid concentrations in plasma, erythrocytes, leukocytes and urine of patients with leukemia 1688
McNeil, Jean H. See HILL, BARKER, MCNEIL, TINGLEY and HIBBETT 523
McPherson, Harry T. See SAVARD, DORFMAN, BAGGETT, FIELDING, ENGEL, MCPHERSON, LISTER, JOHNSON, HAMBLEN and ENGEL 534

M

Macdonell, J. A. See BRODOVSKY, MACDONELL and CHERNIACK 724
Madison, Leonard L., Combes, Burton, Adams, Reuben, and **Strickland, William.** The physiological significance of the secretion of endogenous insulin into the portal circulation. III. Evidence for a direct immediate effect of insulin on the balance of glucose across the liver 507
—, **Combes, Burton,** and **Adams, Reuben.** Insulin's control of the role of the liver in the disposition of a glucose load in diabetic and nondiabetic dogs *1009
—. See UNGER, EISENTRAUT, MCCALL and MADISON *1036
Maengwyn-Davies, G. D. See HOUCK, JACOB and MAENGWYN-DAVIES 1758
Mager, J. See IZAK, WILNER and MAGER 1763
Mallett, David L. See RATNOFF, MALLETT and DAVIE *1019
Mallos, Alexander J. See BARNETT, FOX, MALLOS, GREENFIELD and FRY *971
Malmgren, Richard A. See GOODMAN, FAHEY and MALMGREN 1595
Maloof, F., and **Soodak, M.** The cleavage of disulfide bonds in thyroid tissue by thiourea *1009
Mancusi-Ungaro, Pier L. See WHEELER, MANCUSI-UNGARO and WHITLOCK *1039
Manfredi, F., and **Sieker, H. O.** The effect of carbon dioxide on the pulmonary circulation 295
Mao, R. L. See FALCONE, MAO and SHRAGO *984
Marc-Aurele, Julien, and **Schreiner, George E.** The dialysance of ethanol and methanol: A proposed method for the treatment of massive intoxication by ethyl or methyl alcohol 802
Marin, Hector M., Stefanini, Mario, Soardi, Franco, and **Mueller, Liselotte.** Thrombolytic activity of mold fibrinolysin (aspergillin O) *in vivo* *1010
Marinetti, Guido V. See TROUP, REED, MARINETTI and SWISHER 342
Marks, Bernard H., and **Hills, A. Gorman.** Endocrine influences on serum free fatty acid (FFA) in man *1010
Marks, Paul A., and **Banks, Julia.** Steroid hormone inhibition of mammalian glucose-6-phosphate dehydrogenase *1010
Marshall, G. J. See BIERMAN and MARSHALL *973
Marshall, Robert J. See WANG, SHEPARD and MARSHALL 466
——. See WANG, MARSHALL and SHEPHERD 1051
Martin, Donald B. See RENOLD, MARTIN, DAGENAIS, STEINKE, NICKERSON and SHEPS 1487
——. See SHEPS, NICKERSON, DAGENAIS, STEINKE, MARTIN and RENOLD 1499
Martz, B. L. See FISCH, MARTZ and PRIEBE 1885
Masouredis, S. P. *In vitro* transfer of I^{131} anti-$Rh_0(D)$ from "sensitized" red cells *1011
—. Relationship between $Rh_0(D)$ genotype and quantity of I^{131} anti-$Rh_0(D)$ bound to red cells 1450
Masson, G. M. C. See OMAE and MASSON 21
Mauer, Alvin M. See ATHENS, MAUER, RAAB, HAAB and CARTWRIGHT *969
—, **Athens, J. W., Ashenbrucker, Helen, Cartwright, G. E.,** and **Wintrobe, M. M.** Leukokinetic studies. II. A method for labeling granulocytes *in vitro* with radioactive diisopropylfluorophosphate (DFP^{32}) 1481
Maxwell, G. M. See ROWE, CASTILLO, MAXWELL and CRUMPTON *1022
Maxwell, Morton H. See CUTLER, KLEEMAN, DOWLING and MAXWELL *980
—. See KLEEMAN, KOPLOWITZ, MAXWELL, CUTLER and DOWLING 1472
Meiselas, L. E. See LEE, MEISELAS, ZINGALE and RICHMAN *1005
Meltzer, Jay I. See WHEELER, MELTZER and BRADLEY 1131
Meltzer, Martin. See WEISSMANN, POTTER, MCELLIGOTT, MELTZER and MCCLUSKEY *1039
Mendlowitz, Milton. See GITLOW, MENDLOWITZ, KHASSIS, COHEN and SHA 221
Mengel, Charles E. See LANE, MENGEL and DOHERTY *1004
Merrill, John P. See GIORDANO, WEINSTOK and MERRILL *990
Merritt, Frank L. See BOGDONOFF, WEISSLER and MERRITT 959
Messer, J. V., Wagman, R. J., Levine, H. J., Neill, W. A., and **Gorlin, R.** The influence of peripheral and coronary hemodynamics upon patterns of human myocardial oxygen supply *1011
Metcoff, J. See YOSHIDA, YAMASHITA, KAISER and METCOFF *1041
Miller, Aaron, and **Horiuchi, Martha.** Erythrocyte glutathione synthesis *1011
Miller, Billievelyn. See SMITH, EITZMAN and MILLER *1029
Miller, Edward. See SULLIVAN, MILLER, WOOD, CLIFFORD and DUFF *1034
Miller, Ray. See MORRISON, BUCKALEW, MILLER and LEWIS *1014
Miller, Stephen A. See GREENBERG, WONG, MILLER, SCARLATA and CHALMERS *992
Miller, Wilda A. See STAMLER, LINDBERG, BERKSON, HALL and MILLER *1030
Miller, William F. See SPROULE, MITCHELL and MILLER 378
—, **Cushing, Ivan E.,** and **Wu, Nancy.** The role of the edematous state to respiratory function in patients with primary cor pulmonale *1012
Mills, Ivor H. See BARTTER, MILLS and GANN 1330
Mink, Irving B. See LOWE, AMBRUS, AMBRUS, MOSOVICH, MINK and SOKAL *1007
Mitchell, Jere H. See SPROULE, MITCHELL and MILLER 378
—. See SARNOFF, MITCHELL and GILMORE *1025
Mitchell, Marvin L. Abnormal insulin-binding fraction demonstrated by the electrophoresis on ion exchange paper of sera from diabetic patients *1012
Mithoefer, John C., and **Holford, Fred D.** The myocardial exchange of potassium and sodium during respiratory acidosis *1012

Mitsui, Yukihiko. See JAWETZ, THYGESON, HANNA, DAWSON and MITSUI *1000
Mittman, Charles. See BURROWS, NIDEN, MITTMAN, TALLEY and BARCLAY 943
Moghissi, Kamran, Neuhaus, Otto W., and **Stevenson, Charles C.** Composition and properties of human cervical mucus. I. Electrophoretic separation and identification of proteins 1358
Moldawer, Marc. See HENNEMAN, FORBES, MOLDAWER, DEMPSEY and CARROLL 1223
Mologne, Lewis A., and **Braude, Abraham I.** Destruction of pathogenic staphylococci by human serum *1013
Monroe, L. S., and **Kittinger, A. L.** The biliary dynamics of the metabolites of sulfobromophthalein (BSP) in man *1013
Moore, Frederick J. See RAPAPORT, PATCH and MOORE 1619
Moore, Stanford. See BRIGHAM, STEIN and MOORE 1633
Morrin, Peter A. F. See BRICKER, KIME, MORRIN and ORLOWSKI 864
—, **Bricker, Neal S.,** and **Kime, S. Wesley, Jr.** An evaluation of the acidifying capacity of the chronically diseased kidney in the experimental animal *1013
——. See BRICKER, ORLOWSKI, KIME and MORRIN 1771
Morrison, Ashton B., Buckalew, Vardaman M., Jr., Miller, Ray, and **Lewis, John D.** The reabsorption of phosphate by the kidney in potassium-deficient dogs *1014
Moses, John M. See KOCH-WESER and MOSES *1002
Mosovich, Luis L. See LOWE, AMBRUS, AMBRUS, MOSOVICH, MINK and SOKAL *1007
Muehrcke, Robert C. See POLLAK, BONTING and MUEHRCKE *1018
—. See BONTING, POLLAK, MUEHRCKE and KARK 1372
—. See BONTING, POLLAK, MUEHRCKE and KARK 1381
—. See POLLAK, BONTING, MUEHRCKE and KARK 1386
—. See POLLAK, BONTING, MUEHRCKE and KARK 1394
Mueller, Liselotte. See MARIN, STEFANINI, SOARDI and MUELLER *1010
Muirhead, E. E., Stirman, J. A., and **Jones, F.** Renal autoexplantation and protection against renoprival hypertensive cardiovascular disease and hemolysis 266
Munday, Janet S. See YIELDING, TOMKINS and MUNDAY *1041
Mylle, Margaret. See LASSITER, GOTTSCHALK and MYLLE *1004

N

Naegle, Siegfried. See BALLARD, DANFORTH, NAEGLE and BING 717
Naets, Jean-Pierre. The role of the kidney in erythropoiesis 102
Neill, W. A. See MESSER, WAGMAN, LEVINE, NEILL and GORLIN *1011
Neuhaus, Otto W. See MOGHISSI, NEUHAUS and STEVENSON 1358
Neuwirth, Robert S. See ALBRINK and NEUWIRTH 441
Neville, Gerald J. See MCMENAMY, LUND, NEVILLE and WALLACH 1675
Newton, Margaret. See WOODS, WELT, HOLLANDER and NEWTON 28
Nickerson, Rita J. See RENOLD, MARTIN, DAGENAIS, STEINKE, NICKERSON and SHEPS 1487
—. See SHEPS, NICKERSON, DAGENAIS, STEINKE, MARTIN and RENOLD 1499
Niden, Albert H. See BURROWS, NIDEN, HARPER and BARCLAY 795
—. See BURROWS, NIDEN, MITTMAN, TALLEY and BARCLAY 943
Noehren, Theodore H., and **Riggs, Douglas S.** Ethyl ether elimination by the lungs, a new measure of effective alveolar ventilation *1014
Norcia, Leonard N. See FURMAN, LAKSHMI, NORCIA and HOWARD *988
Nowaczynski, Wojciech. See GENEST, NOWACZYNSKI, KOIW and SANDOR *989

O

Oates, John A., Jr., Gillespie, Louis, Jr., Crout, J. Richard, and **Sjoerdsma, Albert.** Inhibition of aromatic amino acid decarboxylation in man and associated pharmacological effects *1015
Ohanessian, Simon. See FALOON, TAYLOR, HELLMAN and OHANESSIAN *984
Oken, Donald E., and **Solomon, A. K.** Potassium concentration in the proximal tubule of necturus kidney *1015
Oldfield, R. A. A., Jr. See WILLIAMS, OLDFIELD, ISLAND and LIDDLE *1040
Omae, T., and **Masson, G. M. C.** Reversibility of renal atrophy caused by unilateral reduction of renal blood supply 21
Orlowski, Tadeusz. See BRICKER, KIME, MORRIN and ORLOWSKI 864
—. See BRICKER, ORLOWSKI, KIME and MORRIN 1771
Orvis, A. L. See CLOWDUS, HIGGINS, ORVIS and SUMMERSKILL *977
Owen, Charles A., Jr., McCants, Ralph S., and **McConahey, William M.** Abbreviation of Berson technic for estimation of thyroidal clearance of plasma radioiodide: Use of Berson test to recognize thyroidal protein-binding defects 790
Owen, Edward E., Tyor, Malcolm P., Flanagan, John F., and **Berry, J. Norman.** The kidney as a source of blood ammonia in patients with liver disease: The effect of acetazolamide 288
—. See TYOR, HORSWELL and OWEN *1036

P

Pappas, Nicholas C. See ROANTREE and PAPPAS 82
Papper, Solomon, Belsky, Joseph L., and **Bleifer, Kenneth H.** The response to the administration of an isotonic sodium chloride-lactate solution in patients with essential hypertension 876
Parmentier Cherill. See RUBIN, BRANDBORG, FLICK, PARMENTIER, PHELPS and VAN NIEL *1023
Pastan, Ira. See FIELD, PASTAN, JOHNSON and HERRING *986
Patch, Mary Jane. See RAPAPORT, PATCH and MOORE 1619
Pease, Margaret J. See GERALD, EFRON and PEASE *989
Pechet, Liberto. Elevated factors VII and X in pregnancy, a "hypercoagulable" state *1015
Pechet, Maurice M., and **Carroll, Evelyn L.** Studies of the metabolism of calcium, phosphorus and magnesium in subjects with pseudo-hypoparathyroidism *1015

Pecikyan, Rene. See BERGER, PECIKYAN and KANZAKI *971

Perillie, Pasquale E., and **Finch, Stuart C.** The local exudative cellular response in leukemia 1353

Perkins, Herbert A., Acra, D. J., and **Rolfs, Mary R.** Duration of coagulation abnormalities following *in vivo* neutralization of heparin by protamine and polybrene *1016

Perl, William. See LESSER, PERL and STEELE 1791

Pesch, Leroy A., Segal, Stanton, and **Topper, Yale J.** Progesterone effects on galactose metabolism in prepubertal patients with congenital galactosemia and in rats maintained on high galactose diets 178

Petersdorf, Robert G. Relationship of phagocytosis to the fall in spinal fluid glucose in experimental meningitis *1016

Peterson, Lysle H., Feigl, Eric O., and **Gouras, Peter.** On the mechanism of carotid sinus function *1017

Peterson, Ralph E. Adrenocortical steroid metabolism and adrenal cortical function in liver disease 320

—, and **Pierce, Charles E.** The metabolism of corticosterone in man 741

—. See DINGMAN, GAITAN, STAUB, ARIMURA and PETERSON *981

Phelps, Patricia. See RUBIN, BRANDBORG, FLICK, PARMENTIER, PHELPS and VAN NIEL *1023

Philipson, Lennart, and **Choppin, Purnell W.** On the role of virus sulfhydryl groups in the attachment of enteroviruses to cells *1017

Phillips, Gerald B. The lipid composition of serum in patients with liver disease 1639

Phillips, John H., and **Hibbs, Richard G.** Electron microscopic study of tissue mast cells and chromaffin cells in man *1017

Pierce, Charles E. See PETERSON and PIERCE 741

Pierce, John A., and **Hocott, Joe B.** Studies on the collagen and elastin content of the human lung 8

Plentl, Albert A. See FRIEDMAN, GRAY, GRYNFOGEL, HUTCHINSON, KELLY and PLENTL 227

Plough, I. C. See TAKEDA, PLOUGH and REEVE *1034

Plum, Fred. Bladder smooth muscle contributions to micturition *1018

—. See POSNER and PLUM 1246

Pollak, Victor E., Bonting, Sjoerd L., and **Muehrcke, Robert C.** Quantitative assay of alkaline phosphatase and lactic dehydrogenase activities in the nephron in glomerulo-tubular imbalance *1018

—. See BONTING, POLLAK, MUEHRCKE and KARK 1372

—. See BONTING, POLLAK, MUEHRCKE and KARK 1381

—, **Bonting, Sjoerd L., Muehrcke, Robert C.,** and **Kark, Robert M.** Quantitative histochemistry of the nephron. IV. Alkaline phosphatase and lactic dehydrogenase activities in renal tubular diseases 1386

—, **Bonting, Sjoerd L., Muehrcke, Robert C.,** and **Kark, Robert M.** Quantitative histochemistry of the nephron. V. Alkaline phosphatase and lactic dehydrogenase activities in lupus nephritis 1394

Pollard, David S. See FERRIS and POLLARD 143

Porter, Richard. See RELMAN, PORTER, TOBIAS and SCHWARTZ 1551

Posner, Jerome B., and **Plum, Fred.** The toxic effects of carbon dioxide and acetazolamide in hepatic encephalopathy 1246

Potter, Elizabeth V., Stollerman, Gene H., and **Siegel, Alan C.** Recall of type specific immunity by vaccination of human beings with group A streptococcal cell wall vaccines *1018

Potter, Jacobus L. See WEISSMANN, POTTER, MCELLIGOTT, MELTZER and MCCLUSKEY *1039

Preedy, John R. K. See BROWN, SAFFAN and PREEDY *975

Priebe, Fred H. See FISCH, MARTZ and PRIEBE 1885

Prieto, Gustavo. See REEVES, HEFNER, JONES, COGHLAN, PRIETO and CARROLL *1020

Q

Quastler, Henry. See LIPKIN, ALMY and QUASTLER *1007

R

Raab, Spencer O. See ATHENS, MAUER, RAAB, HAAB and CARTWRIGHT *969

Raben, M. S., and **Hollenberg, C. H.** Effect of glucose and insulin on the esterification of fatty acids by isolated adipose tissue 435

Radding, Charles M., and **Steinberg, Daniel.** Studies on the synthesis and secretion of serum lipoproteins by rat liver slices 1560

Raisz, Lawrence G. See AU and RAISZ 1302

Ramos, Oswaldo L. See WHEELER and RAMOS 161

—. See JAVITT, WHEELER, BAKER, RAMOS and BRADLEY 1570

Ranney, Helen M. See KLIPSTEIN and RANNEY 1894

Rantz, Lowell A. See ROANTREE and RANTZ 72

Rapaport, F. T. See LAWRENCE, RAPAPORT, CONVERSE and TILLETT 185

Rapaport, Samuel I., Patch, Mary Jane, and **Moore, Frederick J.** Anti-hemophilic globulin levels in carriers of hemophilia A 1619

Rasmussen, Howard. See SCHWARTZ, RASMUSSEN, SCHOESSLER, FONG and SILVER *1026

Ratnoff, Oscar D., Mallett, David L., and **Davie, Earl W.** An action of Hageman factor: Evidence that plasma thromboplastin antecedent is activated by Hageman factor. *1019

Recant, Lillian. See DUBACH and RECANT *981

—. See DUBACH and RECANT 1364

Rector, Floyd C., Jr., Roberts, Albert D., Jr., Smith, Jerry S., and **Seldin, Donald W.** Role of plasma P_{CO_2} and carbonic anhydrase activity in HCO_3^- reabsorption *1019

—, **Seldin, Donald W., Roberts, Albert D., Jr.,** and **Smith, Jerry S.** The role of plasma CO_2 tension and carbonic anhydrase activity in the renal reabsorption of bicarbonate 1706

Redding, Tommy W. See HENNES and REDDING *996

Redeker, Allan G. See REYNOLDS, GELLER and REDEKER *1021

Reed, Claude F. See TROUP, REED, MARINETTI and SWISHER 342

—, and **Swisher, Scott N.** Abnormalities of *in vitro* behavior of structural lipids of red blood cells from patients with hereditary spherocytosis *1019

Reed, L. C., Jr. See LEWIS, REED, FURUSHO and SNIDER *1006

Reeve, E. B. See TAKEDA, PLOUGH and REEVE *1034

Reeves, John T., Grover, Robert F., Filley, Giles F., and **Blount, S. Gilbert, Jr.** The adaptation of the circulation to supine exercise and treadmill walking *1020

Reeves, T. J., Hefner, Lloyd L., Jones, W. B., Coghlan, Cecil, Prieto, Gustavo, and **Carroll, John.** The

hemodynamic determinants of the rate of pressure change of the left ventricle during isometric contraction *1020
Regan, Timothy J., Timmis, Gerald C., Frank, Martin J., McGinty, John D., and **Hellems, Harper K.** Influence of extracellular calcium concentration upon myocardial potassium transfer *1020
mycardial potassium transfer *1020
Reid, Maria B. See RUDMAN, DI GIROLAMO, SEIDMAN and REID *1023
Reimer, Stanley M. See WESSLER and REIMER 262
—. See DEYKIN, WESSLER and REIMER *981
Reiss, Eric. See KIPNIS and REISS *1002
—. See FIELD and REISS 0000
Relman, Arnold S. See HALL and RELMAN 171
—. See LEVINSKY, TYSON and RELMAN *1005
—, **Porter, Richard, Tobias, James F.,** and **Schwartz, William B.** The diuretic effects of large doses of acetazolamide and an analog lacking carbonic anhydrase inhibiting activity 1551
Rennie, M. H. See KORST, JOHNSON, COBAU, RENNIE and FRENKEL *1003
Renold, Albert E. See CAHILL, WOOD, LEBOEUF and RENOLD *976
—, **Martin, Donald B., Dagenais, Yves M., Steinke, Jurgen, Nickerson, Rita J.,** and **Sheps, Mindel C.** Measurement of small quantities of insulin-like activity using rat adipose tissue. I. A proposed procedure 1487
—. See SHEPS, NICKERSON, DAGENAIS, STEINKE, MARTIN and RENOLD 1499
Reynolds, Telfer B., Geller, Herman M., and **Redeker, Allan G.** The effect of vasopressin on hepatic hemodynamics in patients with portal hypertension *1021
Richman, R. See LEE, MEISELAS, ZINGALE and RICHMAN *1005
Riemer, W. See HOWELL, DELCHAMPS, RIEMER and KIEM 919
Rierson, Herman A. See FERGUSON, WILSON, IATRIDIS, RIERSON and JOHNSTON 0000
Rigatto, Mario, Turino, Gerard M., and **Fishman, Alfred P.** The determination of pulmonary blood flow in man *1021
—, and **Fishman, Alfred P.** The pulsatile nature of the pulmonary capillary blood flow 1626
Riggs, Douglas S. See NOEHREN and RIGGS *1014
Ritzmann, Stephan E., Coleman, Solon L., and **Levin, William C.** The effect of some mercaptanes upon a macrocryogelglobulin; modifications induced by cysteamine, penicillamine and penicillin 1320
Roantree, Robert J., and **Rantz, Lowell A.** A study of the relationship of the normal bactericidal activity of human serum to bacterial infection 72
—, and **Pappas, Nicholas C.** The survival of strains of enteric bacilli in the blood stream as related to their sensitivity to the bactericidal effect of serum 82
Roberts, Albert D., Jr. See RECTOR, ROBERTS, SMITH and SELDIN *1019
—. See RECTOR, SELDIN, ROBERTS and SMITH 1706
Robertson, James S. See SILVER, ROBERTSON and DAHL 420
Robin, Eugene D. See BROMBERG, ROBIN and FORKNER 332
—, **Vester, John W., Wilson, Robert J.,** and **Andrus, Margaret H.** The "internal" pH of mitochondria with observations on the functional significance of mitochondrial membranes *1022
—. See STEIN, FORKNER, SPENCER, ROBIN and KURLAND *1031
Robinson, Roscoe R. See WHEELER, EPSTEIN, ROBINSON and SNELL 236
Rochester, D. F. See FRITTS, HARDEWIG, ROCHESTER, DURAND and COURNAND 1841
Rodnan, Gerald P. See LATHEM, DAVIS and RODNAN *1004
Rolfs, Mary R. See PERKINS, ACRA and ROLFS *1016
Rose, B. See LEZNOFF, FISHMAN, GOODFRIEND, MCGARRY, ROSE and BECK *1006
Rosen, Fred S. See LANDY, TRAPANI and ROSEN 352
Rosenblum, Robert. See GROSSMAN, ROSENBLUM, LAU and WOLFMAN *993
Rosenfeld, R. S. See HELLMAN, FRAZELL and ROSENFELD 1288
Rosenman, Ray H. See FRIEDMAN, ST. GEORGE, BYERS and ROSENMAN 758
—. Occupational and environmental influences on serum cholesterol: Comparative study of two dissimilar groups of female subjects *1022
Rosenthal, Otto. See COOPER, ROSENTHAL and BLAKEMORE *979
Ross, John, Jr., Waldhausen, John A., and **Braunwald, Eugene.** Studies on digitalis. I. Direct effects on peripheral vascular resistance 930
—, **Braunwald, Eugene,** and **Waldhausen, John A.** Studies on digitalis. II. Extracardiac effects on venous return and on the capacity of the peripheral vascular bed 937
Rowe, G. G., Castillo, C. A., Maxwell, G. M., and **Crumpton, C. W.** Hemodynamics of systemic arterial hypertension *1022
Rowe, Wallace P., and **Huebner, Robert J.** Foci of polyoma virus infection in house mice *1023
Rubin, Albert L. See SPRITZ, COHEN and RUBIN *1030
Rubin, Cyrus E., Brandborg, Lloyd L., Flick, Arnold L., Parmentier, Cherill, Phelps, Patricia and **van Niel, Sally.** The effect of wheat instillation into the proximal ileum of patients with idiopathic sprue *1023
Rubini, Joseph R., Cronkite, Eugene P., Bond, Victor P., and **Fliedner, T. M.** The metabolism and fate of tritiated thymidine in man 909
Rudman, Daniel, Di Girolamo, Mario, Seidman, Floyd, and **Reid, Maria B.** Purification and properties of a pituitary component which produces lipemia in the rabbit *1023

S

Sackner, Marvin A., Schnabel, Truman G., Jr., Allan, Mary B., and **Lewis, David H.** Inferior vena cava blockade: A method for studying circulatory dynamics *1023
Saffan, Benjamin D. See BROWN, SAFFAN and PREEDY *975
St. George, Shirley. See FRIEDMAN, ST. GEORGE, BYERS and ROSENMAN 758
Samberg, L. Carl. See LEWIS, MCELROY, HAYFORD-WELSING and SAMBERG 1345
Sandberg, Avery A., Hauschka, Theodore S., Gordy, Edwin, and **Koepf, George F.** Chromosome constitution in human gonadal disorders *1024
—, **Slaunwhite, W. Roy, Jr.,** and **Carter, Anne C.** Transcortin: A corticosteroid-binding protein of plasma. III. The effects of various steroids 1914

Sandor, Thomas. See GENEST, NOWACZYNSKI, KOIW and SANDOR *989
Sandson, John, and **Hamerman, David.** Nondialyzable hexose of human synovial fluid 782
Sanford, Jay P., Hunter, Betty W., Windom, Robert E., and **Hogan, Janet C.** Role of immunity in the genesis of experimental chronic pylonephritis *1024
Sarnoff, Stanley J., Mitchell, Jere H., and **Gilmore, Joseph P.** The effect of changes in atrial systole on the relation between mean atrial pressure and stroke work *1025
Savard, Kenneth, Dorfman, Ralph I., Baggett, Billy, Fielding, Linda L., Engel, Lewis L., McPherson, Harry T., Lister, Leonard M., Johnson, David S., Hamblen, Edwin C., and **Engel, Fránk L.** Clinical, morphological and biochemical studies of a virilizing tumor in the testis 534
Savitsky, J. Philip. Quantitative studies of a prolonged alteration of serum cholesterol induced by desoxyibonucleic acid *1025
Sawyer, William D., Fletcher, Anthony P., Alkjaersig, Norma, and **Sherry, Sol.** Studies on the thrombolytic activity of human plasma 426
Scarlata, Robert W. See GREENBERG, WONG, MILLER, SCARLATA and CHALMERS *992
Schachter, David, Dowdle, Eugene B., Schenker, Harris, and **Kimberg, Daniel V.** Vitamin D and the active transport of calcium *1025
Schapira, Georges. See KRUH, DREYFUS, SCHAPIRA and GEY 1180
Schedl, Harold P., and **Bartter, Frederic C.** An explanation for and experimental correction of the abnormal water diuresis in cirrhosis 248
Schenker, Harris. See SCHACHTER, DOWDLE, SCHENKER and KIMBERG *1025
Schenker, Steven. See WARREN and SCHENKER *1039
Scherbel, Arthur L., McKittrick, Roy L., and **Hawk, William A.** Lesions in rats caused by serotonin and histamine before and after amine oxidase inactivation and serotonin inhibition *1025
Schilb, Theodore P. See BRODSKY and SCHILB *974
Schmid, Rudi. See LIEBER, DECARLI and SCHMID *1007
Schmidt, Johann, and **Clifford, George O.** A sensitive test for the detection of coagulation abnormalities in hyperlipemia *1026
Schnabel, Truman G., Jr. See SACKNER, SCHNABEL, ALLAN and LEWIS *1023
Schnaper, Harold W. See FREIS, WANKO, SCHNAPER and FROHLICH 1277
Schoessler, Mary Anne. See SCHWARTZ, RASMUSSEN, SCHOESSLER, FONG and SILVER *1026
Schreiner, George E. See MARC-AURELE and SCHREINER 802
Schubert, Maxwell. See JOHNSON and SCHUBERT 1752
Schulman, Jerome L., and **Kilbourne, Edwin D.** The induction of heterologous immunity to influenza by aerosol administration of inactivated virus *1026
Schwartz, Irving L., Rasmussen, Howard, Schoessler, Mary Anne, Fong, Conrad T. O., and **Silver, Lawrence.** Relation of hormone-receptor bonding and antidiuretic action of vasopressin *1026
Schwartz, Robert, and **Dameshek, William.** The effects of 6-mercaptopurine on homograft reactions 952
Schwartz, William B. See BANK and SCHWARTZ *970
—. See BANK and SCHWARTZ 1516
—. See RELMAN, PORTER, TOBIAS and SCHWARTZ 1551
Scott, E. M. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia 1176
Scribner, Belding H., Buri, Rachit, and **Caner, John E. Z.** Continuous hemodialysis as a method of preventing uremia in acute renal failure *1027
Seegmiller, J. E. See GRAYZEL, SEEGMILLER and LOVE 447
Segal, Stanton. See PESCH, SEGAL and TOPPER 178
—, **Berman, Mones,** and **Blair, Alberta.** The metabolism of variously C^{14}-labeled glucose and an estimation of the extent of glucose metabolism by the hexosemonophosphate shunt pathway in man *1027
Seidman, Floyd. See RUDMAN, DI GIROLAMO, SEIDMAN and REID *1023
Seldin, Donald W. See RECTOR, ROBERTS, SMITH and SELDIN *1019
—. See RECTOR, SELDIN, ROBERTS and SMITH 1706
Seltzer, Holbrooke S., and **Smith, Walter L.** Effects of glucose, sulfonylureas and other hypoglycemic agents on insulin activity in pancreatic venous blood *1027
Sha, Joanne. See GITLOW, MENDLOWITZ, KHASSIS, COHEN and SHA 221
Shafer, A. William. See BARTLETT and SHAFER 62
—, and **Bartlett, Grant R.** Effect of inosine on the post-transfusion survival of stored rabbit erythrocytes 69
Shafrir, Eleazar, and **Steinberg, Daniel.** The essential role of the adrenal cortex in the response of plasma free fatty acids, cholesterol, and phospholipids to epinephrine injection 310
Shapiro, Alvin P. Effect of hypotensive drugs on the pressor response to noxious stimuli *1028
Shelokov, Alexis I., Craighead, John, and **Brody, Jacob.** Type 2 poliovirus infection and disease in Panama City *1028
Shepherd, John T. See WANG, SHEPHERD and MARSHALL 466
—. See WANG, MARSHALL and SHEPHERD 1051
Sheps, Mindel C. See RENOLD, MARTIN, DAGENAIS, STEINKE, NICKERSON and SHEPS 1487
—, **Nickerson, Rita J., Dagenais, Yves M., Steinke, Jurgen, Martin, Donald B.,** and **Renold Albert E.** Measurement of small quantities of insulin-like activity using rat adipose tissue. II. Evaluation of performance 1499
Sherlock, S. See IBER, KERR, DÖLLE and SHERLOCK 1201
Sherry, Sol. See SAWYER, FLETCHER, ALKJAERSIG and SHERRY 426
Shrago, E. See FALCONE, MAO and SHRAGO *984
Shulman, N. Raphael, Aster, Richard H., Leitner, Alfred, and **Hiller, Merilyn C.** A new syndrome of post-transfusion immunologic purpura *1028
Shuster, Allen. See BOLLET and SHUSTER 1114
Siegel, Alan C. See POTTER, STOLLERMAN and SIEGEL *1018
Sieker, H. O. See MANFREDI and SIEKER 295
—. See KILBURN and SIEKER *1001
Silver, Lawrence, Robertson, James S., and **Dahl, Lewis K.** Magnesium turnover in the human studied with Mg^{28} 420
—. See SCHWARTZ, RASMUSSEN, SCHOESSLER, FONG and SILVER *1026
Simpson, D. P. See VANDERLAAN and SIMPSON *1037
Siperstein, Marvin D. See FOSTER and SIPERSTEIN *986
Sjoerdsma, Albert. See OATES, GILLESPIE, CROUT and SJOERDSMA *1015

Slaunwhite, W. Roy, Jr. See SANDBERG, SLAUNWHITE and CARTER 0000
Slingerland, D. Ward. See BURROWS, SLINGERLAND, LIUZZI, DELL and GRAHAM *975
Smith, Carlisle. See LANGE, SMITH and HECHT 1413
Smith, Gene M. See WADDELL, ZUIDEMA and SMITH 834
Smith, Jerry S. See RECTOR, ROBERTS, SMITH and SELDIN *1019
—. See RECTOR, SELDIN, ROBERTS and SMITH 1706
Smith, Lloyd H., Jr., and **Baker, Faith A.** Pyrimidine metabolism in man. III. Studies on leukocytes and erythrocytes in pernicious anemia 15
—, and **Huguley, Charles M., Jr.** The enzymatic defect of orotic aciduria *1029
Smith, Richard T., Eitzman, Donald V., and **Miller, Billievelyn.** Qualitative differences in the immune response of infants and adults receiving Salmonella vaccines *1029
Smith, Walter L. See SELTZER and SMITH *1027
Snell, Eric S. See WHEELER, EPSTEIN, ROBINSON and SNELL 236
Snider, Thomas H. See LEWIS, REED, FURUSHO and SNIDER *1006
Soardi, Franco. See MARIN, STEFANINI, SOARDI, and MUELLER *1010
Sokal, Joseph E. See LOWE, AMBRUS, AMBRUS, MOSOVICH, MINK and SOKAL *1007
Sokoloff, Louis. See LEWIS, SOKOLOFF, WECHSLER, WENTZ and KETY 707
Solomon, A. K. See OKEN and SOLOMON *1015
Soodak, M. See MALOOF and SOODAK *1009
Spaet, Theodore H., Horowitz, Herbert I., and **Zucker-Franklin, Dorothea.** Reticulo-endothelial clearance of blood thromboplastin in rats *1029
Spencer, E. Martin. See STEIN, FORKNER, SPENCER, ROBIN and KURLAND *1031
Spickard, Warren B. See HULTGREN, SPICKARD and HELLRIEGEL *998
Spink, Wesley W., and **Landeryou, Mary Jean.** Diminution in renal alkaline phosphatase in endotoxin shock 302
Sprinz, Helmuth. See GANGAROSA, BEISEL, BENYAJATI and SPRINZ *988
Spritz, Norton, Cohen, Burton D., and **Rubin, Albert L.** Demonstration of increased proactivator in induced fibrinolytic states *1030
Sproule, Brian J., Mitchell, Jere H., and **Miller, William F.** Cardiopulmonary physiological responses to heavy exercise in patients with anemia 378
—. See CHAPMAN, FISHER and SPROULE 1208
Stakelum, Geneva Sue. See COMBES and STAKELUM *978
—. See COMBES and STAKELUM 1214
Stamler, Jeremiah, Lindberg, Howard A., Berkson, David M., Hall, Yolanda, and **Miller, Wilda A.** Cholesterolemia, hypertension and coronary disease in Negroes compared with whites *1030
Stanbury, John B. See DOW and STANBURY 885
Stanfield, C. Alpheus, Luria, Milton N., Finlayson, James K., Lovejoy, Frank W., Jr., and **Yu, Paul N.** The effects of acetylcholine on pulmonary circulation and alveolar gas exchange *1031
Stanley, Malcolm M., Ball, C. Edwin, and **Jaegers, Kenneth R.** Secretion *in vitro* of recently absorbed cholesterol and absorption of cholesterol *in vivo* and *in vitro* by the rat small intestine *1031
Staub, Max C. See DINGMAN, GAITAN, STAUB, ARIMURA and PETERSON *981
Steele, J. Murray. See LESSER, PERL and STEELE 1791
Stefanini, Mario. See MARIN, STEFANINI, SOARDI and MUELLER *1010
Stein, Myron, Forkner, Claude E., Jr., Spencer, E. Martin, Robin, Eugene D., and **Kurland George S.** Alterations of cardiopulmonary physiology following acute experimental pulmonary embolism *1031
Stein, Samuel W., Abelmann, Walter H., Lieber, Charles S., Leevy, Carroll M., and **Cherrick, Gilbert R.** Hepatic and systemic blood flow in man during intravenous infusion of ethanol *1032
Stein, William H. See BRIGHAM, STEIN and MOORE 1633
Steinberg, Daniel. See SHAFRIR and STEINBERG 310
—, **Avigan, Joel,** and **Feigelson, Eugene B.** The mechanism of action of MER-29 *1032
—. See RADDING and STEINBERG 1560
Steinke, Jurgen. See RENOLD, MARTIN, DAGENAIS, STEINKE, NICKERSON and SHEPS 1487
—. See SHEPS, NICKERSON, DAGENAIS, STEINKE, MARTIN and RENOLD 1499
Stenhagen, Stina. See HALLGREN, STENHAGEN, SVANBORG and SVENNERHOLM 1424
Sterling, Kenneth, and **Tabachnick, Milton.** Free and bound thyroxine of serum 1032
—. The effect of Cushing's syndrome upon serum albumin metabolism 1900
Stevenson, Charles C. See MOGHISSI, NEUHAUS and STEVENSON 1358
Stevenson, G. T. Detection in normal urine of protein resembling Bence Jones protein 1192
Stirman, J. A. See MUIRHEAD, STIRMAN and JONES 266
Stohlman, Fredrick, Jr., Brecher, George, and **MacKinney, Archie A.** Polycythemic response to erythropoietine compared with a short-term assay *1032
Stollerman, Gene H. See POTTER, STOLLERMAN and SIEGEL *1018
Stoloff, Irwin L. Fluorescence microscopy in diseases of the thyroid gland *1033
Stormont, James M., and **Waterhouse, Christine.** The hyponatremia associated with marked over-hydration and water intoxication *1033
Strickland, William. See MADISON, COMBES, ADAMS and STRICKLAND 507
Suchinsky, Richard T. See FINLAYSON, SUCHINSKY and DAYTON 1837
—. A study of eight heated plasma protein preparations 1953
Sullivan, Robert D., Miller, Edward, Wood, A. Michael, Clifford, P. P., and **Duff, John.** Antimetabolite-metabolite cancer chemotherapy: Effects of intra-arterial methotrexate-intramuscular citrovorum factor therapy *1034
Summerskill, W. H. J. See CLOWDUS, HIGGINS, ORVIS and SUMMERSKILL *977
Svanborg, Alvar. See HALLGREN, STENHAGEN, SVANBORG and SVENNERHOLM 1424
Svennerholm, Lars. See HALLGREN, STENHAGEN, SVANBORG and SVENNERHOLM 1424
Swan, H. J. C., and **Kitchin, Arthur H.** Pressure-flow relations in a portion of the pulmonary vascular bed, the wedge segment *1034
Swisher, Scott N. See TROUP, REED, MARINETTI and SWISHER 342

—. See Reed and Swisher *1019
Szanto, Paul B. See Kushner, Szanto and Dubin *1003

T

Tabachnick, Milton. See Sterling and Tabachnick *1032
Takeda, Y., Plough, I. C., and **Reeve, E. B.** Excretion of the radioactive catabolic end products of I^{131}-albumin in human sweat *1034
Talley, Robert C. See Burrows, Niden, Mittman, Talley and Barclay 943
Talmage, David W. See Bernhard and Talmage *972
Tanaka, Kouichi R., Valentine, Wi'liam N., and **Fredricks, Robert E.** Arylsulfatase activity of human leukocytes: Distinctive pattern in eosinophils *1034
—. See Fredricks, Tanaka and Valentine 1651
Tarail, R., and **Bennett, T. E.** On the nature of the hypoglycemic effect of Tris(hydroxymethyl)-aminomethane (Tris buffer) *1035
Taylor, Frederic F. See Faloon, Taylor, Hellman and Ohanessian *984
Terepka, A. Raymond, and **Chen, Philip S., Jr.** A physiological and biochemical comparison of crystalline dihydrotachysterol (AT-10) with Hytakerol *1035
Thompson, David D. See Frimpter and Thompson *987
Thygeson, Phillips. See Jawetz, Thygeson, Hanna, Dawson and Mitsui *1000
Tillett, W. S. See Lawrence, Rapaport, Converse and Tillett 185
Timmis, Gerald C. See Regan, Timmis, Frank, McGinty and Hellems *1020
Tingley, John O. See Hill, Barker, McNeil, Tingley and Hibbett 523
Tobian, Louis. Prevention of Stokes-Adams attacks with chlorothiazide and salt *1035
Tobias, James F. See Relman, Porter, Tobias and Schwartz 1551
Tomkins, Gordon M. See Yielding, Tomkins and Munday *1041
Topper, Yale J. See Pesch, Segal and Topper 178
Trams, Eberhard G., and **Brady, Roscoe O.** Cerebroside synthesis in Gaucher's disease 1546
Trapani, Robert-John. See Landy, Trapani and Rosen 352
Trapasso, Mary. See Davis, Carroll, Trapasso and Yankopoulos 1463
Troup, Stanley B., Reed, Claude F., Marinetti, Guido V., and **Swisher, Scott N.** Tromboplastic factors in platelets and red blood cells: Observations on their chemical nature and function in *in vitro* coagulation 342
Troupkou, V. See Edelmann, Barnett and Troupkou 1062
Trout, D. L. See Friedberg, Harlan, Trout and Estes 215
—. See Friedberg, Klein, Bogdonoff, Estes and Trout *987
—. See Friedberg, Klein, Trout, Bogdonoff and Estes 1511
Ts'o, P. O. P. See Edelman, Ts'o and Vinograd *982
Turino, Gerard M. See Rigatto, Turino and Fishman *1021
Turner, Joseph C. See Anderson and Turner 1
Tyler, John M. The effect of progesterone on the respiration of patients with emphysema and hypercapnia 34
Tyor, Malcolm P. See Owen, Tyor, Flanagan and Berry 288
—, **Horswell, Richard R.,** and **Owen, Edward E.** Absorption of I^{131}-labeled triolein following intraduodenal administration: The relative effect of intestinal hormones, secretagogues and pancreatic enzymes *1036
Tyson, Ian. See Levinsky, Tyson and Relman *1005

U

Ulick, Stanley. See Laragh, Ulick, Januszewicz, Deming, Kelly and Lieberman 1091
Ulmer, David D. See Wacker and Ulmer *1038
Unger, R. H., Eisentraut, A. M., McCall, Mary S., and **Madison, L. L.** The hormonal role of endogenous glucagon in blood: Glucose homeostasis as demonstrated by a specific immunoassay *1036
Utz, John P. The pathogenesis of viruria: Animal kidney infection by viruses isolated from human urine *1037

V

Valentine, William N. See Tanaka, Valentine and Fredricks *1034
—. See Fredricks, Tanaka and Valentine 1651
VanderLaan, W. P., and **Simpson, D. P.** Restoration by growth hormone of normal responses to fasting in a pituitary dwarf *1037
van Niel, Sally. See Rubin, Brandborg, Flick, Parmentier, Phelps and van Niel *1023
Varvis, C. J. See Bates, Varvis, Donevan and Christie 1401
Vaughan, John. See Harris and Vaughan *995
Vester, John W. See Robin, Vester, Wilson and Andrus *1022
Vick, James A. Physiological and pharmacological studies on the reversibility of endotoxin shock in dogs *1037
Victor, Maurice. The role of nutrition in the alcoholic neurological diseases *1037
Vinograd, J. See Edelman, Ts'o and Vinograd *982
Vogel, William C., and **Zieve, Leslie.** A lecithinase A in duodenal contents of man 1295

W

Wacker, Warren E. C., and **Ulmer, David D.** Reciprocal relationship between magnesium and calcium metabolism in tetany *1038
Waddell, William R., Zuidema, George D., and **Smith, Gene M.** Catechol amine excretion by duodenal ulcer patients 834
Wagman, R. J. See Messer, Wagman, Levine, Neill and Gorlin *1011
Waldhausen, John A. See Ross, Waldhausen and Braunwald 930
—. See Ross, Braunwald and Waldhausen 937
Wallace, John M. The removal of norepinephrine (NE) from the blood stream by the extremities of man *1038
Wallach, Donald F. H. See McMenamy, Lund, Neville and Wallach 1675
—. See McMenamy, Lund and Wallach 1688

Wallmark, Gosta, and **Barnes, Mildred W.** Changes in phage types of *Staphylococcus aureus* in a general hospital, 1952 to 1959 *1038
Walser, Mackenzie. Protein-binding of inorganic phosphate in plasma of normal subjects and patients with renal disease 501
Wang, Yang, Shepherd, John T., and **Marshall, Robert J.** Evaluation of the slope-volume method as an index of pulmonary blood volume 466
—, **Marshall, Robert J.,** and **Shepherd, John T.** The effect of changes in posture and of graded exercise on stroke volume in man 1051
Wanko, Annemarie. See FREIS, WANKO, SCHNAPER and FROHLICH 1277
Warren, Kenneth S., and **Schenker, Steven.** Hypoxia and ammonia toxicity *1039
Wasi, Prawase. See HAIBY, WASI and BLOCK *994
Waterhouse, Christine. See STORMONT and WATERHOUSE *1033
Watkin, Donald M. See BERLIN and WATKIN *971
—. See WEINSTEIN and WATKIN 1667
Watson, John F., Cherniack, Neil S., and **Zechman, Fred W.** Respiratory mechanics during forward acceleration 1737
Wechsler, Richard L. See LEWIS, SOKOLOFF, WECHSLER, WENTZ and KETY 707
Weinstein, I. Bernard, and **Watkin, Donald M.** $Co^{58}B_{12}$ absorption, plasma transport and excretion in patients with myeloproliferative disorders, solid tumors and non-neoplastic diseases 1667
Weinstok, Herman. See GIORDANO, WEINSTOCK and MERRILL *990
Weisman, Russell, Jr. See GRIGGS, WEISMAN and HARRIS 89
Weissler, Arnold M. See BOGDONOFF, WEISSLER and MERRITT 959
Weissmann, Gerald, Potter, Jacobus L., McElligott, Frank, Meltzer, Martin, and **McCluskey, Robert T.** Binding of papain protease by alpha-globulin of rabbit and human serum *1039
—, and **Weissmann, Sigmund.** X-ray diffraction studies of human aortic elastin residues 1657
Weissmann, Sigmund. See WEISSMANN and WEISSMANN 1657
Wells, Raymond, Jr. See CHODOS, CHAFFEE and WELLS *977
Welt, Louis G. See WOODS, WELT, HOLLANDER and NEWTON 28
Wentz, W. Budd. See LEWIS, SOKOLOFF, WECHSLER, WENTZ and KETY 707
Wessler, Stanford, and **Reimer, Stanley M.** The role of human coagulation factors in serum-induced thrombosis 262
—. See DEYKIN, WESSLER and REIMER *981
Wheeler, Henry O., and **Ramos, Oswaldo L.** Determinants of the flow and composition of bile in the unanesthetized dog during constant infusions of sodium taurocholate 161
—, **Epstein, Robert M., Robinson, Roscoe R.,** and **Snell, Eric S.** Hepatic storage and excretion of sulfobromophthalein sodium in the dog 236
—, **Mancusi-Ungaro, Pier L.,** and **Whitlock, Robert T.** Bile salt transport in the dog *1039
—, **Meltzer, Jay I.,** and **Bradley, Stanley E.** Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease 1131
—. See JAVITT, WHEELER, BAKER, RAMOS and BRADLEY 1570
Whitby, L. G., and **Lang, Daphne.** Experience with the chromic oxide method of fecal marking in metabolic balance investigations on humans 854
Whitcomb, Fred F., Jr. See HOFFMAN, WHITCOMB, BUTT and BOLLMAN 132
Whitlock, Robert T. See WHEELER, MANCUSI-UNGARO and WHITLOCK *1039
Williams, Bettie Z. See GARDNER, WRIGHT and WILLIAMS *988
Williams, W. C., Jr., Oldfield, R. A. A., Jr., Island, D. P., and **Liddle, G. W.** Blood ACTH in Cushing's disease *1040
Wilner, T. See IZAK, WILNER and MAGER 1763
Wilson, Ella Gray. See FERGUSON, WILSON, IATRIDIS, RIERSON and JOHNSTON 1942
Wilson, Robert J. See ROBIN, VESTER, WILSON and ANDRUS *1022
Wilson, William R., and **Bedell, George N.** The pulmonary abnormalities in myxedema 42
Wiltz, Charles J. See BERTLES, WILTZ and BECK *972
Windom, Robert E. See SANFORD, HUNTER, WINDOM and HOGAN *1024
Wintrobe, M. M. See MAUER, ATHENS, ASHENBRUCKER, CARTWRIGHT and WINTROBE 1481
Wojtczak, Andrzej. See HANDLER, WOJTCZAK and GOLDBERG *994
Wolfman, Morris. See GROSSMAN, ROSENBLUM, LAU and WOLFMAN *993
Wong, Helena. See GREENBERG, WONG, MILLER, SCARLATA and CHALMERS *992
Wood, A. Michael. See SULLIVAN, MILLER, WOOD, CLIFFORD and DUFF *1034
Wood, Francis C., Jr. See CAHILL, WOOD, LEBOEUF and RENOLD *976
Wood, J. Edwin, and **Bass, David E.** Responses of the veins and arterioles of the forearm to walking during acclimatization to heat in man 825
—. Absence of the normal peripheral venoconstrictor response to infusions of synthetic angiotensin II in patients with essential hypertension *1040
Woods, James W., Welt, Louis G., Hollander, Walter, Jr., and **Newton, Margaret.** Susceptibility of rats to experimental pyelonephritis following recovery from potassium depletion 28
—. Susceptibility to experimental pyelonephritis when hormonal hypertension is prevented by hypotensive drugs 1813
Wright, Claude-Starr. See GARDNER, WRIGHT and WILLIAMS *988
Wu, Nancy. See MILLER, CUSHING and WU *1012
Wyngaarden, James B. See HOWELL, ASHTON and WYNGAARDEN *997
—. See ELDER and WYNGAARDEN 1337

Y

Yachnin, Stanley, and **Gardner, Frank H.** Normal serum hemolysins *1040
Yalow, Rosalyn S., and **Berson, Solomon A.** Immunoassay of plasma insulin concentrations in normal and diabetic man: Insulin secretory response to glucose and other agents *1041
—, and **Berson, Solomon A.** Immunoassay of endogenous plasma insulin in man 1157

Yamashita, F. See YOSHIDA, YAMASHITA, KAISER and METCOFF *1041
Yankopoulos, Nicholas A. See DAVIS, YANKOPOULOS, LIEBERMAN, HOLMAN and BAHN 765
—. See DAVIS, CARROLL, TRAPASSO and YANKOPOULOS 1463
Yielding, K. Lemone, Tomkins, Gordon M., and **Munday, Janet S.** The mechanism of the steroid inhibition of pyruvate oxidation *1041
Yoshida, T., Yamashita, F., Kaiser, E., and **Metcoff, J.** Glycolytic and citric acid cycle metabolites related to intracellular ion composition in the experimental nephrotic syndrome *1041
Yu, Paul N. See STANFIELD, LURIA, FINLAYSON, LOVEJOY and YU *1031

Z

Zechman, Fred W. See WATSON, CHERNIACK and ZECHMAN 1737
Zeffren, J. Lester, and **Heinemann, Henry O.** The effects of hypercalcemia on the renal concentrating mechanism in man *1042
Zierler, Kenneth L. The poorly-permeable membrane as an alternative to the carrier hypothesis of facilitated diffusion *1042
Zieve, Leslie. See VOGEL and ZIEVE 1295
Ziff, Morris, Gribetz, H. Joel, and **Lospalluto, Joseph.** Effect of leukocyte and synovial membrane extracts on cartilage mucoprotein 405
—. See LOSPALLUTO, CHEGORIANSKY, LEWIS and ZIFF 473
—. See HESS and ZIFF *996
Ziffer, Herman. See LEEVY, GEORGE, ZIFFER and BAKER *1005
Zingale, S. B. See LEE, MEISELAS, ZINGALE and RICHMAN *1005
Zinneman, Horace H. See GLENCHUR, ZINNEMAN and HALL *990
Zucker-Franklin, Dorothea. See SPAET, HOROWITZ and ZUCKER-FRANKLIN *1029
Zuidema, George D. See WADDELL, ZUIDEMA and SMITH 834
Zweig, Paul H. See LATHEM, DAVIS, ZWEIG and DEW 840

(Page numbers marked with an asterisk refer to abstracts)

A

Acatalasemia, 610–619
Acceleration, and respiratory mechanics, 1737–1743
Acetamide, transport after vasopressin, 995*
in toad bladder, 633
Acetates
See also specific acetates
acetoacetic acid from, 647
and cholesterol synthesis, 642–652, 1566
in peripheral nerves, 112–113
and fatty acid synthesis, 647, 648, 996*, 1007*
ketone bodies from, 648
in lipoprotein-protein synthesis, 1566
metabolism in adrenal insufficiency, 996*
oxidation to carbon dioxide, 647, 648
Acetazolamide
and bicarbonate, reabsorption, 1522–1557, 1708–1717
and bile flow, 164–169
carbonic anhydrase inhibition, 1551, 1708–1710
diuretic effects, 1714
and of analog (CL 8490), 1551–1559
and sodium sulfate, 485, 486
in hepatic encephalopathy, 1252–1256
neurologic deterioration, 1251
and renal concentrating ability, 1303–1310
and respiratory acidosis, 1713
toxicity, 1255, 1256
Acetoacetyl coenzyme A
in cholesterol synthesis pathway, 646, 649–651
in fatty acid synthesis, 646, 647
Acetylcholine
and alveolar gas exchange, 1031*
cardiopulmonary responses, 1001*
and di-isopropylfluorophosphate, 1750
and glucose oxidation, 986*
neuromuscular effects, 1750
in myasthenia gravis, 992*
and pulmonary circulation, 1001*, 1031*
Acetyl coenzyme A
in cholesterol synthesis pathway, 646, 649–651
and ketone bodies, production, 986*
pyruvic acid oxidation to, 1041*
N-Acetyl hyalobiuronic acid, in synovial fluids, 786
Acetylphenylhydrazine
glutathione oxidation, 1826–1829
and hemoglobin, 1820–1826
Acetylstrophanthidin
and cardiopulmonary circulation, 1001*
and digitalis effects, 1887–1891
and peripheral vascular resistance, 932–935
and venous return, 938–942
Acetyltryptophanate
and plasma expanders, 699, 1954–1958
Ac-globulin
deficiency, 262–265
and bishydroxycoumarin, 981*
Achalasia, of esophagus, 1744–1751
Acidity, titratable of urine
after acetazolamide, 1713
after ammonium acetate, 336, 339
after ammonium chloride, 173
and anion penetrating ability, 970*, 1516–1525
after cesium, 174
after ferrocyanide, 970*, 1520–1521
and hydrogen ion excretion, 994*
passive diffusion, 1517, 1523, 1524
in hypercalcemic animals, 985*
and kidney failure, 1014*
in potassium-deficiency, 174
after rubidium, 174
after sodium chloride, 173, 174, 970*, 1518–1519, 1521
after sodium phosphate, 970*, 1516–1525
after sulfate, 970*, 1519–1520
after thiocyanate, 970*, 1522
Acidosis
and ammonium excretion, 174
and kidney function, 1014*
extracellular, 339
and cesium, 171–177
and rubidium, 171–177
during gastrodialysis, 655–656, 659
and hyperkalemia, 657
intracellular, 175
and kidney function, 1014*
and phosphate clearance, 995*
progesterone effect on, 37–39
respiratory, 1019*, 1713
and bicarbonate reabsorption, 1717
myocardial potassium and sodium exchange, 1012*
Acromegaly
adrenocorticotropic hormone response, 819–820
eosinophilic adenoma, 1007*
glucose tolerance test, 1166, 1168–1169, 1174
ACTH. *See* Adrenocorticotropic hormone
Actomyosin, cardiac, in congestive failure, 1470
Addison's disease. *See* Adrenal gland, insufficiency
Adenine
and platelet storage, 970*
reticulocyte nucleotide labeling, 972*
Adenosine
diphosphate, 57
and erythrocyte storage, 57–71
phosphorus transfer to, 59
triphosphate, 63–71
in cholesterol synthesis pathway, 646, 649–651
and fatty acid esterification, 154, 159
and palmitate esterification, 152, 153
and phospholipid synthesis, 157
and pyrophosphate in erythrocytes, 1765–1769
synthesis, 59
Adrenalectomy
and blood glucose, 312–318
and blood pressure, 1097
and corticosterone, turnover rate, 749, 754
and digitalis effects, 932
and epinephrine responses, 310, 313–318
and orthostatic stress, 607–609
and plasma lipids, 313–318, 607–609
and retinal hemorrhage clearance, 1097
Adrenal gland
adenoma, 1094–1096
blood flow, 768, 770, 774
cortex
and acetate metbolism, 996*
and adrenocorticotropic hormone, 313–318, 371–374, 601, 604, 766–767, 816, 819–820, 906, 981*, 1102, 1104
aldosterone secretion, 765–775, 981*, 989*, 1091–1106, 1331–1333
in cirrhosis, 329
in dichorionic monozygotic triplets, 620–625
hyperfunction, 976*, 1040*, 1900–1908
hyperplasia, 364–377, 904–907, 1094–1096, 1102, 1906–1907
hypothalamic-pituitary stimulation, 317
and interstitial cell testicular tumors, 548–549
and malignant hypertension, 1104
and nervous system stimulation, 982*
and plasma 17-hydroxycorticosteroid levels, 601, 604, 982*
steroids. *See* Steroids, adrenal cortical
in glucose-6-phosphate dehydrogenase inhibition, 1010*
insufficiency, 1855–1857
growth hormone effects, 1224, 1233
transcortin binding after stilbestrol, 1922–1925
and vasopressin release, 1851–1853, 1862–1863
medulla, 317
and epinephrine synthesis, 1927–1930
and plasma lipids, 310–319
and steroid biosynthesis, 979*

stress response to centrifugation, 1534–1538
in thermal burn, 1927–1932
weight, 1102, 1192
Adrenaline. *See* Epinephrine
Adrenocorticotropic hormone
and adrenal glands, 313–318, 601, 604, 620–625, 981*
in adrenogenital syndrome, 371–374, 819–821
in aldosterone secretion, 765–767, 770–774, 1102, 1104
and corticosterone, 748
turnover rate, 749
and cortisol, 822
extrahypothalamic releasing center, 982*
and glucose metabolism in adipose tissue, 1496
and insulin, placental degradation, 125–126
and plasma corticoids, 601, 604, 816–824
secretion, 765, 906, 1040*
and sodium balance, 981*
and transcortin cortisol binding, 1915–1926
Adrenogenital syndrome
adrenocorticotropic hormone tests, 819–820
urinary steroids, 364–377
Agammaglobulinemia
antibody erythrocyte destruction in, 1148–1151
heredity factor, 987*
Age
and adrenocorticotropic hormone clearance, 818–819
and airway resistance, 585
and aortic elastin residues, 1660–1666
of bone, 1224–1225
in hypopituitarism, 1226–1229
and calcium transfer after vitamin D, 1025*
and catecholamines in ganglioneuroma, 1731
and cerebral blood flow, 494–496
and cystine stone formation, 1003*
of erythrocytes. *See* Erythrocytes, aging
and fat-free body density, 629
and forced voluntary ventilation, 589
hypertonicity and urea production, 1067
and β-lipoprotein serum levels, 1865–1872
and loop of Henle length, 1062
and lung elastin, 9–14
and membrane diffusion components, 1405, 1410–1411
and nitrogen excretion as urea, 1067
precocious puberty, chromosomes, 1024*
and pulmonary capillary blood, 1405, 1410–1411
and renal phosphatase, 303
and Salmonella vaccine response, 1029*
and thyroxine metabolism, 1592–1594
and urine osmolality, 1068
and water reabsorption, 1068
Agglutination
erythrocytes, 1145
chick, with DA virus, 998*
and destruction, 1149–1150, 1153, 1155
donor cells with ABO isoantibodies, 1011*
and enteroviruses, 1017*
hemolysis capacity, 1040*
serum anti-thyroglobulin activity, 1260, 1264
latex fixation test, 972*
penicillinized cells, 995*
persistence, after brucella, 990*
of platelets post-transfusion, 1029*
of rheumatoid leukocytes, 996*
after Salmonella vaccines, 359–360, 1029*
L-Alanine
and blood glucose concentration, 993*
in erythrocytes, 1690–1691
in leukocytes, 1679, 1680, 1693–1698
in plasma, 987*, 1634–1635, 1689–1691
temperature effects on distribution, 1680
urinary excretion, 1677, 1681, 1697–1698
Albumin
and blood thromboplastin, 1030*
cellulose adsorption, 1164
in cervical mucus, 1361–1362
excretion, in sweat and urine, 1034*
fatty acid uptake, 436–439, 731
and glucose oxidation, 1494
in hypertension, 1094–1097
immunologic reactions, 700–704, 1361–1362
indocyanine green binding, 595
in lymph fluids, 1921–1922
metabolism in Cushing's syndrome, 1900–1908
and palmitate esterification, 738, 739
in plasma. *See* Plasma, albumin
in plasma expanders, 698–705, 1837–1840, 1958–1961
quinidine-interaction, 978*–979
in serum. *See* Serum, albumin
storage, long-term effects, 1837–1840
turnover and half-times, in schizophrenia, 1901–1902
Alcohol
and behavior patterns, 760–762
and carbohydrate metabolism, 999*–1000
and catecholamine discharge, 763
and coronary artery disease, 763
dialysance, 802–807
enzyme activity inhibition, 999*
and fatty acid synthesis, 1007*
and liver, 1007*, 1646
blood flow, 1032*
cirrhosis, 1005*, 1653, 1848–1849
fatty, 1006*
galactose inhibition, 999*
metabolism, individual variation, 805
and nutrition in neurologic diseases, 1037*
and oxytocin action, 969*
protein-bound hexose precipitation, 787–788
and quinidine-albumin binding, 979*
and splanchnic blood flow, 776–781
Aldactone (spironolactone), and serum electrolytes, 977*
Aldosterone
metabolism, 773–774
in liver disease, 323–324, 327, 971*
secretion
and adrenal glands, 765–775, 981*, 989*, 1091–1106, 1331–1333
and anterior pituitary function, 765–775, 981*
and carotid, constriction, 1330–1332
after caval constriction, 770–774, 776, 1334, 1335
in cirrhosis, 329, 971*
and Hering reflexes, 1332, 1333
in hypertension, 1091–1106
neurohormone control theory, 1334–1335
and peripheral arterial pressure, 1331
and tetrohydroaldosterone excretion, 1100
and thyrocarotid arterial junction denervation, 1333, 1335
and sodium intake, 329, 770
and transcortin cortisol binding, 1921–1924
unconjugated metabolites, 1924–1925
urinary excretion, 329, 772, 971*, 989*
Aldosteronism, primary, 1094, 1095–1096, 1104, 1105
Alkaline phosphatase. *See* Phosphatase, alkaline
Alkalosis
and aldosterone secretion, 1094–1098
and carbon dioxide, 1255
in liver disease, 1247, 1253, 1255, 1256
in potassium depletion, 31, 175, 686
respiratory, 1255, 1256
and bicarbonate reabsorption, 1717
Allo-dihydrodesoxycorticosterone acetate, 369, 372
Allotetrahydrocorticosterone
turnover, after adrenocorticotropic hormone, 749
urinary excretion, 748, 752, 753
Allotetrahydrocortisol, urinary excretion, 748, 752
Allotetrahydrocortisone, urinary, in adrenal hyperplasia, 906–907
Altitude
plasma, erythropoetin, and erythropoiesis, 1033*
and pulmonary edema, 998*
Alveolus
ammonia gas tension, 332, 335
carbon dioxide, 51, 297
in myxedema, 44, 47, 52–54
after progesterone, 34, 37
carbon monoxide disappearance, 796

Alveolus (*cont'd*)
diffusing capacity, 52
and capillary permeability, 42, 53
non-uniformity, 946–951
in emphysema, 34, 37, 1080–1081
helium disappearance, 796
krypton transport, 1081–1083
nitrous oxide absorption, 1021*
in obesity, 44, 49, 54
surface tension, 1350
and smoking, 974*
ventilation, 34, 37, 44, 54, 1080–1081
in anemia, and exercise, 379
and chest strapping, 578
and ethyl ether clearance, 1014*
volume, 796, 946–951
and posture, 795
American Society for Clinical Investigation
obituary, Gamble, James Lawder, following 705
proceedings of fifty-second annual meeting, 966–968
papers presented, 969*–1042*
Amine mustards, 973*
Amino acids
See also under specific names
activating enzymes, 1763–1770
in antibodies, 1938–1939
decarboxylation, inhibition, 1015*
in erythrocytes, 1679–1682, 1686
in polycythemia, 1763–1770
in Fanconi syndrome, 1390, 1635–1637
and hemoglobin, 1102
in cyanosis transmission, 989*
synthesis, 1109–1112
in idiopathic hypoglycemia, 993*
intracellular transport, and growth hormone, 1002*
labeled, 1002*, 1568
muscle protein metabolism, 1180–1183
and lecithin conversion to lysolecithin, 1297–1300
in leukemia, 1688–1705
in leukocytes, 1679, 1680, 1686
lipoprotein uptake, in nephrotic syndrome, 1568
in lung fibers, 12, 13
metabolism after leucine feeding, 993*
in plasma, 1633–1635, 1637, 1688–1689
unbound, 1676, 1679–1680, 1686
and potassium in muscle, 1005*
and serotonin, 1026*
in sulfobromophthalein conjugates, 1214, 1217–1218, 1222
in urine, 1002*, 1677, 1681–1686, 1697–1698
in cystine storage disease, 1390
in Fanconi syndrome, 1635–1637
in hypophosphatasia, 1389
E-Aminocaproic acid, and thrombolytic activity, 430–433
3-β-Aminoethypyrazole, and histamine, 680
5-Aminoimidazole ribotide, structural formula, 448
α-Aminoisobutyric acid, 1002*
β-Aminoisobutyric acid
in plasma, 1689
in urine, 1699
after thymidine, 909, 916, 917
α-Amino-*n*-butyric acid
in erythrocytes, 1690, 1691
in plasma, 1676, 1680, 1689, 1691
iodoacetate-treated, 1634–1635
urinary excretion, 1677, 1681, 1686
α-Amino nitrogen, excretion, 1390
Aminonucleoside, nephrosis, 981*, 1364
Ammonium
after acetazolamide, 288–294, 1252–1255
alveolar gas tension, 332, 335
in blood, 332–341
and arterial pH, 337, 1252–1255
arteriovenous differences, 289, 338, 1252–1255
in gastrointestinal tract, 972*
in hepatic coma, 1039*
pK'_α determination after, 332, 335
and sodium glutamate, 972*
and carbon dioxide tension, 335, 337, 1251–1256
cerebral, 1251–1256
in hypoxia, 1039*
in cerebrospinal fluid, 335–340
chloride, acidifying agent, 174–176, 687, 688, 1039*
excretion, 289
and acidosis, 174, 1014*
after cesium, 173–176
and kidney function, 288–294, 687, 688, 1014*, 1303–1310
in liver disease, 293, 972*, 1255
in potassium deficiency, 171–172, 174, 687, 688
after rubidium, 173–176
and urine pH, 173, 176, 336
in liver mitochondria, 1022*
and placental insulin, 122
toxicity, 973*, 1039*
Amyloidosis
and plasma thrombolytic activity, 429
serum gamma globulin components, 474, 477–480
Amylopectin sulfate, in serum β-lipoprotein determination, 1864–1873
Androgens
See also specific substances
and thyroxine-binding by globulin, 999*
and virilizing testis tumor, 534–553
1-Androstene-3,17-dione, in liver cirrhosis, 971*
4-Androstene-3,17-dione
in testis tumor, 535, 541, 546, 548, 551
and transcortin, g111
5-Androstene-3β-17β-diol, 541
Androsterone
in adrenogenital syndrome, 369
glucuronide conjugation by kidney, 978*, 1584–1589
in monozygotic dichorionic triplets, 620–625
in virilizing testicular tumor, 535, 538, 541, 546, 547, 551
Anemia
and amino acid activating enzymes, 1766–1769
cardiopulmonary responses to exercise, 378–388
Heinz body and red cell aging, 1000*, 1818–1819, 1832–1834
and iron absorption, 1006*
and leukemia, 1691
megaloblastic, 19, 1008*, 1029*
after nephrectomy, 274
and orotic aciduria, 19, 1029*
pernicious, pyrimidine metabolism in cells, 15–20
after phlebotomies, 994*
and riboflavin therapy, 1004*
Angiotensin II, in hypertension, 1040*
1,5-Anhydroglusitol, and bladder permeability, 632
Anhydrohydroxyprogesterone, 35
structural formula, 41
Anions
See also specific anions
penetrating ability, and urine acidification, 970*, 1516–1525
Anorexia and growth hormone therapy, 1230, 1233
Anthrone, erythrocyte reaction, 65, 66
Antibiotics
See also specific substances
gram-negative bacilli, 82
and staphylococcus strains, 1039*
Antibodies
albumin precipitable, 701–702
and antigens, 995*, 1018*, 1148–1153, 1933–1939
and macrocryogelglobulin, 1325
after penicillamine, 1326
after brucella hyperimmunization, 990*
to DA virus, 998*
to diphtheria toxin, 986*, 1938–1939
erythrocyte, 975*, 1011*
destruction, 1145–1156
storage effect, 1453, 1454
formation, 1006*
and endotoxin-detoxifying component, 352–362
and lipo-polysaccharide tolerance, 1002*
gamma globulin, 986*, 1596–1597, 1603, 1933–1941
in glomerulonephritis, 1003*
to horse serum, 1936–1939
insulin-binding, 1073, 1076
in nephrotic syndrome, 1596–1597
nitrogen, and genotype, 1454–1461
in pyelonephritis, 1024*
in rheumatoid arthritis, 1005*
in scleroderma, 1596–1597
in serum. *See* Serum, antibodies
specificity, 1018*, 1023*, 1938–1939
in streptococcal disease, 1003*, 1018*
to streptokinase, 1938–1940
in fibrinolysis, 1001*
in systemic lupus erythematosus, 1005*
to thyroglobulin, 1259–1265, 1603
transfer to recipient cells, 1011*
platelet reaction, 1029*
Anticholinesterase, 1750
in myasthenia gravis, 993*
Antidiuretic hormone. *See* Diuresis

Antigens
and antibody, 990*, 1018*, 1148–1153, 1325, 1326, 1933–1941
erythrocytes, 1452–1461
and insulin precipitation, 1075
in leukocyte extract, for sensitivity transfer, 193–194
from Mycobacterium tuberculosis, 985*
and plasma expanders, 698–704
pyelonephritis production, 1024*
in recipient cells, after transfusion, 1011*, 1029*
Salmonella, 360, 1029*
thyroid, 1033*, 1259, 1263, 1264
viral, 1026*
crossing with mumps and simian myxoviruses, 998*
trachoma, Asgh strain, 1000*
Antihemophilic factor, 262–265
and bishydroxycoumarin, 981*
in hemophilia A carrier, 1619–1625
after thromboplastin infusion, 977*
Antipyrine, and total body water measurement, 1798–1799
Aorta
atherosclerosis after hypothalamic stimulation, 994*
coarctation and arterial blood flow, 1414, 1416, 1422
constriction, and renal hypertrophy, 23–26
and urine osmolality, 867–868, 870–871
elastin residues, 1657–1666
pressures, after acetylstrophanthidin, 939
Aperistalsis, esophageal, 1744–1751
Arcus senilis, 760–762
Arfonad. *See* Trimethaphan
Arginine
in erythrocytes, 1690
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
excretion in cystinuria, 1002*
in leukemia, 1689, 1690, 1693–1695
in leukocytes, 1693–1695, 1697–1698
in plasma, 1634–1635, 1676, 1680, 1689
urinary excretion, 1677, 1681, 1686, 1697–1698
Arthralgia, in hypertension, 1094, 1096–1097
Arylsulfatase, in leukocytes, 1034*
Ascites
and cardiac myosin, 1464–1465
cortisol plasma clearance, 323
and electrolytes, 977*, 984*
in liver cirrhosis, 971*
and portal collateral blood flow, 1204
and proteinuria in nephrosis, 1366
Ascorbic acid
and chondromucoprotein viscosity, 407
and serum folic acid activity, 996*
Asiatic cholera, 988*
Asparagine, in plasma, 1634
Aspartate carbamyltransferase, in pyrimidine synthesis, 16–19
Aspartic acid
in deproteinized plasma, 987*
in erythrocytes, 1762–1765
in pyrimidine synthesis, 16–19
urinary excretion, 1677, 1681, 1686
Aspergillin O, thrombolytic activity, 1010*
Aspirin, and ventilation after progesterone, 33, 39, 40
Asthma
airway resistance, 587, 588–590
histamine metabolism in, 676–682
and lung vital capacity, 588–590
Atherosclerosis
cholesterol-induced, hypothalamic stimulation, 993*, 1964–1972
plasma thrombolytic activity, 429–430
and renal hypertension, 980*
serum β-lipoprotein levels, 1865–1872
Atrioventricular node, conduction block, 1885–1892
Atrium
fibrillation, 1878–1883
pressure, 940
and heat acclimatization, 825
after mephentermine, 997*
and stroke work, 825, 1025*
septal defect, 1406, 1410, 1416
Atropine
and airway conductance, 588, 590
and atrioventricular block, 1891–1892
Autotransplantation. *See* Transplant
Azaserine, structural formula, 447
Azide
and fatty acids, 984*
and vitamin B_{12}, 205–206, 212
Azotemia
aldosterone metabolites, excretion, 1102
after nephrectomy, 273–274
plasma phosphate, protein binding, 501–506

B

Bacilli. *See* Endotoxin
Behavior patterns, and hormonal excretion, 758–764
Bicarbonate
amniotic fluid exchange, 227–235
in bile, after taurocholate infusion, 164–169, 1039*
and carbon dioxide, 229–230, 1035*, 1709–1710
excretion, 1709–1713
fetal circulation kinetics, 227–235
and hydrogen exchange, 656
intramitochondrial concentration and pH, 1022*
and pancreatic juice flow rates, 1000*
in plasma and urine, 1709–1710
reabsorption, 1014*, 1706–1721
after acetazolamide, 1552–1553, 1713–1721
transfer during gastrodialysis, 655–656
Bile
after acetazolamide, 164–169
bilirubin conjugation, 141
common duct, 162–169
obstruction, 135–137, 141, 1138–1139
composition, 134, 135, 163–169
corticosterone metabolite excretion in, 746–747
fistula, 132, 134, 135, 1643–1649
flow, 161–169, 1139–1140
gallbladder, 134, 164
van den Bergh reaction, 140
after glutathione, 1577
indocyanine green clearance, 595–596
leucine aminopeptidase activity, 672–675
pH, 164–169, 1297
pigments in jaundice, 132–141
salts, 730–740, 1039*
See also specific salts
lecithin conversion to lysolecithin, 1297–1300
palmitate esterification, 732–734
secretion, 1040*
sulfobromophthalen, 1013*
conjugation, 1214–1222
excretion, 1013*, 1571–1573
transport mechanism, 1131–1143
after taurocholate, 161–170, 733–734, 1039*
Bilirubin
excretion in bile, 134–135, 139
fractionation pattern, 138, 141
in serum
in hepatic dysfunction, 135–141, 1643
and indocyanine green tests, 598
after nephrectomy, 134–135
in spherocytosis, hereditary, 90
3,4-*Bis*(3-ally-4-hydroxyphenyl)-hexane
and plasma 17-hydroxycorticosteroid levels, 1918–1924
and postmenopausal transcortin cortisol binding, 1918–1924
Bishydroxycoumarin, 981*
Bladder
permeability, 630–641, 1026*
rhythmicity, and micturition, 1018*
toad, 630–641, 995*, 1026*
turtle, 974*
Blood
amino acid activating enzymes, distribution, 1765–1766
ammonia, 289–293, 332–341
arteriovenous difference, 289, 299, 338, 1252–1255
bile pigment composition, 135
carbon dioxide tension, 35, 234, 299, 380–388
catalase activity, heredity factors, 610–619
coagulation
and acid citrate dextrose, 4–5
antihemophilic factor, 262–265, 977*, 981*, 1619–1625
after Aspergillin O, 1010*
and behavior patterns, 760–762
and bishydroxycoumarin, 981*
Christmas factor, 1942–1951
and Hageman factor, 262–265, 981*, 1019*
and Hageman factor, 1942–1948
and heparin, 977*, 1016*
and hepatic defects, 1007*
in hyperlipemia, 1026*
papain, 1945–1946
plasma thromboplastin antecedent, 1942–1951
plasmin, 1945–1951
plasminogen concentration and fibrin lysis, 430–433

Blood (*cont'd*)
polybrene effects, 1016*
in pregnancy, 1015*
and proconvertin, 555, 1015*, 1942–1951
protamine effects, 1016*
in renal failure, 1027*
serum clotting factors, 262–265
in silicone, 1945–1946
and Stuart factor, 1015*, 1942–1951
Stypven time, 1026*, 1945–1946
tests, 426–434, 981*, 1944–1951
and thrombin formation, 1945–1951
thrombolytic activity assay, 426–434
thromboplastin time, 1019*, 1947
and trypsin, 1942–1951
cord, insulin degradation, 119–120
endotoxin-detoxifying component, 352–363
after erythropoietin, 994*
ethanol in, after infusion, 777–780
genotypes, 1450–1462
race differences, 1460
glucagon, immunoassay, 1036*
glucose levels, 511, 722, 1027*
in acromegaly, 1166, 1168–1169, 1174
after adrenalectomy, 311–318
after adrenocorticotropic hormone, 313
after cortisone, 311–318
after desoxycorticosterone, 311
in diabetes, 1035*, 1164–1168, 1174
after epinephrine, 311–318
fasting, 444–446, 1037*, 1169, 1232
in gastrodialysis, 657
after glucose, 1027*, 1037*, 1074–1075, 1167
and growth hormone, 1232
hepatic arteriovenous difference, 509–511, 1009*
and hyperglucagonemia, 1036*
and insulin infusion rate, 507–513
after leucine feeding, 993*
after mannose infusions, 976*
and measurement methods, 519–520
and peritubular osmotic activity, 974*
and placental extracts, 122
tolerance test, 1164–1168, 1172–1174
granulocyte clearance rates, 1482–1486
after storage, 1483, 1485
indocyanine green concentrations, 596
insulin clearance, 1077
ketone bodies, 1037*
krypton concentrations, 712, 1081–1083, 1848–1849
arteriovenous difference, 712
in leukemia, 1356, 1688–1705
nitrous oxide arteriovenous difference, 712
nonprotein nitrogen, 657
in ganglioneuroma, 1730
oxygen. *See* Oxygen
penicillin clearance, 851
pH, 332, 337, 340
and acetazolamide, 288–294, 1031*, 1252–1255, 1713
and adenosine triphosphate pyrophosphate exchange, 1766–1768
and ammonia concentration, 288–294, 332–341, 687, 972*, 1014*, 1039, 1251, 1256, 1303–1310
in anemia, 380–388
after carbon dioxide, 297, 300
and carbonic anhydrase, 1019*, 1552, 1713
and cardiac output, 998*
and CL 8490, 1552–1553
in encephalopathy, 1247–1248, 1253
in endotoxin shock, 1037*
and exercise, 380–388
in myxedema, 48, 53
and obesity, 53
after sodium phosphate, 1519
and sodium reabsorption, 970*
after Tris-(hydroxymethyl) aminomethane, 1035*
phenylhydrazine-treated, and cyanide, 1830–1831
phosphate compounds, 56–71
pK_a, determination for ammonia, 335, 336
storage
inosine effect, 62–71
and plasma thrombolytic activity, 430–433
streptomycin clearance, 851
sulfobromophthalein clearance, 239–241
sugar. *See* Blood, glucose
in thalassemia minor, 1898–1899
thromboplastin clearance, 1030*
transfusion, 1045
and purpura, immunologic, 1029*
triolein distribution, 1036*
urea nitrogen, 1101
and aldosterone secretion, 1098–1099
gastrodialysis stabilization, 658
growth hormone effects, 1224
in hypertension, 1097–1099
in obesity, 1230
and potassium nephropathy, 29
after protein ingestion, 1066
and renal atrophy, 24
in thermal burn stress, 1929–1930
and urea excretion in infant, 1067
after urea loading, 990*
after ureteral ligation, 109
and urinary tetrahydroaldosterone metabolite, 1098–1099
and vitamin D, 985*
velocity, 832
pressure relationship, 971*
venous volume after angiotensin II, 1040*
vessels. *See* Vascular system
in viruria, 1037*
volume, 53, 54, 466–472, 1040*
and acetylstrophanthidin, 939
and body position, 1348–1351
and cardiac hemodynamics, 417, 1044–1049
in failure, 977*
after digitalis, 940
and diisopropylfluorophosphate-labeled granulocytes, 1483
and exercise, 413–419, 1350, 1401–1412
forearm, and heat acclimatization, 825–833
after mephentermine, 997*
in polycythemia, 1724–1727
and renal atrophy reversibility, 21–27
and trimethaphan, 1350

Blood flow
and acetazolamide, 289–293, 1252–1255
and acetylcholine, 1031*
and acetylstrophanthidin, 933, 938–942
to adipose tissue, and cyclopropane, 1799–1804
adrenal, after hypophysectomy, 768
in alcoholic cirrhosis, 1848–1849
arterial, and indicator dilution, 1413–1423
after atrial septal defect repair, 1414, 1416
and autonomic nervous system, 1049
bacilli survival, 82, 309
cardiopulmonary bypass and venous return, 938
cerebral, 494, 707–716, 1252–1255
in dementia, organic, 491–500
in hepatic coma, 1039*
and coarctation of aorta, 1414, 1416, 1422
coronary, 718–723, 1011*
in hypertension, 1022*
digitalis direct effects, 930–936
and ethanol infusion, 776–781, 1032*
and exercise, 416–417, 1011*, 1406, 1410
in anemia, 379–388
in extremities, 416–417, 933
forearm, 825–833
and fatty acids, 718–720, 1780–1783
to fetus from placenta at birth, 1112
heat acclimatization, 825–833
hepatic, 237–238, 940, 1021*, 1032*
estimation by indocyanine green, 596–599
and glucose concentrations, 511–522
after insulin infusion, 509–511
sulfobromophthalein removal rate, 246
after lanatoside C, 938
and norepinephrine, 714
after ouabain, 933
portal collateral, 1201–1207
portal venous, 338
and venous return after digitalis, 930–942
pulmonary, 1021*, 1031*, 1049, 1841–1850
and membrane diffusion components, 1406, 1409, 1410
pulsatile nature, 1626–1632

renal, 289–293, 309
in diseased kidneys, 873
pyelonephritis susceptibility, 1813–1817
and uninephrectomy, 26
reticuloendothelial system erythrocyte sequestration, 1145–1146
shunt
arteriovenous, 1841–1850
portacaval, 511, 517, 1204, 1206
and water, collecting duct permeability, 487

Body
bromide and chloride distribution, 282–287
density, 971*
underwater weighing, 627
ether-extractable material in, 1791–1792
fat-free mass, 626–629, 971*, 1791–1806
heat loss in hot environment, 831–832
iron stores, 992*, 1006*
magnesium, total and bone exchange, 424–425
position. *See* Posture
size, and cardiac hemodynamics, 1044
and sulfobromophthalein transport, 1137–1138
three compartment model in emphysema, 1080–1085
water, and ascites, treatment, 977*

Bone
calcium, 885, 901, 982*
uptake, 895–897
density, in body fat estimation, 628–629
growth rate, 1224
after growth hormone, 1225
in hypopituitarism, 1226–1229
in hypophosphatasia, 1389
and interstitial cell tumors of testis, 548
magnesium, 424–425
calcium and citrate interrelationships, 982*
marrow, 912–913
cyclophosphamide effects, 1003*
in cystine storage disease, 1389–1390
deoxyribonucleic acid synthesis, 997*
erythroblasts, 103, 107, 109
fatty infiltration, 1785–1787
ferrokinetic studies, 108
in hemochromatosis, 1006*
hypocellular, blastic, 1357
after iron feeding, 992*
in myxedema, 901
in Paget's disease, 901
strontium uptake, 895–896, 901
thymidine uptake, 912–913, 917
in thyrotoxicosis, 901

Brain
ammonia levels, 1039*, 1251–1256
blood flow, 707–716
carbon dioxide, 1251, 1255, 1256
craniopharyngioma and growth hormone, 1237
enzyme activity, 1255, 1369
fungi, 1439
and cortisone, 1441–1442
metabolism, and acetazolamide, 1252–1255
organic dementia, 493–500
oxygen uptake, 494, 499, 1039*, 1252
and respiratory alkalosis, 1256
tumors, urinary β-aminoisobutyric acid, 916
in viruria, 1037*

Bromelin, and serum erythrocytes, 1040*

Bromide, and body chloride, 282–287

Bromsulphalein. *See* Sulfobromophthalein

Bronchitis, and airway resistance, 589

Brucellosis, 990*

Buffer
gelatin-containing, and glucose oxidation, 1492–1493
hemoglobin responses, 1895–1898
and phenylhydrazine, 1826–1829
methylethyl ketone, and indocyanine, 595
pH, 1297
and carbonic acid formation, 1489–1491
and chondromucoprotein viscosity, 407, 408, 410
erythrocyte membrane homogenization, 1897–1898
and fatty acids, 436, 731
and ferrocyanide, 1826–1829
and hemoglobin, 1825–1826
and insulin degradation, 118–119, 123, 128, 1073
and lecithinase A activity, 1297–1298, 1300–1301
and lipoprotein synthesis, 1564–1565
and mitochondrial pH, 1022*
and palmitate esterification, 154–159, 733–734
and platelet storage, 970*
and reticulocytes in mature erythrocytes, 972*
and vitamin B_{12} intrinsic factor binding, 207–208, 210
preincubation in, and lipolytic activity, 1284–1285
prolonged effect on hemoglobin, 1829–1830
"Tris," 1297
hypoglycemia production by, 1028*

Burns, thermal, and adrenal medullary insufficiency, 1927–1932

Butanol, and placental insulin, 122

Butyramide, and membrane permeability, 995*

C

Calcium
absorption, 203, 1235, 1807–1812
in aortic residues, 1661
balance in obesity, 1230–1231
in bone, 885, 901, 982*, 983*, 1233
uptake, 895–897
in calf costal cartilage, 924–928
and endotoxin activation, 354
excretion, 857–860, 889, 901, 1225, 1230
and basal metabolic rate, 886
after dihydrotachysterol, 1016*
in Fanconi syndrome, 1390
and growth hormone, 1225–1231, 1233
extracellular, 1021*
in ganglioneuroma, 1730
after growth hormone, 1225–1231, 1233
in hyperparathyroidism, 899
secondary, 1810
and lecithinase A, 1297–1301
and magnesium, 982*, 1038*
meralluride response, 991*
metabolism, 664–665, 895–897, 900–901
in myxedema, 899
in Paget's disease
pathway, 885
in pseudo-hypoparathyroidism, 1015*
by muscle, 1233
myocardial transfer, 1020*
in nephrocalcinosis, 693–704, 985*
and phosphate reabsorption in rickets, 1807–1812
plasma. *See* Plasma
and potassium transfer, 1020*
and protein-binding, 504–505
and quinidine-albumin binding, 979*
retention, 888, 1225–1230, 1233
in serum. *See* Serum
and strontium, skeletal function index, 885–903
tetany, 1038*
and thrombin formation, 1947–1951
tissue deposits, 1337, 1341
in hypophosphatasia, 1389
tolerance tests for parathyroid function, 662, 666
transport, 885, 1020*
after vitamin D, 1025*
urinary concentration, 1016*
and estrogen therapy, 900

Calories. *See* Diet, caloric intake

Cancer
antimetabolite-metabolite chemotherapy, 1034*
hypercalcemia, 900–901
leucine aminopeptidase in serum, 672, 675
β-lipoprotein levels, 1869–1870
plasma 17-hydroxycorticosteroids, 1917–1920, 1922, 1923
protein-bound iodine, 1923
serum vitamin B_{12} absorption, 1668
thrombolytic activity in plasma, 429–430
and transcortin cortisol binding, 1917–1920, 1922–1925

Candidiasis, 1276

Capillaries
and alveoli, 1350
krypton diffusion, 1080
in diabetes, 991*

Capillary
blood volumes, 53, 54, 1403, 1626
and body position, 1347–1352
and exercise, 1401–1412
in emphysema, 1081
and ganglionic blockade, 1345–1352
in myxedema, 53, 54
and norepinephrine, 1350

Carbamylaspartic acid, 16–19

Carbazole, and erythrocyte storage, 66
Carbohydrates
anthrone-reacting, 784
dietary
and behavior patterns, 760–762
and fat metabolism, 441–446
in gamma globulin Cohn fraction, II, 1938–1940
in liver glycogen storage disease, 997*
metabolism, 999*
in erythrocytes during storage, 62
gestational changes, 129, 130
insulin, direct effect, 507–522
in pregnancy, 116–130
and plasma fatty acids, 441–446
in synovial fluid, 784, 788
and triolein, fecal radioactivity, 1036*
Carbon dioxide
acetate oxidation to, 646–648
and airway resistance, 586–590, 726–729
amniotic fluid content, 227–235
and bicarbonate excretion, 1711–1712
reabsorption, 1619*, 1708–1710, 1714
and blood ammonia levels, 337, 1251, 1256
in calf costal cartilage, 925
and cerebral blood flow, 712, 713, 715, 1250–1255
galactose conversion to, 182
in ganglioneuroma, 1730
and hydrogen ion production, 1713–1716
mechanical work response to, 726–729
output, and physical activity, 379, 1012*
after oxalate, 1340–1341
and pulmonary circulation, 295–301, 1012*
in embolization, 1031*
pyruvic acid oxidation to and steroid hormones, 1041*
and respiratory acidosis, 1013*
for respiratory alkalosis, 1255
synthesis in nerves, 113, 114
tension, 53, 289–293, 1019*, 1708–1710
after acetazolamide, 289–293, 1251–1255, 1712, 1713
in anemia, 380–388
after carbon dioxide breathing, 51, 297–301
in emphysema, 725–726
and mitochondria pH, 1022*
in myxedema, 48, 53
and obesity, 53
after progesterone, 34–41
after rubidium, 172
after sodium chloride loading, 172–173
toxicity, 1254
transfer from fetus to mother, 227–235
and ventilation, 51, 1405
respiratory center sensitivity, 725–726
Carbon monoxide
alveolar clearance, 795–796
and blood pressure, 1346
and body position, 1346
and pulse pressure, 1346
and helium, 796
during washout period, 798–799
and phenylhydrazine-like drugs, 1826
and hemoglobin, 1833, 1895, 1896
lung diffusion capacity, 43–54, 1346
and acetylcholine, 1031*
non-uniformity, 946–949
tidal volume control, 796–801
Carbon tetrachloride
and jaundice, 136
and kinase activity, in liver, 997*
Carbonic acid
in electrolytes of costochondral junctions, 919–929
and intracellular hydrogen ion, 1716
S-Carboxymethyl cysteine, in plasma, 1634
Carcinoid, and serotonin, 1008*
Cardiac output
in anemia, 378–388
and blood volume, 467, 993*, 1044–1048, 1406, 1410
and body position, 1020*, 1052–1060, 1348
after digitalization, 940
after ethanol infusion, 1032*
and exercise, 414–418, 1020*, 1052, 1055, 1210–1212, 1348, 1406, 1410
and ganglionic blockade, 1049
and heat acclimatization, 825
in hypertension, 1022*
and isoproterenol, 1001*
and mephentermine, 997*
metabolic regulation, 998*
and norepinephrine, 1348
oxygen supply pattern, 1011*
in polycythemia vera, 1725, 1726
after pulmonary embolization, 1031*
and trimethaphan, 1348
Cardiovascular system
after acetylcholine, 1001*
and acetylstrophanthidin, 1001*
adaptation, 415–418
to heat, 825–832
and behavior patterns, 760–762
blood pressure regulation, 1017*
hypertensive, 25, 994*
and serum β-lipoprotein levels, 1866, 1869, 1871
and Starling's law, 1043–1050
and vena caval obstruction, 1023*
Carotid artery
constriction, and aldosterone secretion, 1330–1331, 1335
thrombosis, serum β-lipoprotein levels, 1868
Carotid sinus
denervation, and aldosterone secretion, 1332–1335
function mechanism, 1017*
Cartilage
collagen synthesis, 980*
costal, proteinpolysaccharides, 1752–1757
maturation and electrolyte content, 919–929
mucoprotein, 405–412
papain uptake, 1039*
in rheumatoid arthritis, 409–412
thermoelastic properties, 928
Catecholamines
and corticosteroid formation, 979*
excretion, 834–839
and alcohol ingestion, 763
and behavior pattern, 758–764
in ganglioneuroma, 1731, 1732
metabolism, 225
in neural tumor, 1729–1736
routes, 1733
Catheterization
bladder, renal plasma flow of separate kidneys, 392–393
cardiac, 1034*, 1876, 1877
for end-diastolic pressure correlation, 974*
after fluid volume loading, 993*
membrane diffusion components, 1406, 1410
for mixed venous nitrous oxide, 1021*
for "common duct bile," 162
coronary sinus, 1011*
pulmonary artery, 1011*
ureteral, 392–393
for renal function, 402–403
Cations
See also specific cations
exchange resin, 1012*
pituitary extract Fraction H, 1023*
extracellular, and chondroitin sulfate, 926
intracellular, and cesium, 171
in muscle, 1005*
Cells
See also Erythrocytes; Leukocytes
arylsulfatase activity, 1035*
basophils, 1035*, 1354, 1356
bilirubin-stained after hepatic explants, 276
blast, in subleukemic leukemia, 1357
calcification, 920
chromaffin, 1017*
of costal cartilage, 920–922, 927
in cystine storage disease, 1390
cytoplasmic inclusions, 536
differentiation, 988*
after erythropoietin, 994*
diffusion phenomena, 1042*
enteroviruses, attachment and sulfhydryl groups, 1017*
eosinophils, 1035*, 1354
pituitary, and growth hormone, 1007*
epithelial, 1007*
of renal explants, 274–276, 278
fibrous membrane, after agar disc implantation, 847–849, 852
giant, 848
granulocytes, 1354, 1355
histiocytes, 1354
interstitial, 549, 1033*
"lipochrome" pigment, 536
karyorrhexis, 848
Kupffer, in hemochromatosis, 994*
leucine clearance, 1007*
in leukemia. *See* Leukemia
Leydig, 549

liver, and internal pH, 1022*
lupus erythematosus, 1602–1603
mast, 1017*, 1026*
mesothelial, 848
muscle, 1002*
in dystrophic mice, 1183
myelocytic, 912–913, 988*
neoplastic, "biologic variation," 973*
neutrophil, 1035*
and overhydration, 1033*
pancreatic, 1007*
pyknosis, 848
Reinke crystalloids, 537
reticuloendothelial, 1145, 1389
Schwann, 112, 114
in thalassemia minor, 1899
thymidine uptake, 909, 912–913, 916
reutilization, 917
thyroid, 1033*
tubule, and sodium excretion, 883
tumor, 536, 549, 973*
vascularization, 849
yeast, pyrogenicity, 1275
Cephalalgia, histaminic, 676–682
after thyroactive substances, 531, 532
Cephalin
clotting tests, g131–g133
in liver disease, 1642, 1644, 1649
Cerebrosides, in Gaucher's disease, 1546–1550
Cervix, mucus proteins, 1358–1363
Chlorambucil, in leukemia, 1691–1696
Chloramphenicol, and bacilli, 354
Chloride
in bile, 164–169, 1039*
and bromide in body, 282–287
in calf costal cartilage, 921, 924–928
and chondromucoprotein viscosity, 407
diuresis, after acetazolamide, 1552–1553
excretion, 173, 1039*
after sodium phosphate infusion, 1517–1518
in ganglioneuroma, 1730
mercuric, 213
and virus hemagglutinating activity, 1017*
in pancreatic juice, bicarbonate exchange, 1000*
and quinidine-albumin binding, 979*
in skin, 1760
and sodium intake, 877–884, 1553
and titratable acid excretion, 970*
transfer during dialysis, 655
urine patterns during stop flow, 485–489
***p*-Chloromercuribenzoate**
bladder pretreatment and vasopressin effect, 1027*
and insulin, placental degradation, 125
and thimerosal, 1017*
Chlorothiazide
and aldosterone secretion, 1093–1095
and artherosclerosis, 981*
blood pressure responses, 981*, 1028*, 1277–1280
in diabetes insipidus, 980*
reactivity to levarterenol, 1278–1280
and renal concentrating mechanism, 1303–1310
and serum electrolytes, 977*
Stokes-Adams attacks, prevention, 1035*
and urinary volume, 980*
Chlorpromazine, jaundice, 137
sulfobromophthalein transport and storage, 1138–1139, 1142
Chlorpropamide
blood-sugar-lowering effect in diabetics, 1010*
and pancreatic venous insulin activity, 1028*
Cholecystokinen
and fecal triolein uptake, 1036*
Cholera, Asiatic, 988*
Cholesterol
absorption, direct measurement, 1288–1294
and atherosclerosis, after hypothalamic stimulation, 993*, 1963–1972
bile secretion, 814
24-dehydrocholesterol reduction to, 1032*
in erythrocytes, 345
after MER–29, 1032*
esters
in adrenal insufficiency, 996*
fatty acids of, 984*, 1186, 1430
after growth hormone therapy, 1231
after hydrogenation, 1429
intestinal transport, 737
in plasma, 1427, 1642–1649
and transport, 737, 1288–1294
in familial hyperlipemia, 1778, 1788
feedback control, proposed site, 646, 649–651
and glucose-6-phosphate dehydrogenase, 1010*
intake, 643–644, 810–813, 1566–1568
and intestinal digestion, 809–815
and mucosa secretion, 812, 1031*
and lipoprotein, 988*
serum β-levels, 1870
synthesis, 1566–1567
in liver disease, 1642–1649
loss in spherocytosis, 1020*
in plasma. *See* Plasma
in platelets, 345
and race, 1030*
serum. *See* Serum, cholesterol
synthesis, 642–652, 1566
pathway, 649–651
in peripheral nerve fractions, 111–115
and Triton, 1566–1568
Choline
and neuromuscular transmission in myasthenia, 992*
and phospholipid synthesis, 157
and triglyceride synthesis, 157
Cholinesterase, and esophageal achalasia and aperistalsis, 1744–1751
Chondroitin sulfates, 1757
and extracellular cations, 926
mucoprotein, 405–412
fractionation, 1752, 1755
Chorion, insulin degradation, 119–120
Christmas factor, 1942–1948
Chromium sesquioxide for fecal analysis, 854–863
Chylomicrons, and lipids, in hyperlipemic siblings, 1786
Cirrhosis
acetazolamide toxic effects, 1255
alcoholic, 1005*, 1653, 1848
antinuclear globulin tests, 976*
carbon dioxide breathing, 1254
corticosterone metabolism rate, 745
cortisol clearance, 322–323, 327
and electrolyte excretion, 971*
electrolyte intake, 984*
glucose tolerance test, 1166, 1168–1169
and histamine metabolism, 676–682
indocyanine green clearance, 596–599
nutritional, 976*
pulmonary arteriovenous shunt-flow estimation, 1846
respiratory alkalosis, 1253
serum composition, 249, 977*
bile pigments, 1641, 1643–1649
leucine aminopeptidase, 672
phospholipid composition, 1644, 1649
therapy, 971*, 977*
water diuresis, 248–261
Citrate
acid dextrose, 4–5
and erythrocyte phosphate compounds, 56–71
assay, in diabetes, 986*
in bone, 982*
in calf-rib costochondral junctions, 919–929
and cellular contents, 1042*
Citric acid, metabolites, in nephrotic syndrome, 1041*
Citrovorum factor therapy, in cancer, 1034*
Citrulline, in plasma, 1634–1635
Coenzyme A
acetate activation, 646, 649–651
and fatty acid esterification by intestine, 154, 159
and palmitate esterification, 152
and phospholipid synthesis, 157
and triglyceride synthesis, 157
Collagen
of aorta, 1658
and diphenylhydantoin, 1759–1762
diseases, and plasma thrombolytic activity, 429–430
of lung, 8–14
mucoprotein fractions, 11
synthesis after hypophysectomy, 980*
Colon
and bile pigments, 137, 737
enterocolitis, after serotonin, 1026*
mucosa, fatty acids, esterification, 150–160
after renal explantation, 274
Coma
alcoholic intoxication, 806
and blood ammonia levels, 289, 1039*
and carbon dioxide inhalation, 1254
hepatic, 1039*
malignant hypertension, 1102
and sodium balance, 981*

Compound S. *See* 11-Desoxycortisol
Connective tissue
in agammaglobulinemia, 987*
leucine uptake, 1007*
of lung, 8–14
metabolism, 1115, 1117
and antirheumatic agents, 973*
mucopolysaccharides, 1114
of peripheral nerve, 113
proliferation after phlebotomies, 994*
wasting disease after serotonin, 1026*
Conn's syndrome. *See* Aldosteronism, primary
Convertin, and thrombosis, 262–265
Coprostanol, from cholesterol, 811
Cor pulmonale, respiratory function, 1012*
Coronary artery
atherosclerosis after hypothalamic stimulation, 994*
blood flow, 722, 1011*, 1022*
disease, 1011*
and behavior patterns, 758, 760–762
and physical activity, 764, 1011*
and race, 1030*
serum β-lipoprotein levels, 1867, 1868
resistance in hypertension, 1022*
Coronary sinus
digoxin clearance, 1580
and myocardial fatty acid metabolism, 718–719, 722
Corticosteroids
catecholamine stimulation, 979*
and chromaffin and mast cells, 1017*
in coronary atherosclerosis, after hypothalamic stimulation, 994*
diurnal variation, 818–823
and glucose-6-phosphate dehydrogenase, 1010*
plasma values, analog computer, 816–824
urinary excretion, 538
in adrenogenital syndrome, 364–365
in liver disease, 322
in virilizing testis tumor, 535, 538
Corticosterone
absorption from gastrointestinal tract, 752
and adrenocorticotropic hormone, 743, 771–774
and aldosterone secretion, 767, 773–774
diffusion of pharmacologic doses, 327–328
metabolism, 327, 329, 741–757
plasma clearance, 322, 329, 743, 745, 746, 752
secretion, 329, 741, 754, 765–775, 979*
and transcortin cortisol binding, 1921–1924
turnover rate, 748–749, 753–754
urinary metabolite excretion, 745–747, 751–753, 755
Cortisol
absorption, 752
and antidiuretic responses, 1853
after nicotine, 1475, 1476
and water diuresis, 980*, 1473–1475
blood levels, 1040*
in congenital adrenal hyperplasia, 371, 907
diffusion, 821
of pharmacologic doses, 327–328
in endotoxin shock, 1037*
excretion in adrenal hyperplasia, 906–907
urinary, 325, 326, 751, 1098
glucosamine synthesis, inhibition, 973*
infusion tests, diurnal variation, 818–823
metabolism
in liver disease, 322–329, 751
in myxedema, 751
in thyrotoxicosis, 751
metabolites, 326, 328, 329, 751, 907, 1923
unconjugated, 1924
after 2-methyl-1,2-*bis*-(3-pyridyl)-propanone, 905
in plasma, 729, 750
clearance, 604, 752, 816–824
protein binding, 1923
precursors, after adrenocorticotropic hormone, 906, 907
secretion, 754, 755, 1040*
transcortin binding, 1914–1926
after estrogens, 602
turnover rate, 325, 748, 752
Cortisone
absorption, 752
in adrenal insufficiency, 996*
and albumin turnover, 1901, 1902, 1906
and antidiuretic responses, 1853–1857
and cholesterol metabolism, 314, 318
and hyperaldosteronism, 767
in hyponatremia, postoperative, 981*
in hypopituitarism, 1225, 1226–1229
in infections, fungus, 1435–1448
17-ketosteroids excretion, after, 371
metabolism in liver disease, 323, 327
in Paget's disease, 883, 886, 889, 893, 900
and pituitary dwarf, 1037*
and plasma lipid responses to epinephrine, 311–318
and sodium balance, 981*
and triglyceride synthesis, 996*
and urinary excretion, 1857
of calcium, 893
of α-ketols, 366–367, 371
of labeled metabolites, 751
of sodium, 981*
of water, 1857
Craniopharyngioma, and growth hormone, 1224–1227, 1229
Creatinine
clearance
in adult Fanconi syndrome, 1390
after calcium infusion, 664, 665, 1808–1811
in kidney disease, 1098
after lactate load, 877–884, 1527
after mannitol load, 254, 1306–1307
after mercaptomerin, 1306–1307
after nicotine, 1952–1856, 1862, 1863
and phosphate clearance, simultaneous, 995*
in pregnancy, 1527
and renal concentrating ability, 1303
and sodium intake, 877–884
and triiodothyronine, 1226, 1228
excretion
and behavior patterns, 761
Cryptococcosis, 1275, 1276
Cushing's syndrome. *See* Adrenal gland, hyperfunction
Cyanamide, and membrane permeability, 995*
Cyanide
and cardiac output in hypoxia, 998*
and hemoglobin, 1822, 1826–1829
in perfusion fluid, and vitamin B_{12} uptake, 205–206
Cyanmethemoglobin, 1894–1897
Cyanocobalamin, in blood, in alcoholism, 1005*
Cyclophosphamide, intracellular activation, 1003*
Cysteic acid
from cysteine, 1573, 1574
in glutathione hydrolysates, 1219
Cysteine
and *p*-chloromercuribenzoate-treated virus, 1017*
and chondromucoprotein viscosity, 407
conversion to S-carboxymethyl derivative, 1635–1637
in erythrocytes
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in storage, 66
excretion in cystinuria, 1003*, 1635–1637
gamma globulin, treatment with, 986*, 1934
and insulin, 1041*, 1071, 1163–1164, 1173
in plasma, 1041*, 1163–1164, 1173, 1634–1635
plasma-urine ratio, ureteral stop flow method, 841–845
sulfhydryl group, thioether bond with sulfobromophthalein, 1220–1221
sulfobromophthalein conjugation, 1222, 1575
and thiourea, desulfuration, 1009*
in urine, 1635–1637
and 6-diazo-5-oxo-L-norleucine, 448
after growth hormone, 1224, 1226, 1228
in hypopituitarism, 1226, 1228
in thermal burn stress, 1929
Cystine
erythrocyte impermeability, 1012*
excretion in cystinuria, 1003*, 1635–1637
in plasma, 1633–1638
storage disease, 1387–1393
in sulfobromophthalein conjugation products, 1219

thiourea cleavage, 1010*
urinary excretion, 1002*, 1636–1637
Cytidine
and aspartate carbamyltransferase, 19
diphosphate, and triglyceride synthesis, 157
of extracellular fluid, 972*
Cytochrome C, 1041*

D

DA virus, 998*
DCA. *See* Desoxycorticosterone
Deglutition, post-di-isopropylfluorophosphate, 1747, 1749
24-Dehydrocholesterol, and Mer 29, 1032*
11-Dehydrocorticosterone, metabolite excretion, 371, 752
Dehydroepiandrosterone
in testis tumor, 535
and triphosphopyridine nucleotide, 1010*
1,2 Dehydroprogesterone
and gas exchange, 36, 37
structural formula, 41
11-Dehydrotetrahydrocorticosterone, 751–753
Deoxyribonuclease
and leukocyte, differentiation, 988*
sensitivity transfer, 185–198
Deoxyribonucleic acid
in nerve fractions, 112
and protein papain binding, 1039*
and serum cholesterol levels, 1025*
synthesis *in vivo,* 996*
tritiated thymidine uptake, 909–918
Desoxycholic acid
and fatty acids, 984*
and glucose transport, 735, 738
and palmitate esterification, 734, 735
Desoxycorticosterone
in Addison's disease, 1861
and blood pressure, 374–375
glucocorticoid-like action on neurohypophyseal function, 1860
hydroxylation and catecholamines, 979*
and malignant hypertension, 1104
metabolite excretion, 373
and cortisone therapy, 371
and nicotine antidiuresis, 1851, 1856
and plasma lipid responses to epinephrine, 311–318
in potassium deficiency, 686, 1014*
and pyelonephritis susceptibility, 1813
11-Desoxycortisol
excretion, 371, 372
hydroxylation, and catecholamines, 979*
production in adrenal hyperplasia, 904
synthesis, 906
transcortin binding, competition with cortisol, 1922, 1924
Dextran
and central blood volume, 1047
and pressor response to chlorothiazide, 1278–1280
Dextrose
acid citrate, and erythrocytes, 56–71
post-transfusion survival, 69–71
in gastrodialysis, 656, 660
and plasma expanders, 699
and water, diuresis of cirrhosis, 248–261
transfer for control, 657
Diabetes insipidus
antidiuretic hormone activity, 1472–1480, 1543–1545
and growth hormone, 1231
in hypopituitarism, 1226–1229
nephrogenic, familial, 980*
and oxytocin, 969*
water diuresis, 1472–1474
Diabetes mellitus
adrenocorticotropic hormone tests, 820
and aldosterone excretion, 1094, 1096–1097
metabolites in nephropathy, 1100
alloxan, amino acid transport, 1002*
carbohydrate metabolism, 991*
early maturity-onset, 1041*, 1164–1168, 1173, 1174
and fatty acids, 1010*, 1424–1434
myocardial metabolism, 718–723
glucose, 976*, 1035, 1041*
blood levels, 1009*, 1164–1168, 1174
hepatic output, 511, 513–522, 1009*
tolerance test, 1164–1168, 1172–1174
hyperglycemia, 1173
infection susceptibility, 1013*
and insulin, 513–522, 1012*, 1041*, 1167, 1170–1174
resistance, 1072, 1075
ketogenesis, 986*
and lipids, 1424–1434
lipoprotein levels, 1869
mannose metabolism, 976*
plasma glucagon levels and hyperlabile, insulin-sensitive, 1036*
pregnancy in prediabetic, 128–129
thrombolytic activity, 429
and weight loss, controlled, 971*
2,4-Diaminobutyric acid, and muscle potassium, 1005*
Diamox. *See* Acetazolamide
6-Diazo-5-oxo-L-norleucine
structural formula, 447
and uric acid, in serum and urine, 447–453
Dicumarol
See also bishydroxycoumarin
antithrombotic action, 981*
Diet
bowel adjustment and intestinal flora, 859
calcium intake, 1025*
and fecal chromium oxide recovery, 857–860
caloric intake, 760–762, 1778–1780
and growth hormone, 1228, 1230–1231, 1235, 1237
and plasma fatty acids, 441–446
and weight, 971*, 1228
carbohydrate, adaptation and fat metabolism, 441–446
chloride intake, 685
cholesterol
and atherosclerosis, 980*, 993*, 1963–1972
and fatty acids, synthesis, 646
and synthesis, 644–646, 648
cholic acid, 980*
choline, 685
coconut oil, 1001*
corn oil, 685, 811, 1001*, 1430
and cystine stone formation, 1003*
and delirium tremens, 1037*
fat intake, 760–762, 811, 1430
and adipose tissue responsiveness, 722
and fecal fat content, 992*
and lipogenesis, 650, 811, 1430
and lipoprotein lipase, 1782
metabolism of, after starvation, 443–446
omission in idiopathic hyperlipemia, 1777
and plasma chylomicrons, 1785
and plasma fatty acids, 441–446
and serum triglycerides, 1779–1780
and fatty acids. *See* Fatty acids
fluid restriction, 1474
in hydropenia, 1064, 1068
and folic acid levels, 1005*
galactose, and cataract incidence, 180–182
gluten-free, in sprue, 1023*
habits, and behavior patterns, 760–762
in hyperlipemia, 1778–1780, 1787
in Korsakoff's psychosis, 1038*
mineral mixture, 685
and nicotinamide levels, 1005*
nitrogen intake, 1232
and pantothenic acid levels, 1005*
and potassium depletion, 684–692, 984*, 1014*
protein intake
and kidney concentrating capacity in newborn, 1062–1069
and postnephrectomy hypertension, 268
riboflavin restricted, 1004*
sodium, 685, 971*
and aldosterone secretion, 770, 1098, 1104
and corticosterone secretion, 770
in hypercalcemia, 693
and natriuresis, 882–883
and serum electrolytes, 977*
and sodium conservation, 689–691
with spironolactone, 984*
and thiamine levels, 1005*
in Wernicke's disease, 1038*
xylose, and cataract incidence, 182
Diethylstilbestrol
and plasma 17-hydroxycorticosteroids, 601–604
and thyroxine metabolism kinetics, 1120–1129
and transcortin binding capacity, 602–605
Digitalis
and atrioventicular block, potassium-induced 1885–1893
and cardiac output, 934
and glucose transport after insulin, 1009*

Digitalis (*cont'd*)
and peripheral vascular bed resistance, 930–936, 939
pressor response, 933–935
and sino-atrial block, 1890
tritium-labeled digoxin distribution, 1578–1583
1:2 Diglyceride
and phospholipid synthesis, 157
silicic acid chromatography, 737
Di Guglielmo's disease, erythrocytes, 15–19
vitamin B_{12} kinetics, 1667–1674
Dihydrocortisol
in liver disease, 323, 327, 328
and transcortin cortisol binding, 1922–1924
Dihydrocortisone
metabolism in liver disease, 323, 327
and plasma albumin binding, 1922
and transcortin cortisol binding, 1921–1925
Dihydrodesoxycorticosterone, excretion in adrenogenital syndrome, 368–369
Dihydroorotic acid, and pyrimidine synthesis, 16–19
Dihydrotachysterol, 1035*
in pseudo-hypoparathyroidism, 1016*
Dihydroxyphenylacetic acid, excrecretion in ganglioneuroma, 1733–1734
Dihydroxyphenylserine, in catecholamine synthesis, 1733
3α,17α-Dihydroxypregnane-20-one, excretion, 368, 370–371, 373
3α,11β,Dihydroxypregnane-20-one, in urine, after corticosterone, 752
Di-isopropylfluorophosphate
and esophageal muscular activity, 1745–1751
Hageman factor inhibition, 1019*
radiolabeled, in leukokinetic studies, 1481–1486
Dilantin. *See* diphenylhydantoin
Dimercaprol, in hydrated subjects, 991*
Dimethylformamide, and membrane permeability, 995*
Dinitrophenol, and palmitate esterification, 732
Dioxane, and placental insulin, 122
Diphenylhydantoin, dermal response, 1758–1762
2,3-Diphosphoglycerate, in erythrocytes, 59, 62–71
Diphosphopyridine nucleotide
and fatty acid synthesis in liver, 1007*
and lactic dehydrogenase assay, 1381, 1384
liver levels after alcohol, 999*
in methemoglobinemia, 1176
oxidation, 1041*
Diphtheria toxin, and gamma globulin fractions, 968*, 1938
Diuresis
after acetazolamide, dosage effects, 1552–1553
and adrenocorticotropic hormone secretion, 1544, 1545
antidiuretic hormone, 871, 873
and collecting tubule permeability to urea, 640
and galactose oxidation by red blood cells, 999*
in newborn infants, 1062–1069
plasma activity assay, 1539
thiol-disulphide interchange reaction, 1027*
bicarbonate, and plasma carbon dioxide tension, 1713
in diabetes insipidus, 980*, 1472–1480, 1543–1545
and glucocorticoids, 1476, 1853
in hypercalcemia, 1042*
mannitol, 257, 1543–1545
tubular function, 484–485
meralluride, 991*
in myxedema, 44
and nicotine, 1474–1475, 1479, 1543–1545, 1851, 1853
and renal concentrating ability, 866, 867, 873, 1031–1311
and sodium, 254, 259, 1474, 1475
sodium chloride, 483
sodium sulfate, 485, 486
urea loading, 1068
vasopressin, 1477, 1478
and diseased kidney, 865–870
and venous congestion of extremities, 1475–1477, 1479
and water, 248–261, 871, 980*, 1552–1553, 1851, 1855
Dodecyl sulfate, and erythrocyte amino acids, 1678–1679
DOPA (Dihydroxyphenylalanine), epinephrine precursor, 1929–1930
Dopamine
in catecholamine synthesis, 1733
from 3,4-dihydroxy-L-phenylalanine, 1015*
urinary excretion in ganglioneuroma, 1731–1734
Dubin-Johnson syndrome, and sulfobromophthalein, 1138–1139, 1142
Dwarf, pituitary, fasting metabolic responses, 1037*
Dyspnea, 999*
after di-isopropylfluorophosphate, 1745

E

Edema, 971*
pulmonary, 1012*
high altitude, 998*
in renal failure, and acidosis, 656
Elastin
in aortic residue, 1657–1666
in lung, and collagen, 8–14
Electrolytes
See also specific electrolytes
in bile and taurocholate, 162–169, 1039*
costochondral junctions, calf-rib pools, 928
excretion, 255–257, 1093
after acetazolamide, 1552–1559
and analog CL, 8490, 1552, 1557
after fluid loading, 993*
and oxytocin, 969*
and sodium intake, 877–884
intake and natriuresis during spironolactone, 984*
intracellular, in nephrotic syndrome 1041*
metabolism, and aminonucleoside, 1041*
plasma. *See* Plasma, electrolytes
in potassium depletion, 30
storage, 928
transfer, 984*
by gastrodialysis, 653–661
and tubular functions, 483–484
urine concentration patterns, during stop flow, 485–489
Electron microscopy, 991*
Electronic analog computer, plasma corticoids, 816–824
Emotions
and hormonal excretion, 762–763, 1535–1537
and plasma fatty acids, 608
Emphysema
and airway conductance, 586–590, 1080–1085, 1089
carbon dioxide tension, 34, 37, 41, 725–727
diffusing capacity lung volume, 587
non-uniformity, 946–951
and isoproterenol, 1001*
mechanical work response, 725–727
and myxedema, 49–51
oxygen consumption, 726, 1001*
and progesterone, 34–41
pulmonary artery pressure, and acetylcholine, 1001*
pulmonary arteriovenous shunt-flow estimation, 1846–1847
Endotoxins
and antimicrobial drugs, 846–853
and calcium ion, 354
enteric bacilli, 82–88
inactivation, 352–363, 1002*, 1029*, 1039*
lethal action, 305–307
and pyrimidine synthesis, 19
serum bactericidal activity, 76–80, 355
shock, 1037*
renal phosphatase, 302–309
Shwartzman phenomenon, 1002*
survival, species differences, 82–88, 991*
tumor damage after injection, 354, 357, 361–362
typhoid, 354–355
Enzymes
amino acid activating, 1763–1770
fractionation, 1765–1766
precipitation, pH, 1763–1765
in blood disorders, 1763–1770
clotting defects, 1942–1951
brain patterns, 1369–1370
carbonic anhydrase, and acetazolamide, 1551, 1708–1710, 1713, 1715
and bicarbonate reabsorption, 1019*, 1708–1710
catalase, hereditary absence, 610–618
cholesterol synthesis inhibition, 644, 649, 650
in chondromucoprotein hydrolysis, 410
defect in congenital adrenal hyperplasia, 907
defect in orotic aciduria, 1029*

duodenal contents, 1295–1301
feedback control of cholesterol synthesis, 650
in galactose metabolism, 1546
and alcohol, 999*
glucosamine synthesis activity, 1114, 1117
after gold sodium thiomalate, 973*
heparin activation, 1777–1778
hepatic, 328, 1007*, 1117, 1369–1370
sulfobromophthalein conjugation, 978*
and individual hypersusceptibility, 1819–1820
intracellular activation, 1003*
lecithin conversion to lysolecithin, 1299–1301
pancreatic, triolein absorption, 1036*
phosphoglycericmutase reaction, 59
and placental insulin degradation, 125
purine nucleotides inhibition, 650
pyrimidine biosynthesis, 15
receptor-destroying, and erythrocyte hemolysis, 1040*
renal, 978*, 1391
in nephrosis, 981*, 1364–1371
thermo-labile activity and hypothermia, 120, 124–126
and triphosphopyridine nucleotide, 1819–1820

Ephedrine, and urinary vanillylmandelic acid, *223*, *225*

Epinephrine
and airway conductance, 587
and cardiac output in hypoxia, 998*
in catecholamine synthesis, 1733
and corticosteroid formation, 979*
and glucose oxidation, 986*
in adipose tissue, 1495
and leucine, 993*
and lipid responses, 310, 313–318
liver uptake, 998*
and myocardial contractility, 1020*
plasma fatty acid responses, 311–318, 1010*
and phentolamine, 608
plasminogen activation, 1030*
and pressure-volume curves, 831
synthesis, 1927–1928
pathway, 1929–1930
urinary excretion, 1928–1930
and behavior patterns, 761
and centrifugation acceleration, 1533–1538
in duodenal ulcer, 834
in ganglioneuroma, 1731
in pheochromocytoma, *221–226*
and physical activity, 762

Ergothioneine, in leukemia, 1676, 1680, 1690, 1691

Erythrocytes
See also Erythropoiesis
and acetylphenylhydrazine, 1820–1824
in agammaglobulinemia, 1148, 1149
agglutination, 1040*, 1149–1150, 1153–1155
isoantibodies, 1011*
and thyroglobin, 1260, 1264
viral, 998*, 1017*
aging, 99, 1000*, 1818–1820
amino acids in, 1679–1682, 1686
activating enzymes, 1769–1770
in leukemia, 1690, 1691, 1700
ammonium concentrations, 332, 336–340
in anemia, 15, 385–388, 1763, 1818–1819
dihydroorotic dehydrogenase, 16
antibodies, 975*, 1011*
destruction of, 1145–1156
antigens, 975*, 1452–1461
aspartate carbamyltransferase, 15, 1029*
bromide-chloride ratio, 286
buffer incubation effects, 1829–1831
carbon dioxide in, with exercise, 385–388
carbonmonoxyhemoglobin preparation, 1895–1896
catalase activity, 618
cholesterol after MER-29, 1032*
corpuscular volume, in cirrhosis, 1653
cystine uptake, 1011*
24-dehydrocholesterol accumulation, 1032*
diaphorase levels, 1176, 1178
Di Guglielmo syndrome, 15, 16
dihydroorotase, 16, 1029*
diisopropylfluorophosphate uptake, 1482
in esophageal motor disorders, 1745
fragility patterns, 89–101, 1766–1769
galactose oxidation by alcohol, 999*
genotypes, 1457–1461
glucose-6-phosphate dehydrogenase, 1010*, 1819–1820
glutathione synthesis, 1011*
in heart failure, 977*
and Heinz body anemia, 1000*, 1818–1836
and hemoglobin, 1–7, 1109–1112
components, 1894–1899
metabolic adaptation, 1107
hepatic trapping, 1145
injury susceptibility, 1818–1836
intracellular pH, 340
iron
turnover, 977*
uptake, 90–93, 104, 106, 994*
life span, 90, 96
after nephrectomy, *273*, *278*, *279*
after splenectomy, 96, 98–100
after transfusion, *62*, 69–71
lipid composition, 1019*, 1020*
and marrow erythroblast depletion, 105, 109
in methemoglobinemia, 1176–1179
orotidylic pyrophosphorylase, 1029*
oxidation, 1833–1834
adult and fetal, 1111–1112
phenotypes, 1454–1461
and phenylhydrazine, 1824–1826
in polycythemia, 1724–1727, 1763
after renal autoexplantation, *273*, *274*, *278*
in reticulocytosis, 15–19
in spherocytosis, 89–101, 979*, 1019*
splenic reticuloendothelial system, 1145
storage effects, 1452–1453, 1459–1460
on phosphate compounds, 56–71
thromboplastic factors, 342–351
thymidine, tritiated, uptake, 912–913
transcortin cortisol binding, after estrogen, 1921–1925
transfusion with, washed, in myxedema, 54
trichloroacetic acid extracts, 63–71
zinc content, 1652–1656

Erythromycin, and staphylococci, 1039*

Erythropoiesis
after cyclophosphamide, 1003*
dual regulation, 1033*
erythropoietic factor, 105, 107, 994*, 1032*
in heart failure, 977*
in hereditary spherocytosis, 89
and iron, 994*, 1006*
after nephrectomy, 107
kidney role, 102–110
polycythemic response, 1032*
and riboflavin, 1004*

Esophagus
achalasia, 1745–1751
aperistalsis, 1745–1751
and di-isopropylfluorophosphate, 1745–1751
and gastrodialysis complications, 659
and lung volume changes, 146–148
pressure, after chest restriction, 586–590

Estradiol
renal handling in late pregnancy, 975*

Estrogens
and calcium metabolism, 894
and glucose-6-phosphate dehydrogenase, 1010*
in osteoporosis, 900, 901
and plasma, 999*
corticosterone clearance, 751
cortisol clearance, 751
17-hydroxycorticosteroids, 601–605, 1917–1920, 1922–1924
thyroxine clearance, 999*
and transcortin levels, 1920–1921, 1922–1924
in pregnancy, 975*
and steroid metabolism, 604
and strontium metabolism, 894
and thyroxine, 999*
metabolism, 1119–1130
and transcortin cortisol binding, 602, 604, 1917–1921, 1922–1924
and urinary steroid excretion, 602, 975*
in urine, and testicular tumor, 548

Estrone, 817, 975*

Ethanol
See also Alcohol
dialysance, 802–807
and splanchnic blood flow, 776–781

Ethanolamine
in leukemia, 1679, 1680, 1689–1698
phosphatidyl, 345–350
urinary excretion, 1677, 1681, 1686, 1697–1698

Ethinyl estradiol, and plasma 17-hydroxycorticosteroid levels, 1917–1918, 1922–1924

Ethionine, and jaundice, 136
Ethylenediamine hydrogen trisodium acetate, 667
Ethylenediamine tetraacetate
gamma globulin treatment with, 1934
and lecithinase A in duodenal contents, 1297–1301
and protein-binding of phosphate, 504–505
and serum bactericidal action, 355–359
tolerance tests for parathyroid function, 662, 666
and vitamin B_{12a}, 203–207, 212
Etiocholanolone
and androsterone, 1586, 1588
glucuronide, 978*, 1586
kidney conjugation, 1584–1589
in monozygotic dichorionic triplets, 620–625
urinary levels, 369–370
in virilizing testis tumor, 535
Exercise
and airway resistance, 586–590
and amino acids, excretion, 1684–1686
in anemia, 378
and arteriovenous oxygen difference, 1209
and blood volume, 413–419
pulmonary, 1405, 1410–1411
and carbon dioxide tension, 381
cardiac response, 976*–977*, 998*, 1001*, 1051–1061, 1208–1213
circulatory effects, 1001*, 1011*
adaptation, 1020*
in heated arm, 416
in cor pulmonale, 1012*
and forced breathing, 586–590
and granulocyte kinetics, 969*
in hot environment, 825–833
and membrane diffusion components, 1405, 1410–1411
and myocardial efficiency, 1011*
and oxygen consumption, 998*, 1011*, 1055
and plasma fatty acids, 215–220
and pulmonary arterial pressure, 1001*, 1348
and pulse rate, 976*, 1209
and thrombolytic activity, 428–429
and ventilation, 1405, 1410–1411
Extremities
See also Forearm
arteriovenous free fatty acids, 1515
blood volume and angiotensin II, 1040*
and exercise, 416–417, 1058
hind leg paresis after di-isopropylfluorophosphate, 1745–1751
norepinephrine clearance, 1038*
plasma expander reactions, 702
venous congestion, and adrenocorticotropic hormone release, 1475–1477
Eyes
cataract incidence, 181–182
conjunctivitis, 1000*
corneas, in cystine storage disease, 1390
lens senescence, 1833–1834
trachoma viruses, 1000*

F

Fanconi syndrome
alkaline phosphatase assay, 1387, 1390
lactic dehydrogenase assay, 1018*, 1388, 1390–1391
and plasma amino acids, 1635, 1637
Fatty acid
activation to acetyl-coenzyme A derivative, 156–159
cholesterol ester, 1433
in adenocarcinoma, 1186–1190
composition
in axons, 113
in diabetes, 1424–1434
and dietary fats, 984*, 1001*, 1431
of intracellular, 983*
in thoracic duct lymph, 1185–1190
fecal excretion, 1186
free, 435–445
in adenocarcinoma, 1186–1190
of adipose tissue, 435–439, 997*, 1787–1788
arteriovenous difference, 987*
in limb, 1512–1515
and epinephrine responses, 310–313, 317
and fasting, 718, 722, 1283
in hyperlipemia, 1780–1782, 1785–1787
intestinal contents, 731, 734, 814–815
lipoprotein lipase activity, 1783–1785
in liver glycogen storage disease, 998*
in myocardial metabolism, 717–723
neuroadrenergic stimulation, 606–609
in plasma, 215–220, 606–609, 1424–1430, 1512, 1780–1787
in vegetarian, 1429
production with coconut oil emulsion, 1783–1785, 1787–1788
and glucose, 734, 964, 1010*, 1037*
after growth hormone therapy, 1037*, 1231
from lecithin, 1295–1301
and sodium deoxycholate, 1298
leukocyte uptake, 983*
in lipoprotein fraction, 1001*
of lymph, 1186, 1190
and chylomicrons, 1001*
nonesterified. *See* Fatty acids, free
orthophosphate uptake, 984*
phospholipid, 1186, 1427–1429
in serum, 1001*, 1010*, 1023*
autonomic nervous system role, 959–965
solubility and bile salts, 739
synthesis, 114
and cholesterol feeding 646
hepatic, and ethanol, 1007*
in nerve fractions, 111–115
and sorbitol-fructose, 1007*
triglyceride fat incorporation, 150–160
unesterified. *See* Fatty acids, free
Feces
in Asiatic cholera, 988*
in bowel habit irregularities, 856–857
calcium, 886, 901, 1016*, 1225, 1230
in controlled weight loss, 971*
fatty acids, 1186
and growth hormone, 1225, 1227, 1228, 1230
incontinence after di-isopropylfluorophosphate, 1745
magnesium excretion, 421–425, 1016*
nitrogen, 886
after dihydrotachysterol II, 1016*
phosphorus, 886, 1016*
potassium, 1227
and proconvertin extract, 562–563
strontium excretion, 901
thyroxine, after estrogen, 1122
and unabsorbed dietary fat, 992*
urobilinogen excretion in heart failure, 977*
vitamin B_{12} excretion, 1673
Ferrocyanide
and hemoglobin, after phenylhydrazine, 1825–1829, 1833–1834
and urine, titratable acid excretion, 970*, 1520–1521
Fetus
bicarbonate metabolism, 227–234
deoxyribonucleic acid synthesis, 997*
hemoglobin, 1107
lactic acid metabolism, 227–234
and maternal carbon dioxide exchange, 227, 229, 234
Fever
after cryptococcal lysate, 1273
in fungus infections, 1266–1276
and natriuresis in liver cirrhosis, 971*
after staphylococci inoculation, 969*
Fibrinogen
euglobulin fraction lysinemethyl esterase, 1030*
fibrinolytic activity, 1001*
and coagulation factors, g134
after electroconvulsive shock, 1030*
after epinephrine, 1030*
and urokinase concentration, 427
and heparin, protamine effects on, 1016*
in thromboembolic phenomena, 997*
Fibrosis, pulmonary, 1407, 1410, 1411
Ficin, and serum erythrocytes, 1040*
Fistula, bile, 132, 134, 135
and serum lipid composition, 1643–1649
Fluids
amino acid concentrations, 1676, 1681
unbound, 1781
amniotic, in maternal-fetal exchanges, 227–235
ascitic, 323, 977*
cell-lipid uptake rate, 983*
leucine aminopeptidase, 672, 673
cerebrospinal, 286
ammonium concentration, 332, 335–340
bromide/chloride ratio, 286
and electrolyte transfer, 655, 659, 660

excretion and sodium intake, 877–884
extracellular, 174–176, 286
and glomerular filtration rate, 259
histamine clearance, 678
magnesium concentration and bone exchange, 983*
purine and pyrimidine components, 972*
thymidine clearance, 912
hypertonicity vasopressin release, 1859–1862
intake
and adrenocorticotropic hormone, 1474
in diabetes insipidus, 1543–1545
and urine concentration in infants, 1068
interstitial, renal, 487, 640, 695, 696, 1309
leucine aminopeptidase, 671–675
lymph globulins and transcortin, 1921–1922, 1924–1926
nitrogen removal, 657
pleural, 672–675
retention, 1033*
after estrogen, 999*
synovial, 782–789
tubular, 259, 1004*
hydrogen ion secretion into, 995*
Fluoride
and fatty acid esterification, 154, 159
and palmitate esterification, 153–154
9α-Fluorocortisol
in Addison's disease, 1857–1858
metabolism, in liver disease, 323, 327
and nicotine antidiuresis, 1853, 1855–1856, 1862–1863
and transcortin cortisol binding, 1921, 1924–1925
and vasopressin release, 1859–1862
5-Fluorouracil, activity in liver, 997*
Fluothane, and bicarbonate excretion, 1711–1712
Folic acid
blood levels in alcoholism, 1005*
serum activity, 996, 1008*
Follicle-stimulating hormone and glucose oxidation, 986*
Forearm
blood flow, with exercise in hot environment, 825–833
venous tone after digitalization, 940
5-Formamide 4-imidazole-carboxamide-ribotide, structural formula, 448
Forminoglutamic acid, excretion, and folic acid deficiency, 1908*
Formol gel test, 1323, 1324
Formylglycinamidine ribotide, 452
structural formula, 448
Fructose diphosphate
and erythrocyte storage, 57, 62–68
in liver glycogen stress, 998*
Fructose-6-phosphate
glucosamine-6-phosphate synthesis, 973*
and glutamine transamidase activity, 1115, 1117
and hexosamine synthesis, 1115
Fucose, in synovial fluid, 785–786
Fungi, infections, and cortisone, 1435–1448

G

Galactoflavin, and riboflavin deficiency, 1004*
Galactosamine, in proteinpolysaccharides, 1756, 1757
Galactose
and alcohol, 999*
in cerebrosides of Gaucher's spleens, 1547–1549
metabolism and progesterone, 178–184
in synovial fluid, 785–786
Gamble, James Lawder, obituary, following 705
Ganglioneuroma, 1729–1736
Gas
alveolar, 1082–1083
and chest restriction, 578–582
end tidal values, 797
in myxedema, 47
and ventilation in emphysema, 1080–1081
arterial blood, and acetylcholine, 1031*
exchange, 297
in anemia, and exercise, 379–381
in cor pulmonale, 1012*
after ethyl ether, 1014*
in hepatic encephalopathy, 1247–1248, 1253
and progesterone, 35–37
expired, 37
after 19 nor-ethinyl-testosterone, 37
inert, equilibration, 796
uptake, 496–497
krypton concentrations, 708, 1082–1083
lung volume in asthma, 588–590
plethysmographic and pneumotachographic records, 1626–1632
single breath test, 578, 581
trapping, 589, 590
Gastric juice
bromide/chloride ratio, 286
after histamine, 835–836, 838
after insulin, 835–836, 838
after peptone, 835–836, 838
and vitamin B_{12}, 200–205, 212
Gastrointestinal tract
amino acid lecithinase activator in duodenal contents, 1295–1301
ammonemia due to blood in, 972*
biopsy in Asiatic cholera, 988*
cholesterol absorption, 809–815, 1031*, 1291
dialysis, in renal failure, 653–661
lecithinase in duodenal contents, 1295–1301
magnesium absorption, 424–425
mucosa, 1031*
atrophic changes, 988*
deoxyribonucleic acid synthesis, 997*
after mercurial agents, 1617
and wheat gluten, 1023*
sodium absorption, 1607–1618
thymidine uptake, 916
and vitamin B_{12}, 202–214, 1668
Gaucher's disease, cerebroside synthesis, 1546–1550
Glass factor, and blood clotting time, 1947
Globulin
agar precipitin patterns, 1195
alpha, and papain binding, 1039*
and thyroxine, 1032*
alpha$_1$, 456, 595, 1322–1323
in proteinuria, 1003*
and transcortin in cancer, 1921–1922, 1924–1926
alpha$_2$, 595
in plasma expanders, g139
antihemophilic, 262–263, 977*, 981*
in hemophilia A carrier, 1619–1625
antinuclear tests, 976*, 1604
anti-thyroid factors, 1259–1265
beta, 1921–1922, 1958–1959
components in lupus erythematosus sera, 1598, 1602–1604
and infection, 990*
beta$_1$, 456, 595, 1322–1323
and DL-penicillamine, 1322–1323, 1326
erythrocyte-coating, 975*
gamma, 1003*, 1194–1199, 1322–1323, 1604
in aggammaglobulinemia, 987*
in amyloidosis, 474–480
anti-Rh$_0$(D), 1451
anti-thyroglobulin activity, 1259–1265
binding, 195, 477, 479
from cervical mucus, 1361–1362
Cohn fraction II, 1933–1940
carbohydrate content, 1938–1940
fractionation, 473–480, 995*
and glucose oxidation, 1494
heterogeneity, 1936–1939
in liver disease, 474–480
in lupus erythematosus cell formation, 1602–1603
in lymph fluids, 1921–1922
in lymphosarcoma, 474–480
in macroglobulinemia sera, 474–480, 1326
migratory phenomenon, 990*
molecular weights, 475–480, 1939–1940
in myeloma, 474–480, 565, 568–571
in pituitary, 1007*
in plasma expanders, g139
radioinsulin movement with, 1012*
and rheumatoid factor, 477, 972*
rheumatoid leukocyte aggregation by, 996*
7S, 474, 477–480, 986*
and streptokinase, 1938–1940
structural units, 1933–1941
and indocyanine green binding, 595
insulin-binding in diabetic, 1012*
thyroxine-binding, 999*
after estrogens, 1120–1129
in Waldenström syndrome, 477
Glomerular filtration rate
after acetazolamide, 1552–1553
in acidosis, 1014*
and aldosteronism, 1094–1096
and antidiuretic hormone, 1473–1474

Glomerular filtration rate (*cont'd*)
and aortic constriction, 868
after chlorothiazide, 980*
in cirrhosis, 250–261
in diabetes insipidus, 980*, 1473
in glomerulonephritis, 1003*
and glucose reabsorption, 1775–1776
after hexamethonium infusion, 980*
and hydration, 871
in hypertension, 398–404
in late pregnancy, 975*
and mannitol diuresis, 866–867, 872, 873
and nicotine antidiuresis, 1475, 1477, 1862–1863
and oxytocin, 969*
per nephron in diseased kidneys, 873
and plasma carbon dioxide tension, 1713
in pyelonephritis, 871
and renal concentrating ability, 389–391, 867–874, 1042*, 1771–1774
in sodium excretion, 883
after sodium loading, 258–259, 1553
and solute excretion, 874
and sulfate clearance, 1910–1911
and urate clearance, 1529
and urine osmolality, 980*
and vasopressin, 865, 866, 872, 873
and venous congestion of extremities, 1477
and water diuresis, 872, 980*
after water loading, 250
Glomerulonephritis
acute, progression to chronic, 1003*
and renal phosphatase, 303, 1018*
Glomerulus
diabetic, electron microscopy of, 991*
enzymic activity patterns, 505, 1018*, 1364–1371
hyalinized, after renal explantation, 274
Glucagon
and glucose, 998*
homeostasis, 1036*
and insulin, placental degradation, 125–126
liver uptake, 998*
Glucosamine
cartilage cell content, 921
synthesis, 973*, 1114–1118
Glucose
in adipose tissue, 435–439, 1007*, 1491
in amniotic fluid, 228
and anthrone reagent in synovial fluid, 784
blood. *See* blood, glucose
cerebroside uptake rate, 1548–1549
cerebrospinal fluid in meningitis, 1016*
deficiency and hemoglobin synthesis, 1109–1112
in the diabetic, 976*, 1035*, 1041*, 1164–1174
alloxan, 1009*
in erythrocytes, 1020*
storage effects, 62–68
fasting responses, 443–444, 997*, 1037*
and fatty acids, 435–439, 734, 964, 1010*, 1037*
and growth hormone, 1496
and insulin, 976*, 1008*, 1014*, 1074–1076, 1492–1493
activity, insulin-like, in sera, 1506–1507
direct action, 507
hepatic output after, 509–514, 517
in pancreatic venous blood, 1027*
placental degradation, 119
and ketonemia, 1037*
metabolism, 507
and adrenocorticotropic hormone, 1496
intracellular, 736
pathways, 986*, 1027*
oxidation, 993*, 1492–1493, 1496
and thyroid stimulating hormone, 986*
pituitary storage, 992*
in plasma, 443–444, 1035*, 1041*
and plasma lipids in nephrosis, 463
and platelet storage, 970*
reabsorption, 974*, 1392, 1771–1774
in serum lipids and lipoproteins, 997*
in spherocytosis, 1019*
in synovial fluid, 785–786
tolerance test, 128, 1164, 1166, 1168–1169, 1174
transport, 974*
and bile salts, 735
and desoxycholate, 736
and digitonin, 1009*
in gastrodialysis, 657, 659
and taurodesoxycholate, 736
urinary excretion, 865–870, 1390, 1772–1776
and water diuresis, 1476
Glucose 1,6-diphosphate, in erythrocytes in storage, 64–65
Glucose-1-phosphate, 182
Glucose-6-phosphate
and adipose tissue lipogenesis, 997*
of erythrocytes in storage, 66
glomerular, in nephrosis, 1364–1370
and hexosamine synthesis, 1115
and insulin, 1008*
oxidation, pyridine nucleotides during, 992*
Glucose-6-phosphate dehydrogenase
in aminonucleoside nephrosis, 981*
in liver glycogen stress disease, 998*
in nephrosis, 1364–1371
in proteinuria, 1370
steroid inhibition, 1010*
and thyroid stimulating hormone, 986*
Glucuronic acid, and cortisol excretion, 325, 326–327
Glucuronidase
and corticosterone metabolites, 747
and tetrahydroaldosterone release, 1100
Glutamic acid
bile content, 1573, 1574
in erythrocytes, 1012*, 1690, 1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukemia, 1689–1698
in leukocytes, 1692–1695
in nephrotic syndrome, 1042*
in plasma, 1634–1635, 1676, 1680
from sulfobromophthalein conjugates, 978*, 1218–1219, 1222, 1572, 1575
in uremia, 987*
urinary excretion, 1677, 1681, 1686, 1697–1698
Glutamine
in connective tissue, 1115
in erythrocytes, 1012*, 1690, 1691
glucosamine-6-phosphate synthesis and gold chloride, 973*
in leukemia, 1690–1695
in leukocytes, 1693–1695
in liver, 1115
in plasma, 1634, 1689–1691
structural formula, 447
urinary excretion, 1677, 1681, 1685, 1686, 1697–1698
Glutathione
amino acid constituents, 1222
and cysteine, 1017*, 1214
and glucose oxidation, 1494–1495
and mercuric chloride, 1017*
and phenylhydrazine in Heinz body formation, 1000*
and sulfobromophthalein conjugates, 978*, 1215–1227, 1570–1577
synthesis in erythrocytes, 1011*
by triphosphopyridine nucleotide reduction, 1833–1834
Glycerol, toad bladder permeability and vasopressin, 632
Glycinamide ribotide, structural formula, 448
Glycine
absorption from intestine, 452
and blood glucose concentration, 993*
conversion to oxalic acid via glyoxylic acid, 1342
in dystrophic mice, 1182–1183
in erythrocytes, 1012*, 1690–1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukocytes, 1679–1680, 1693–1695
metabolic pools, 1342
and palmitate esterification, 733
phosphatidyl seryl glycyl, 347
in plasma, 987*, 1634–1635, 1676, 1680, 1689
purine synthesis, 450
in sulfobromophthalein hydrolysates, 978*, 1218–1219, 1572
in uremia, 987*
uric acid synthesis from, 451
urinary excretion, 1342, 1390, 1677, 1681, 1685, 1686, 1697–1698
urinary oxalate uptake, 1339, 1343
Glycocholate, and palmitate esterification, 732–734, 738
Glycogen
liver content, 997*
mobilization, pituitary, 992*
Gold
chloride, 973*
colloidal, and bladder permeability, 632
sodium thiomalate, 973*, 1117
Gonadotropins, in virilizing testis tumor, 535, 538

Gout, tophaceous, 448–453
Granulocytes
diisopropylfluorophosphate labeled, 1481–1486
fluorescent staining of buffy coat, 996*
turnover rate, 969*
viscosity-reducing activity, 409
Graves disease, 790–794
and thyroxine survival time, 983*
Growth hormone. *See* Pituitary, growth hormone
Guanine
polynucleotide labeling, 972*
urinary excretion, 1677, 1681, 1686
Guanosine triphosphate, 60

H

Hageman factor, 262–265, 981*, 1019*, 1942–1948
Hashimoto's disease, 792–794, 1033*
Heart
catheterization, 974*, 993*, 1021*, 1406, 1410, 1875–1878
conduction, and potassium depletion, 1036*
cycle, plethysmographic record, 1632
and digitalis, 1580–1581, 1881–1883
and acetyl strophanthidin, 1886–1890
and potassium, 1886–1892
dilatation after serotonin, 1026*
after endocrine kidney, 22
and exercise, 414–418, 1052–1060, 1208–1213
fungi, and cortisone, 1439, 1441–1442
hemodynamics, 993*, 1011*, 1044, 1049
in anemia, 378–388
lipoprotein lipase activity and fasting, 1282–1287
metabolism, 524
and thyroid extracts, 525, 530
pulsations, 1626
after nitrous oxide breathing, 1631
rate, 414–418, 1052–1060
and body position, 1052, 1059–1060
after calcium infusion, 1021*
after chlorothiazide, 1278
and digitoxin toxicity, 1891–1892
after mephentermine, 997*
in polycythemia, 1724–1727
and saline infusion, 961, 964
and trimethaphan infusion, 961
size, 23, 24
and cardiac myosin, 1464–1465
Starling's law, 974*, 976*–977, 1043–1050, 1208, 1212, 1874–1884
stroke volume, 997*, 1208–1213
after calcium infusion, 1021*
posture effect, 1052–1060
in viruria, 1037*
Heart disease
arteriosclerotic, serum β-lipoprotein levels in, 1866–1870
coronary, racial difference in cholesterol patterns, 1030*
Heart failure
cardiac myosin, 1463–1471
and coronary vascular resistance, 1011*
and emphysema, 1002*
erythropoiesis, 977*
and isoproterenol, 1001*–1002
and myxedema, 49–51
and plasma thrombolytic activity, 429–430
and pulmonic stenosis, 1464
and renal response to fluid loading, 993*
and tricuspid insufficiency, 1464
Heinz body anemia, 1000*, 1818–1836
Helium, breathing, 945
and blood pressure, 1346
and pulmonary diffusion, non-uniformity, 946–949
Hematocrit
ammonium concentration, 336–340
in anemia, 1763–1764
and bishydroxycoumarin, 981*
and cardiac output, 1725
after phlebotomies, 1044, 1048–1049
after chlorothiazide, 1278, 1279
in cirrhosis, 1653
in endotoxin shock, 1037*
and ganglionic blockade, 1044
in hypervolemia, 1723
and lung carbon monoxide diffusing capacity, 54
in myxedema, 48, 53
after nephrectomy, 103
in obesity, 53
in polycythemia vera, 1723–1725, 1727, 1764
and red cell volume, 1453, 1459
after renal explantation, 278
after sodium chloride-lactate infusion, 882
in spherocytosis, hereditary, 90
after urea loading, 990*
after ureteral ligation, 103
after volume loading, 54, 993*, 1006*
Hemochromatosis
glucose tolerance test, 1166
iron in, after phlebotomies, 994*
and marrow erythroid hyperplasia, 1006*
Hemodynamics
cardiac, 1044
after acetyl strophanthidin, 930–942
in hypervolemia, 993*, 1049
compensatory mechanisms in anemia, 378–388
coronary, 1011*
and exercise, 414, 1348
and fluid shifts after digitalis, 940
hepatic, and vasopressin, 1021*
in hypertension, 396–404, 1021*–1022
and mephentermine, 997*
peripheral, 1011*
pulmonary, 993*, 1348
and body position, 1348
and chest restriction, 573–583
renal, 389–404, 993*
after antidiuretic hormones, 1473–1474
Hemoglobin
and acetylphenylhydrazine, 1820–1831
and amino acid composition, 989*, 1110
in anemia, 15–20, 382, 1764
and pyrophosphate-adenosine triphosphate exchange, 1765–1768
and bile pigments after injection, 134–135
and carbon monoxide, 1826
carbonmonoxyhemoglobin in cyanmethemoglobin, 1895–1896
and erythrocyte membranes, 1–7, 1894–1899
and ferrocyanide, 1826–1832
green, 1832–1833
in hemoglobin C trait, 1896–1899
histidine content, 1110
isoleucine, 1110
in myxedema, 48, 53
oxidation, 1109–1110, 1826–1833
and Heinz body formation, 1000*, 1833–1834
to methemoglobin, 1825–1829
after phenylhydrazine, 1000*, 1821–1832
in plasma after antiserum injection, 1148
plasma-urine ratio, ureteral stop flow method, 841–845
in polycythemia vera, 1763–1765
and proconvertin extract, 562–563
after renal explantation, 278
in sickle cell hemoglobin C disease, 1896–1899
in sickle cell trait, 1896–1899
in spherocytosis, hereditary, 90
spleen content, 1145
and sulfhydryl groups, 1828, 1833
synthesis, adult and fetal, 1107–1113
cyanide effect, 1109–1112
erythropoietin effect, 994*
and glucose deficiency, 1109–1112
in hypoxia, 1108–1112
temperature effects, 1824–1826, 1831
after transfusion, 54
tubular reabsorption, stop flow analysis, 840–845
Hemophilia, 1484
carriers, 1619–1625
See also Antihemophilic factor
Hemorrhage
and aldosterone secretion, 772, 1094–1097
cardiac, after endocrine kidney, 22
cerebral, 1867–1868
gastrointestinal, after sulfobromophthalein, 1139–1140
and renal phosphatase, 303
retinal, 1095, 1096
submucosal, after serotonin, 1026*
and serum β-lipoprotein levels, 1867–1871
Heparin
for clotting control, 977*, 1010*
in hyperlipemia, 1779–1785
and lipoprotein lipase, 1282–1283, 1786–1787
and myocardial fatty acid metabolism, 718–720
and polybrene, 1016*

Heparin (*cont'd*)
and protamine, 1016*
in renal failure, 1027*
and serum triglyceride concentration, 1779–1782
Hepatitis
bile pigment patterns, 137
cholangiolitic, 674
cortisol clearance from plasma, 322–323
infectious, 672–674, 675
plasma cortisol levels, 327
plasma phospholipid composition, 1644, 1649
proconvertin clearance, 555–563
serum leucine aminopeptidase, 672, 674
sulfobromophthalein transport and storage, 1138–1139, 1142
viral, indocyanine green tests, 598
Heredity
aberration, in immunologic response, 987*–988
acatalasemia, 610–619
agammaglobulinemia, 987*
chromosomal patterns in gonadal disorders, 1024*
diabetes insipidus, nephrogenic, 980*
hemophilia A disease, 1619–1625
hypocatalasemia, 610–619
liver glycogen disease, 1007*
methemoglobinemia, 1176–1179
mongolism, 989*, 990*
myopathic mutation, 1180–1183
orotic aciduria, 1029*
and pulmonary edema at high altitude, 999*
steroid patterns in dichorionic monozygotic triplets, 620–625
and vitamin D-resistant rickets, 1807–1812
Hexamethonium
and digitalis effects, 932
and ouabain effects, 934
and urinary volume, 980*
Hexokinase, glomerular
in nephrosis, 1364–1371
in proteinuria, 1370
Hexosamine
in aortic residues, 1661
in connective tissue, 1115
and diphenylhydantoin, 1758–1762
in gamma globulin fractions, 1938–1939
in synovial fluids, 784, 786
mucoprotein, 408
Hexoses
in cerebrosides, 1547–1548
of erythrocytes, 57
and storage, 63–71
in gamma globulin fractions, 1938–1939
in synovial fluid, 782–789
Hexuronic acid, in synovial fluids, 786
Hippuric acid excretion after glycine, 1339–1342
Histamine
and connective tissue, 1025*–1026
and gastric secretion, 835–836, 838
and glucose oxidation, 986*
metabolism, 676–682
Histidine
in erythrocytes, 1690, 1691
and pyrophosphate-adenosine triphosphate exchange, 1764
and folic assay deficiency, 1008*
and hemoglobin synthesis, 1109–1112
in leukocytes, 1679, 1680, 1693–1695
in plasma, 1680, 1689, 1691
iodoacetate treated, 1634–1635
urinary excretion, 1677, 1681, 1685, 1686, 1697–1698
Homograft. *See* Transplantation
Homovanillic acid, excretion in ganglioneuroma, 1731–1734
Hormones
See also specific glands; specific hormones
antidiuretic. *See* Diuresis, Antidiuretic hormone
lactogenic and insulin placental degradation, 125
neurohypophyseal, 1027*
"pore theory" inadequacy, 995*
and toad bladder permeability to urea, 630–641
renal excretion and behavior patterns, 760–762, 764
thyroid-stimulating and thyroidal radioiodide uptake, 792
intestinal, and triolein absorption, 1036*
Hyaluronate, in synovial fluid, 407, 788
Hyaluronidase, and papain binding, 1039*
Hydralazine
and aldosterone secretory rates, 1093–1095
and hypertension, 981*, 1093, 1094
and pyelonephritis susceptibility, 1815–1816
Hydration
in diabetes insipidus, 980*, 1543, 1545
after hypertonic saline, 1474
and hyponatremia, 1033*
and renal concentrating ability, 871
and urine urea, 636
and water diuresis, 991*
Hydrochloric acid
intraduodenal, and bile flow, 164–165, 167
pituitary extract Fraction H, 1023*
Hydrochlorothiazide, and aldosterone excretion, 1094, 1096–1097
Hydrocortisone. *See* Cortisol
Hydrogen ion
and acidity, 995*, 1014*
of urine, 970*
and ammonium excretion, 176
and bicarbonate, exchange, 656
reabsorption, 1713, 1714, 1716
and gastric acid production, 660
and quinidine-albumin binding, 979*
and subcellular structure pH, 1022*
and sulfobromophthalein glutathione conjugation, 1574
transfer during gastrodialysis, 655–656
Hydrogen peroxide, phenylhydrazine hemoglobin destruction, 1832–1833
Hydropenia
aortic compression, after water deprivation, 870
in newborn, and urine urea concentration, 1068
and potassium depletion, 688
urine osmolality, 872, 875, 1068, 1474
and water clearance, 1474
Hydroxamic acid, iron complex, 1218
11β-Hydroxyandrosterone
excretion in testis tumor, 535, 538
in monozygotic dichorionic triplets, 620–625
Hydroxyapatite, in aortic elastin residue, 1658, 1600–1665
β-Hydroxybutyric acid synthesis, 646
and cholesterol, 647
17-Hydroxycorticosteroids
and adrenal glands, 982*, 1906–1907, 1924–1925
and estrogens, 602, 1923–1924
and lymph, 1922
plasma concentrations, 601, 604, 996*
and adrenocorticotropic hormone, 1102, 1921, 1924
after 9α-fluorocortisol, 1921, 1924–1925
in post-menopausal women, 1915–1917
postpartum, 1918–1920, 1922–1924
after surgery, 1920–1921, 1924–1925
and transcortin, 1914–1915, 1921–1922
cortisol binding, 1915–1917
urinary excretion, 602
and growth hormone therapy, 1224, 1226–1231
and overt behavior pattern, 758–764
in secondary hyperaldosteronism, 772
20β-Hydroxycortisol, 817
metabolism rate, 751
11β-Hydroxyetiocholanolone
in monozygotic dichorionic triplets, 620–625
in virilizing testis tumor, 535
5-Hydroxyindole acetic acid
in carcinoid syndrome, 223
excretion and behavior patterns, 761
excretion in ganglioneuroma, 1733–1734
and glucose oxidation, 986*
and serotonin, 1008*
and vanillylmandelic acid chromatogram, 222
Hydroxylamine, and hemoglobin conversion, 1826–1829
17α-Hydroxyprogesterone
metabolites, excretion, 372, 373
after 2-methyl-1,2-*bis*-(3-pyridyl)-propanone, 906, 907
and transcortin cortisol binding, 1921–1925
Hydroxyproline
in connective tissue and diphenylhydantoin, 1758–1762
of costochondral junction, 927–928

Hydroxytyramine, epinephrine precursor, 1929–1930
Hypercalcemia
in cancer, 900–901
mitochondrial calcium concentrations in heart muscle, 1021*
renal concentrating ability, 693–696, 985*, 1042*
urinary osmolality, 695
Hypercholesterolemia, 651
race difference, 1030*–1031
serum lipoprotein levels, 988*, 1869–1872
of stress, 318
Hypergammaglobulinemia
familial predisposition, 988*
gamma globulin turnover, 567–569
serum anti-thyroglobulin activity, 1260
Hyperglobulinemia, 477
Hyperglycemia, without glycosuria, 974*
Hyperinsulinism, in idiopathic hypoglycemia, 993*
Hyperkalemia
acidosis correction, 657
atrioventricular block, 1890–1891
and gastrodialysis, 660
Hyperlipemia
cholesterol absorption, 1293
and coagulation abnormalities, 1026*
and heparin, 722, 1785–1787
idiopathic, 988*, 1777–1789
Hyperparathyroidism, calcium and strontium metabolism, 885–903
Hyperphosphaturia, in resistant rickets, 1807–1812
Hyperplasia, adrenal, 1104
in aldosteronism, 1094, 1096
congenital, 906
Hyperpnea
in liver cirrhosis, 1254
in metabolic acidosis, 1253
Hypertension
and adrenocortical function, 989*, 1091–1106
in adrenogenital syndrome, 373–375
and aldosterone secretion, 1091–1106
and angiotensin II, 1040*
after aortic stenosis, 25
atherogenesis potentiation, 980*–981
blood urea nitrogen concentration, 1099
and cardiac output, 1022*
and chlorothiazide, 1277–1280
and electrolyte excretion, 880–884
and fluid excretion, 880–884
hormonal, and pyelonephritis susceptibility, 1813–1817
liver explantation, no protection, 271, 272
magnesium excretion, 421–425
malignant, 1095–1099, 1102, 1869–1872
and primary aldosteronism classification, 1104
metacorticoid, 1105
α-methyl-3,4-dihydroxy-DL-phenylalanine treatment, 1015*
after nephrectomy, 21–27, 268, 1093, 1096, 1104
protection by renal explantation, 266–281
portal, 1203, 1206
in pregnancy, 1530
pulmonary, 1001*
and acetylcholine, 1031*, 1034*
and membrane diffusion component, 1409
and race, 1030*
and renal blood supply, 21
and renal function, 883
in separate kidneys, 395–404
and serum β-lipoprotein levels, 1865–1872
after sodium chloride-lactate, 876–884
spleen explantation, no protection, 271, 272
urinary hormone excretion, 223–226,989*
Hyperthyroidism
Berson clearance test, 790–794
calcium and strontium metabolism, 885–903
glucose tolerance test, 1168–1169
metabolic responses to fasting and food-taking, 1010*
Hyperventilation
and cerebral blood flow, 713, 715
in liver disease, 1253–1254
and membrane diffusion components, 1405, 1410–1411
and neurological changes, 1253
and progesterone, 34–41
and pulmonary capillary blood, 1405, 1410–1411
Hypoalbuminemia
hypervolemic, 1902–1906
of nephrotic syndrome, 462, 463
Hypoaldosteronism, in panhypopituitarism, 981*
Hypocapnia, and carbon dioxide therapy, 1253
Hypocatalasemia, 610–619
Hypoglycemia
glucagon secretion, 1036*
glucose tolerance test, 1166, 1173
"idiopathic," 993*
and insulin, 1173
hepatic effect, 507, 508
and norepinephrine excretion, 836
islet cell tumors, 1173
leucine-induced, 993*
plasma insulin concentrations, 1166, 1168, 1174
phloridzinization, 1036*
and Tris-(hydroxymethyl) aminomethane, 1035*
Hypokalemia
in aldosteronism, 1096
in ganglioneuroma, 1730
in malignant hypertension, 1105
in potassium depletion, 686
Hyponatremia
in ascites, 978*
electrolyte reciprocal changes, 1033*
in gastrodialysis, 659
and overhydration, 1033*
urinary aldosterone, 981*
and vasopressin, 1033*
and water intoxication, 1033*
Hypoparathyroidism
congenital and hypercalcemia, 985*
phosphate excretion, after calcium infusion, 1808–1812
pseudo-, 1016*
Hypophosphatasia, alkaline phosphatase assay, 1387, 1388–1389
Hypophosphatemia
and calcium injection, 1809–1812
in ganglioneuroma, 1730
Hypophysectomy
and adrenocortical function, 765–775
and blood glucose, 313–318
and plasma lipids, 310–318
Hypopituitarism
cortisone effects, 1228
growth hormone effects, 1224–1227, 1229
and hyponatremia, postoperative, 981*
plasma free fatty acids, 1241
Hypoproconvertinemia, 554–564
Hyposthenuria
in nephrocalcinosis, 693–704
in potassium depletion, 684–692
Hypotension
after hexamethonium and mephentermine, 997*
histamine responses, 678
Hypothalamus
in coronary atherosclerosis, 994*
and serum lipid levels, 1964–1966
and vasopressin release, 1857–1863
Hypothermia
and acetylcholine response in myasthenia, 993*
and placental insulin degradation, 120
Hypothyroidism. *See* Myxedema
Hypoxia
See also Oxygen
and ammonia toxicity, 1039*
and cardiac output, 998*
and hemoglobin synthesis, 1108–1109
iron absorption and turnover, 992*
and membrane diffusion components, 1405, 1410–1411
and pulmonary capillary blood, 1405, 1410–1411
and ventilation, 1405, 1410–1411
Hytakerol, composition of, 1035*

I

Ileum
idiopathic steatorrhea, 156–159
mucosa fatty acids, esterification, 150–160
Immune reaction
beef and human insulin in guinea pig, 1162–1163, 1170, 1171, 1173
in brucella-infected mice, 990*
endotoxin, 82–88, 361
and erythrocyte sequestration, 975*
liver-spleen ratios, 1148, 1154–1155
nonreacting Rh_0(D) positive phenotypes, 1458–1459
and storage, 1452–1453
and familial predisposition, 988*
to fungus, passive transfer, 1273–1275
tolerance development, 1271–1272
gamma globulin fractions, 478

Immune reaction (*cont'd*)
to Group A streptococci, 1018*
hypersensitivity in geographic areas, 1005*
to influenza, 1026*
and 6-mercaptopurine, 952–958
plasma expanders, 698–705
for plasma insulin concentration measurement, 1157–1175
poliomyelitis, dosage schedule, 970*
proteins of cervical mucus, 1362
in pyelonephritis, 1024*
to Salmonella vaccines, 1029*
serum factors, 72–88
anti-thyroglobulin, 1263
with nucleoprotein extracts, 1595–1604
thrombocytopenic purpura post-transfusion, 1029*
tuberculins, 985*
avian, Battery, and human cross-activity, 1005*
Indocyanine green, 592–599, 1040*
structural formula, 592
Indole-3-acetic acid, hypoglycemia production, 1028*
Infants
dehydration, 1067
hemoglobin production, regulation and synthesis, 1112
kidneys in hypophosphatasia, 1388, 1389
newborn
hemolytic disease due to Rh incompatibility, 1461
renal concentrating mechanisms, 1062–1069
Inosine
and erythrocyte storage in acid citrate dextrose, 62–71
and platelet storage, viability index, 970*
Inosinic acid
structural formula, 448
Inositol phosphatide, 345–350
Insulin
and adipose tissue, 435–439, 976*, 1487–1498
administration rate and response, 514
antibody complex, 1072, 1075
and urea, 1076
assay, 1069–1079, 1157–1175, 1487–1498
methods, variability, 1169–1173
beef, 1496
and human reactivity differences, 1162–1163, 1170, 1171, 1172
mixtures, and guinea pig anti-beef, 1160–1162
cellulose absorption, 1163–1164, 1174
in diabetes, 992*, 1041*
and glucagon levels, 1036*
protein complex, 1012*
enzymatic proteolysis, 119
and fatty acids, 435–439, 987*
and gastric secretion, 835–836, 838
glassware adsorption, 118–119
and glucose, 507–522, 976*, 1028*, 1041*, 1167–1171
tolerance test, 1165, 1172–1173
half-time, 1167, 1172
hexokinase stimulation, 1008*
after islet cell tumors, 1041*
and L-leucine, 1041*, 1168
loss on glassware, gelatin prevention, 1491
metabolism, 976*, 1167, 1172
placental degradation, 116–130
plasma concentration, 1041*, 1163–1164, 1167–1173
secretion, 1165, 1167, 1172–1173
daily rate, 1174
in serum, 1012*
bovine and human, 1074–1076
trichloroacetic acid-precipitable activity, 1076–1077
thermo-lability, 120, 124–126
Tietze and Fisher, 1161, 1162
and tolbutamide, 1171
turnover rate, 1167, 1172
Insulinase, liver, 127–128
Intestine. *See* Gastrointestinal tract
Inulin clearance
and antidiuretic hormone, 1473–1474
dextrose, 254
fluid-plasma ratios, 1004*
in hypertension, 396–404
mannitol, 254
in newborn infants, 1063
renal tubule permeability, 974*
of separate kidneys, 389–391
and smoking, 1477
and sodium excretion, 389–393, 883
sulfate ratios, 1910–1911
and toad bladder permeability, 632
and venous congestion of extremities, 1477
Inulin distribution
and insulin, 1008*
and sodium chloride diuresis, 487
stop-flow analysis, 485, 841–845
Iodine
clearance, and thyroid function, 790–794
extrathyroidal, after estrogen, 1124
intestinal absorption in Asiatic cholera, 988*
protein bound, 792
in myxedema, 45, 49
in obesity, 49
and plasma clearance, 790–794, 999*
serum uptake, and growth hormone, 1231
and thyroxine, 983*, 999*, 1119
and thyroid function, 790–794, 1120–1129
and virus hemagglutinating activity, 1017*
Iodoacetamide, ECHO 11 and 22 inactivation, 1017*
Iodoacetic acid
cell-lipid uptake rate, 983*
and insulin, placental degradation, 125
Iproniazid, and metastatic carcinoid, 1008*
Iron
absorption, 992*, 1006*
and amino acid deficiencies, 1110–1112
deficiency, spherocytosis correction, 980*
and erythropoiesis, 94, 103, 1006*
hemoglobin synthesis, 1108–1109, 1111
in hypoxia, 992*
intracellular pool, 1109
labile pool, after nephrectomy, 108
serum, in anemia, 1763
storage, 992*
in hemochromatosis, 994*
transferrin-bound, 979*
turnover, 103, 977*, 992*
after cyclophosphamide, 1003*
uptake, 994*, 1033*
in vivo distribution, 91, 94, 99
Irradiation, and amino acids, 1692, 1693, 1697
Ischemia, renal, 1396
after serotonin, 1026*
D-**Iso-ascorbic acid** and serum folic acid activity, 996*
Isocitrate
assay in diabetes, 986*
glomerular in nephrosis, 1364–1370
and glucose-6-phosphate dehydrogenase, 1010*
L-**Isoleucine**
and blood glucose concentration, 993*
in erythrocytes, and pyrophosphate-adenosine triphosphate exchange, 1763–1765
and hemoglobin synthesis, 1109–1112
in leukemia, 1689–1695
in leukocytes, 1679, 1680, 1693–1695
in plasma, 1676, 1680, 1689
iodoacetate-treated, 1634–1635
urinary excretion, 1677, 1681, 1686, 1697–1698
Isoproterenol
aerosol, 587, 590
and blood velocity, 971*
and cardiac output, 1014*
cardiopulmonary effects, 1001*
and corticosteroid formation, 979*
and urinary vanillyl-mandelic acid excretion, 223, 225

J

Jaundice
bile pigments, 132–142
chlorpromazine, 1138–1142
congenital nonhemolytic, cortisol metabolism, 328
and serum lipid composition, 1643–1649
sulfobromophthalein transport and storage, 1138–1139, 1142
Jejunum
idiopathic steatorrhea, 156–159
mucosa, fatty acid esterification, 150–160
Joints, synovial fluid, 405–412
hexose, nondialyzable, 782–789

K

11-Ketoandrosterone, urinary excretion
in adrenogenital syndrome, 369
in virilizing testis tumor, 535
11-Ketoetiocholanolone, 369, 535
in monozygotic dichorionic triplets, 620–625
α-**Ketoisocaproic acid,** and hypoglycemia, 993*
Ketone bodies
after cortisone, 1037*
after glucose, 1037*

after growth hormone, 1037*
and Krebs cycle in diabetic liver, 986*
synthesis and cholesterol feeding, 646, 647
after thyroid, 1037*
Ketopentose-5-phosphates, 66
17-Ketosteroids
glucuronides formed from, 978*, 1584–1589
in gonadal dysgenesis, growth hormone effect, 1224
renal artery blood clearance, 978*, 1584–1589
urinary excretion
in adrenogenital syndrome, 369, 372–373
and behavior patterns, 761
in congenital adrenal hyperplasia, 906
and growth hormone therapy, 1224, 1230–1231
in liver disease, 322
after 2-methyl-1,2-*bis*-(3-pyridyl)-propanone, 906
in virilizing testis tumor, 535, 538
Kidneys
abscess, 31, 32
mycotic, 1273, 1274
acidifying capacity, 1013*
in adult Fanconi syndrome, 1386–1393
in alcohol poisoning, 806
alkaline phosphatase assay, 302–309, 1372–1380, 1394–1400
in hypophosphatasia, 1389
and ammonia, 694–696, 1255
after acetazolamide, 289–293
atrophy, 274–278, 1003*
reversibility, 21–27
after cesium treatment, 174–175
collecting ducts, 691
in nephrocalcinosis, 696
concentrating ability, 487, 695, 864–875, 1302–1311
in newborn infants, 1062–1069
cortex, 31, 687, 688, 694–696
explantation to peritoneum, 268–271, 278–279
in cystine storage disease, 1386–1393
deoxyribonucleic acid synthesis, 997*
digoxin uptake, 1580–1581
diseased, 864–875
glucose titration technique, 1772–1776
serum lipoprotein levels, 1869–1872
and diuretic agents, 1302–1311, 1618
and adrenocorticotropic hormone, 1544, 1545
mannitol, 865–873
oxytocin, 969*
vasopressin, 865–869, 872, 873
in endotoxin shock, 302–309, 1037*
enzyme activities, 1716
and aminonucleoside, 1041*
and bicarbonate reabsorption, 1708–1710
in nephrosis, 981*, 1364–1371
and erythropoiesis, 102–110
explantation, 266–281
and arteriolar thickening, 272, 273, 278–279
and body weight, 268, 272
and hypertension, 268–281
extracellular fluid volume after acetazolamide, 1714
extracts and chondromucoprotein viscosity, 407
failure, 1099
and gastrodialysis, 653–661
prostate transurethral resection complication, 658
in thermal burn stress, 1929–1930
in familial renal glycosuria, 1386–1393
function, 393, 396–404
adaptations to diminished nephrons, 874, 875
nonexcretory, 279
and size, 392
and vitamin D intoxication, 693–704
and glomerular filtration rate, 874
and glucose reabsorption, 1771–1774
in glomerulonephritis, 1364–1371, 1395
and glucose metabolism, 976*
glucuronide formation, *in vivo*, 978*, 1584–1589
glutaminase activity, 174–175
glycerophosphatase, 1369
hemi-infarcted, 865–866, 872, 873
hemodynamics, 1473–1479
after fluid volume loading, 993*
in hydropenia, 688
in hypercalcemia, 693–696, 985*, 1042*
and hypertension, 268, 272–273, 396–404, 1093–1098
malignant, 1101, 1104–1105
hypertrophy, 272–273, 686
and uninephrectomy, 22–26
in hypophosphatasia, 1386–1393
infection, 1274, 1448
and cortisone, 1439–1446
insufficiency, 1098, 1100–1105
and aldosterone secretion, 1094–1098
and plasma expanders, 1954–1958
interstitial tissue, 1444–1445, 1448
calcium deposits, 1389
and intracellular water after acetazolamide, 1714
and 17-ketosteroid conversion to glucuronides, 978*, 1584–1589
lactic dehydrogenase, 1364–1371, 1381–1385, 1392–1400
lupus nephritis, 1394–1400
and mannose metabolism, 976*
medulla, and concentrating mechanism, 688, 693–696
explanted to lungs, 270–279
necrosis, mortality, 23
Necturus proximal tubule, 1015*
neonatal, 997*
in nephrocalcinosis, 693–704
nephrons, 872, 1381–1385
in diabetes insipidus, 980*
functional homogeneity, 1772–1776
and hemoglobin urine-plasma ratio, 842
residual, and hydrogen ion secretion, 1014*
in nephrosis, 1364–1371
oxygen consumption, 289–293
in thyroidectomized rats after thyroactive materials, 524, 530
papilla, 686–690, 694–696
in phosphate-losing tubular disease, 1386–1393
in potassium depletion, 28–33, 174–175, 686–696, 1014*, 1015*
pyelonephritis susceptibility and hypotensive agents, 1813–1817
after rubidium treatment, 174–176
and serum bilirubin patterns, 134
and sodium, 174, 693–696
excretion, 865–870
transport, 1309, 1618
solute excretion, 865–870
in thyrotoxicosis, 898
tubules, 28–33, 696, 874, 980*, 1014*
bicarbonate reabsorption, 1719
collapsed basement membranes, 275–276
and hemoglobin reabsorption, 840–845
permeability, and antidiuretic hormone, 1066
stop-flow technique, 481–490
and urea, 694–696, 869, 990*, 1004*
in virturia, 1037*
and vitamin B_{12}, 1315–1318
after vitamin D, 695
water content, 694–696, 1714
weights, 23, 268, 272–274
Klinefelter's syndrome, 1024*
Korsakoff's psychosis, 1038*
Krypton
blood flow measurement, 707–716, 1841–1850
in emphysema, 1080–1088

L

Lactate
blood concentration, 1529–1530
uric acid-creatinine clearance ratio after delivery, 1531
and cellular contents, 1042*
and liver glucagon uptake, 998*
metabolism to carbon dioxide, 227–235
natriuretic response to infusion, 883
oxidation to pyruvic acid in nonparticulate fraction, 1385
and plasma fatty acids, 219
production in spherocytosis, 1019*
and urate clearance, in toxemia of late pregnancy, 1526–1532
Lactic dehydrogenase, 1018*, 1381–1396
assay in kidney structures, 1381–1385, 1388, 1396
Lanatoside C
and blood volume, 938
pressor effect, 932
Latex fixation test, 972*
and antinuclear globulin test, 976*
Lecithin
bilirubin, and phospholipids in liver disease, 1642–1649
conversion to lysolecithin, 1299–1301
egg, and cobra venom, 1296

Lecithin (*cont'd*)
in erythrocytes, 345–350
and fatty acid release, 1295
and lecithinase A in duodenal contents, 1297
loss in spherocytosis, 1020*
in plasma lipids, 1430
in platelets, 345
Lecithinase A, in duodenal contents, 1295–1301
Leucine
aminopeptidase in body fluids, 671–675
and blood glucose concentration, 993*
cholesterol synthesis, 1566
in erythrocytes, 1690–1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
hemoglobin uptake, 1108
hypoglycemia production, 1166–1169, 1174
via extrapancreatic mechanisms, 1028*
and insulin activity, 1028*, 1041*
in leukemia, 1689–1691
in leukocytes, 1679–1680, 1693–1695
lipoprotein-protein synthesis, 1566
in plasma, 1041*, 1676, 1680, 1689, 1691
iodoacetate-treated, 1634–1635
urinary excretion, 1677, 1681, 1686, 1697–1698
Leukemia
amino acids, 1688–1705
anti-erythrocyte serum factors, 975*
arylsulfatase values, 1035*
aspartate carbamyltransferase, 15
cellular response, local exudative, 1353–1357
dihydroorotase activity, 16
and granulocytes, 1357
turnover rate, 969*
serum β-lipoprotein levels, 1869–1872
susceptibility to infection, 1356–1357
and transcortin cortisol binding, 1920–1921
urine hydrolysis test, 988*
vitamin B_{12} kinetics, 1667–1674
Leukocytes
amino acids, 1675–1687
activating enzymes, distribution, 1765–1768
and antinuclear globulin tests, 976*
arylsulfatase activity, 1034*
aspartate carbamyltransferase, 15
and cerebrospinal fluid glucose levels, 1016*
in cirrhosis, 1652–1656
dihydroorotic dehydrogenase activity, 16
diisopropylfluorophosphate uptake, 1482
fungi responses, 1270–1272
glutamic acid concentrations, 1700
after irradiation, 1692, 1693
in leukemia, 15, 988*, 1356–1357, 1693–1695
linoleic acid transport, 983*
mucoprotein hydrolysis by extracts, 405–412
after nephrectomy, 274
in polycythemia, 1723–1724, 1727
polymorphonuclear, 411–412, 1357
in peritoneal cavity, agar disc membrane, 847–849
rheumatoid, and gamma globulin, 996*
and soya bean inhibitor, 406
transfer of sensitivity to skin homografts, 185–198
zinc content, 1652–1656
Levarterenol, and pressor response to chlorothiazide, 1278–1280
Linoleic acid
cell-lipid uptake rate, 983*
in plasma lipids, in vegetarian, 1430, 1434
Lipids
See also Cholesterol; Fatty acids
absorption, 811, 814, 815, 1186
after gluten, 1023*
species difference, 158
in biliary fistulae, 739
in adenocarcinoma, 1186–1190
adipose tissue, adaptation to fasting and feeding, 997*
and aminonucleoside, 1041*
and catecholamines, 763
in cerebrosides, 1546, 1547
and coagulation, 345, 1026*, 1950–1951
emulsification in intestine, 814
in erythrocytes, 345, 1020*
essential, in fat-free lean mass, 1791–1792
in familial hyperlipemia, 1787–1788
and glucose, 443–444, 733, 734, 1020*
pathway, reactions, 1027*
and taurocholate, 737
and heparin, 720, 722, 1780–1782
hypothalamic stimulation, 994*, 1964–1966
in liver glycogen storage disease, 997*
metabolism, 720, 722
and bile salts, 730–740
and fat meal after starvation, 441–446
and pantothenic acid levels, 1005*
and palmitate, 737
esterification, 154–159
phosphorus concentration in jaundice, 1644
after pituitary extract fraction H, 1023*
in plasma, 441–446, 1427
and adrenal glands, 313–318, 607–609
in diabetes, 1429–1430
in vegetarian, 1429
in platelets, 345
secretagogue effect after triolein, 1036*
serum levels, 997*, 1025*, 1964–1966
in bile fistula, 1641, 1644, 1649
in nephrosis, 455–465
in skin, and diphenylhydantoin, 1759–1761
in testis tumor, 535
in thoracic duct lymph, 1185–1190
transport, in three siblings, 1787–1788
turnover, 1564–1565
urinary excretion, in testis tumor, 538
Lipoproteins
and amylopectin sulfate concentrations, 1870–1871
β, 988*, 1864–1873
binding of α- and β-, 988*
chylomicron fraction, 1778–1780
distribution, sonic oscillation, 988*
and epinephrine, 317
fatty acid composition after corn oil ingestion, 1001*
after heparin, 1782–1783, 1787–1788
in hyperlipemia, 988*, 1777–1787
lipase activity, 1777–1789
and fasting, 1282–1287
and heparin, 1782–1787
lipid content, 988*
of lymph, fatty acid composition and oil feeding, 1001*
peptide patterns, 1562–1564
in plasma, 1777–1787
polysaccharide, tolerance induction and transfer, 1002*
protein, 1564–1565
and cholesterol synthesis rate, 1566
in serum, 462, 1001*, 1778–1780, 1864–1873
in nephrosis, 455–465
synthesis by liver, 1560–1569
Liver
adrenocorticotropic hormone clearance, 821
alcohol effects, 999*, 1005*, 1032*
blood flow, 1032*
and portacaval shunt, 517
cells, 994*, 1135, 1651–1656
chloride bromide ratios, 283–284
cholesterol, 643, 648
pool, 1289
synthesis, 645–646
uptake after Triton, 1556–1557
chromium uptake, 1553
cirrhosis. *See* Cirrhosis
and coenzyme A activity, 1005*
congestion and cardiac myosin, 1465
and cortisol clearance, 821, 822
and DA virus, 998*
deoxyribonucleic acid synthesis, 997*
in diabetes, 986*, 1009*
digoxin uptake, 1580–1581
and dihydrocortisone clearance, 323
disease, 971*, 1651–1656
and aldosterone metabolism, 323–324, 377
and antinuclear globulin tests, 976*
and blood ammonia after acetazolamide, 288–293
and cholesterol esters, 1642–1649
gamma globulin fractions, 474–480
and histamine clearance, 678
infiltrative, 674
plasma thrombolytic activity, 429–430
encephalopathy 1247–1248, 1253
and epinephrine, 317, 998*, 1930–1932

erythrocyte sequestration, 1148–1152
explanted, no protection against hypertension, 271, 272
extracts, 1599
and chondromucoprotein viscosity, 407
fatty, 675, 998*, 1005*, 1138–1139, 1142
fatty acids, 1007*
and dietary fats, 984*
function, 976*, 1930–1932
and indocyanine green uptake, 592–599, 1040*
fungus, 1439
and cortisone, 1441–1442
and glucose, 520, 1009*
metabolism 517, 976*
tolerance, 998*
glucosamine synthesis inhibition, 973*, 1010*
glycogen disease, 997*
bleeding diathesis, 1007*
in hemochromatosis after phlebotomies, 994*
hexosamine synthesis, 1115
in hypophosphatasia, 1389
and insulin, 520, 1167, 1172
"insulinase," 127–128
and iron, 91, 94, 104–106
and jaundice. *See* Jaundice
and lipids, 317, 1639–1650
and liproprotein levels, 1560, 1869–1872
in lupus erythematosus, 1596–1597
lymphoma, 137
and lysolecithin concentration, 1649
and mannose metabolism, 976*
metabolism, 1117
and antirheumatic agents, 973*
in thyroidectomized rats after thyroactive materials, 524–530
mevalonate uptake, 647
mitochondria, 1022*
monoamine oxidase activity after urea loading, 990*
necrosis, 1139–1140
in nephrosis, 981*
and pantothenic acid levels, 1005*
and phospholipid composition, 1644, 1649
regeneration, and kinase activity, 997*
after renal explantation, 274
in rheumatoid arthritis, 1596–1597
and steroid synthesis, 320–331, 731
and sulfobromophthalein, 236, 239–241, 1013*, 1039*, 1131, 1135, 1138–1139, 1142
thromboplastic activity, 1030*
and thyroxine survival time, 983*
and vitamin B_{12}, 1315–1318, 1667–1674

Lung
abscesses, 31, 32, 1273
in acceleration, pressure-volume relationships, 1739–1743
airway conductance, 573–583, 727, 1014*, 1626
in asthma, 587, 588
and altitudes, 999*
and alveolar volume, 1014*
diffusion, non-uniformity, 943–951
and ammonia excretion, 338
blood flow, 466–472
and infused fluids, 1049
and body position, 144–148, 795–801, 1347–1351
bronchodilator drugs, 589
and chest cage restriction, 573–583
compliance, 144–148, 1006*, 1739–1743
and deep inspiration, 143–149, 478, 579–582
and quiet breathing, 484
and spontaneous breathing, 576
cysts, and respiratory mechanics, 946–951, 1006*
deoxyribonucleic acid synthesis, 997*
diffusing capacity, 43–54, 114–148, 574–582, 1006*, 1031*, 1739–1743
and alveolar volume, 796, 943–951
and breathholding technique, 946–951
carbon monoxide, 54, 795–801, 1031*, 1346, 1348–1351, 1404
membrane components, 1401, 1404, 1406, 1409, 1411
non-uniformity, 944–951
residual, 1739–1743
elastic properties, 8–14, 1739–1743
emboli, lobar arteries, 1031*
emphysema, 587, 725, 1080–1090
and exercise, 586–590, 1404, 1410
expiratory volume, 46, 50, 574–582, 1739
explant of renal medulla in epithelial cells, 276
extracts and chondromucoprotein viscosity, 407
fibrin deposits after thromboplastin, 977*
and gas volume, 578, 796, 1409
krypton measurement, 1081, 1083
in heart disease, 1024*, 1031*
in industrial bronchitis, 589
infections, 1439
fungus, and cortisone, 1441–1442
and pulmonary arteriovenous shunt-flow, 1846–1848
and isoproterenol, 587–590, 1001*
lipo-polysaccharide trapping, 1002*
in myxedema, 42–55
in obesity, 50–53
renal medulla explants into, 266
and blood pressure, 270–279
resistance, 586–590, 725, 1006*
and acetylcholine infusion, 1031*
and age, 589, 590
and bronchomotor drugs, 588–590
in cor pulmonale, 1012*
and panting, 578, 585
and water aerosol, 586–590
surface tension after smoking, 973*
and thoracic constriction, 573–583
after thyroid therapy, 54
two-compartment model, 797–799
ventilation-perfusion relationship, 1080–1090
vital capacity, 40–51, 574–582, 725, 1404, 1739
and nitrous oxide uptake, 1021*
and progesterone, 35
volume, 576–582, 585, 587, 795, 946–951
and alveolar perfusion, 1085–1090
and cyclopropane uptake, 1794–1798
and esophageal activity, 146–148, 577
and forward acceleration, 1739–1743
in lung disease, 50–53
residual, 574–582, 1006*, 1739
scleroprotein per unit, 13
and transpulmonary pressure, 577–582
weight and cardiac myosin, 1464–1465
work of breathing, 1740–1741

Lupus erythematosus
antibody production, 1005*
antinuclear globulin, 976*
in agammaglobulinemia, 987*
hemagglutination, 995*
serum factors, 995*, 1260, 1595–1605
nephritis, renal lactic dehydrogenase, 1018*, 1381–1396

Lymph
and cholesterol, 1288–1292
fatty acids, 1001*, 1185–1190
hepatic, bile pigment composition, 135–136
17-hydroxycorticosteroids, 1921–1926
lecithins, 1190
transcortin cortisol binding, 1921–1926

Lymphocytes, 1035*
interstitial, and streptococcal glomerulonephritis, 1003*
in leukemia, 1354, 1356
viscosity-reducing activity, 409

Lymphoma
anemia, serum factors, 975*
liver, and bile pigment patterns, 137
serum β-lipoprotein levels, 1869–1872

Lysine
in erythrocytes and pyrophosphate-adenosine triphosphate exchange, 1763–1765
hyperexcretion in cystinuria, 1002*
in leukemia, 1689–1695, 1697–1698
in plasma, 1634–1635, 1676, 1680, 1689, 1691

Lysolecithin
conversion from lecithin, 1299–1301
egg, and cobra venom, 1296
and lecithinase A in duodenal contents, 1297
in liver disease, 1642–1649
in plasma lipids, 1430

M

Macrocryogelglobulinemia, thermosedimentation rates, 1324–1325, 1327

Macroglobulinemia
serum anti-thyroglobulin activity, 1260
serum globulin content, 474–480
mercaptane effects in, 1320–1329

Magnesium
adenosine triphosphate amino acid-dependent, 1766–1768

Magnesium (*cont'd*)
bone concentration, calcium and citrate interrelationships, 982*
and calcium metabolism in tetany, 1038*
chloride and palmitate esterification, 152–153
in costal cartilage, 925, 928
exchangeable, 422–425
in bone and extracellular fluid, 983*
and fatty acid esterification, 154, 159
and gastric juice in vitamin B_{12} absorption, 203, 212
in hypopituitarism, 1226–1229
and lecithinase A, in duodenal contents, 1297–1301
metabolism, 420–425
in pseudo-hypoparathyroidism, 1015*
in microsomal nucleoprotein and ribonucleic acid, 982*
in obesity, 1230
and protein-binding of phosphate, 504–505
turnover, 420–425
Malic dehydrogenase, in nephrotic syndrome, 1042*, 1364–1371
Manganese
and chondromucoprotein viscosity, 407
and plasma transmanganin, 979*
in vitamin B_{12} absorption, 203, 212
Mannitol diuresis
and antidiuretic activity, in diabetes insipidus, 1543–1545
and aortic constriction, 867, 868
creatinine clearance, 254
and electrolyte excretion, 256
hydration effects, 870, 871
inulin clearance, 254
and renal concentrating ability, 484–485, 865–870, 1301–1311
response after meralluride, 991*
and urine flow, 1543–1545
and water clearance, 250, 253, 259, 1067, 1543–1545, 1555–1558
Mannose
and serum insulin-like activity, 976, 1506–1507
in synovial fluid, 784–786
Mecamylamine
and aldosterone secretion rate, 1095
pressor response, 981*, 1028*
Melanoma, malignant, growth hormone effects, 1224, 1232
β-Melanophore-stimulating hormone, and adrenocortical steroid secretion, 769–774
Meningitis, and hypoglycorrhachia, 1016
Mephentermine, and blood volume, 997*
MER-29, in cholesterol biosynthesis, 1032*
Meralluride, and renal concentrating mechanism, 1303–1310
Mercaptanes, in macroglobulinemia, 1320–1329
2-Mercaptoethanol, and agglutinin activity, 1029*
and *p*-chloromercuribenzoate-treated virus hemagglutinating activity, 1017*
and sulfobromophthalein compounds, 1218
Mercaptomerin
and chloride excretion, 1614
and renal concentrating mechanism, 1303–1310
and serum electrolytes, 977*
and sodium absorption, 1609, 1614, 1618
and urinary flow, 1614
6-Mercaptopurine
and amino acids in leukocytes, 1693
homograft reactions, 952–958
Metahexamide, and pancreatic venous insulin activity, 1028*
Metanephrine, excretion in ganglioneuroma, 1733–1734
Metaraminol, in endotoxin shock, 1037*
Methacholine chloride, and esophageal motor activity, 1747–1750
Methanol, dialysance, 802–807
Methemalbumin, 1824–1825
Methemoglobin
and acetylphenylhydrazine, 1820–1829
and carbon monoxide, 1825–1826
and ferrocyanide, 1825–1829
and oxygen, 1825–1826
and phenylhydrazine, 1822–1829
Methemoglobinemia, hereditary, 1176–1179
Methionine
and cystine excretion, 1002*
in erythrocytes, 1690, 1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukocytes, 1679–1680, 1693–1695
in plasma, 1634–1635, 1676, 1680, 1689
urinary excretion, 1677, 1681, 1686, 1697–1698
Methotrexate, in cancer, 1034*
Methoxamine
and blood velocity, 971*
and myocardial contractility, 1020*
3-Methoxy-4-hydroxymandelic acid, urinary output
and centrifugal acceleration tolerance, 1533–1538
in ganglioneuroma, 1731–1732, 1734
in pheochromocytoma, 221–226
3-Methoxy-4-hydroxyphenylalanine, urinary excretion, 1015*
in ganglioneuroma, 1733–1734
2-Methyl-1,2-*bis*[3-pyridyl]-1-propanone, 11β-hydroxylase inhibitor, 374, 904–907
2α-Methyldihydrotestosterone propionate
and 17-hydroxycorticosteroids, 1922–1924
and transcortin, 1918–1926
1-Methylhistidine
in plasma, 1634–1635
1,4-Methylimidazole-4(5)-acetic acid, excretion after histamine, 676–682
1-Methyl-methergine-tartrate, and serotonin effects, 1026*
17α-Methyl-19-nortestosterone
and 17-hydroxycorticosteroids, 1922–1924
and transcortin, 1918–1926
6α-Methyl-prednisolone
and transcortin cortisol binding, 1921–1922
and water diuresis, 1473–1475
Meticorten, and amino acids in leukocytes, 1693
Metrazol, toxicity and hypoxia, 1039*
Mevalonic acid, and cholesterol, 644–648, 1032*
Micturition, neurogenic and vesicogenic changes, 1018*
Mitochondria, ammonia concentrations and transfer, 1022*
Mitral valve, stenosis
and blood volume, 993*, 1407, 1410, 1411
and isoproterenol, 1001*
and ventricular contraction, 1878–1880
Mongolism, chromosomal complement, 989*
Monoamine oxidase, and fibroplasia, 1026*
Mucopolysaccharide
acid-soluble, after diphenylhydantoin, 1762
in aortic elastin residue, 1658
connective tissue content after gold sodium thiomalate, 973*
matrix acid of costal cartilage, 927
metabolism in connective tissue, 1114–118
Mucoproteins
cartilage, and extracts, 405–412
collagen fiber fractions, 11
Muscle
arteriolar smooth, and direct digitalis action, 935
atrophy, in Cushing's syndrome, 1906–1907
blood flow, and heat acclimation, 825
bladder and micturition, 1018*
cardiac, after caval constriction, 1465
cationic amino acids, 1005*
chloride/bromide ratios, 283–284
development, and testicular tumors, 548
after diisopropylfluorophosphate, 1746
dystrophy, and protein turnover, 1180–1184
and glycine, 1181–1183
-nerve junction, in myasthenia gravis, and acetylcholine, 992*
in potassium depletion, 29–31, 686, 689–691
respiratory, 728
mechanics, 585
water content, 686
and water-soluble substances, 1042*
Myasthenia gravis, neuromuscular block, 992*
Myelin sheath, 114
and fatty acid synthesis, 113
Myeloid metaplasia, 1035*
Myeloma
cyclophosphamide effects, 1003*
gamma globulin, 474–480
half-life, 565
penicillin effects, 1324–1327
turnover, 567

and infection, 78
serum anti-thyroglobulin activity, 1260
serum B_{12} concentration, 1668
Myleran
and amino acids in leukocytes, 1693
and neoplastic cell population, 973*
Myocardium
damage, and blood velocity, 971*
efficiency, and exercise, 1011*
fatty acid metabolism and heparin, 718–723
infarction, 885–903
and behavior patterns, 760–762, 763
and calcium metabolism, 885–903
and plasma thrombolytic activity, 429
and serum β-lipoprotein levels, 1865–1869
and strontium metabolism, 885–903
oxygen uptake, 1011*
coronary sinus arteriovenous difference, 719–723
potassium shift in respiratory acidosis, 1013*
after serotonin, 1026*
sodium transfer, 1021*
Myosin
metabolism in dystrophic mice, 1180–1184
ventricular, in failing muscle, 1465–1468, 1470
Myxedema
basal metabolic rate, 43–45, 59, 526–529
and calcium metabolism, 893–901
corticosterone metabolism rate, 745, 751
estrogenic treatment and thyroxine, 1120–1129
and lung disease, 49–53
nitrogen metabolism, 886
and obesity, 49–53
phosphorus metabolism, 886
respiratory mechanics, 42–55
serum composition, 886, 901, 1033*
and strontium metabolism, 893–901
3,5,3′,5′-tetraiodothyroacetic acid treatment, 526–532
and thyroxine survival time, 983*
and thyroxine treatment, 526–532
and 3,5,3′-triiodothyroacetic acid treatment, 526–532
and triiodothyronine treatment, 526–532

N

Naphazoline, and vanillylmandelic acid excretion, 223, 225
Naphthoquinone, 1833–1834
Nephrectomy
and arteriolar thickening, 272, 273, 278–279
and azotemia, 273–274
bile pigment pattern, 134–135
and hypertension, 21–27, 268, 1093, 1096, 1104
and marrow erythroblasts, 103
and reticulocytes, 103
Nephritis
aminonucleoside, and renal concentrating ability, 865–870
alkaline phosphatase activity, 1018*, 1394
lactic dehydrogenase assay, 1394
serum β-lipoprotein levels, 1869–1872
and tetrahydroaldosterone excretion, 1100
Nephrocalcinosis, and renal function, 693–704, 985*
Nephrosclerosis
in adult Fanconi syndrome, 1390
and aldosteronism, 1094–1096
and hypertension, 26
macroscopic, after endocrine kidney, 22
and plasma corticoid levels, 820
and renal blood supply, 21
tetrahydroaldosterone excretion, 1100
Nephrosis
aminonucleoside, 981*, 1041*, 1369–1370
enzymatic alterations, 981*, 1364
hyperlipidemia, 463
and lipoproteins, 455–465, 1567, 1568
and proteinuria, 1367
tetrahydroaldosterone excretion, 1100
Nerves
and acetylcholine sensitivity in myasthenia gravis, 992*
autonomic, 1534–1538
and fatty acids, 606–609, 959, 961
and heart rates, 1025*
and hypervolemia induction, 1043, 1049
and medullary failure, 1930–1932
and norepinephrine excretion, 1535–1537
and cholesterol synthesis, 112–114
impulses, carotid sinus wall properties and pressure, 1017*
central, 1334–1335
adrenocorticotropic hormone-releasing center, 982*
diseases, serum lipoprotein levels, 1869–1871
and duodenal ulceration, 834–839
Nicotinamide, in alcoholism, 1005*
Nicotine
antidiuretic effect, 1543–1545, 1851–1863
and adrenocortical steroids, 1475, 1853–1862
in diabetes insipidus, 1543–1545
and behavior patterns, 760–762
and water excretion, 1474, 1543–1545, 1851–1853
Nicotinic acid, and thrombolytic activity, 428, 429
Niemann-Pick disease, cerebroside constituents, 1547–1549
Nitrogen
in adipose tissue, 1490
alveolar gas distribution tests, 52
amino, 1226, 1228
in uremic deproteinized plasma, 987*
anti-Rh_0(D) content, 1454–1461
in aortic residues, 1661–1666
balance, 657, 886
and weight, 971*, 1228, 1230–1231
in bovine neck ligament, 9
in connective tissue and diphenyl hydantoin, 1758–1762
of costochondral junction, 927–928
dilution, and oxygen inspiration, 579–582
in hemoglobin, 3–6
and phenylhydrazine-like drugs, 1825–1826
metabolism, growth hormone effects, 1224–1237
nonhexosamine of chondromucoprotein, 407–408
nonprotein, 657
in plasma expanders, 1954–1958
and tetrahydroaldosterone excretion delay, 1105
and palmitate uptake, 732
removal, in renal failure, 657, 1027*
retention of bone, 1233
in malignant hypertension, 1096–1099, 1105
synovial fluid, 784
urinary excretion, 1226, 1228
Nitrogen mustard, in leukemia, 1691–1696
Noradrenaline. *See* Norepinephrine
Norepinephrine
and arterial pressure, 766, 770–774, 1038*
and blood velocity, 971*
in catecholamine synthesis, 1733
and cerebral blood flow, 713, 715
and corticosteroid formation, 979*
and 3-methoxy-4-hydroxymandelic acid in urine, 1533–1537
in plasma, 1038*
and plasma free fatty acids, 607
and pulmonary hemodynamics, 1348
synthesis pathways, 221, 1929–1930
after thermal burns, 1928–1930
urinary excretion, 1731–1732, 1928–1930
and behavior patterns, 761–764
and centrifugal acceleration tolerance, 1533–1538
in diarrhea, 1734
in duodenal ulcer, 834
in neural tumors, 1734
in pheochromocytoma, 221–226
venoconstrictor responses, 1040*
venous pressure-volume curves, 831
Nutrition
and adipose tissue fatty acids, 435–445
in alcoholic neurological diseases, 1037*
and body density, 627
deficiencies and cholera, 988*
starvation and plasma fatty acids, 443, 445
and thymidine, 917

O

Obesity
and cyclopropane absorption, 1794–1796
and fat-free body density, 629, 971*
growth hormone effects, 1224, 1230, 1231
and myxedema, 49
respiratory mechanics, 51–54
serum β-lipoprotein levels, 1869–1871

Oleic acid
and fatty acids in adipose tissue, 437–439
and lecithin, 1297–1301
Ornithine
in leukocytes, 1679, 1680, 1692–1698
in plasma, 1634–1635, 1688–1691
urinary excretion, 1002*, 1677, 1681, 1686, 1697–1698
Orotic acid
pyrimidine synthesis, 15–19, 1029*
urine excretion, 19, 1029*
Orotidylic decarboxylase, in orotic aciduria, 1029*
Orthophosphate
exchange rate in erythrocytes, 1765–1766
fatty acid inhibition of incorporation, 984*
Osteitis deformans. *See* Paget's disease
Osteoarthritis, synovial fluid, 784, 786
Osteoporosis
body water and fat-free mass, 628–629
in Cushing's syndrome, 1901–1907
estrogen therapy, calcium and strontium metabolism, 885–903
Ouabain, pressor effect, 932
Ovarian dysgenesis, 1024*
Oxalacetic acid, in diabetes, 986*
Oxalate
and lecithinase A, 1297–1301
synthesis, 1337–1344
Oxygen
and acetazolamide, 289–293, 1251–1255, 1712
alveolar tension, 300, 1347
and ammonium chloride toxicity, 1039*
arterial concentration, 1031*, 1725
in anemia, 380–388
and chest restriction, 576–582
in cirrhosis, 1848–1849
in hypervolemia, 1723
in industrial bronchitis, 589
and lung disease, 53
in myxedema, 48, 51, 53
and obesity, 53
in polycythemia vera, 1722, 1723
after pulmonary embolization, 1031*
arteriovenous differences, 414–418
coronary, 719–723, 1011*, 1020*, 1055, 1209–1210, 1252–1255
consumption, 1031*, 1346
and airway resistance, 586–590, 726–729
in anemia, 379
and arterial carbon dioxide tension, 725–726
and bicarbonate excretion, 1711–1712
and blood pressure, 1346
cardiac, 415–418, 524–532, 718–723, 1011*, 1020*, 1022*
cerebral, 491–500, 1252
and diethylstibestrol, 1126
in emphysema, 725–726, 1001*
and exercise, 379, 414–418, 998*, 1011*, 1020*, 1055, 1209–1210, 1252–1255
hepatic, 524
in hepatic encephalopathy, 1252
at high altitude, 999*
in hypercapnia, 40
and mechanical work of breathing, 725–726
in myxedema, 48, 51, 53
in obesity, 49, 53
in polycythemia, 1724–1727
and posture, 795, 1020*, 1055
after progesterone, 33, 39, 40
renal, 289–290, 524
after thyroactive materials, 524–532
after vena caval obstruction, 1024*
deficiency. *See* Oxygen, hypoxia
and fetal hemoglobin production, 1112
hypoxia, 1039*
in congenital adrenal hyperplasia, 374
and hemoglobin synthesis, 1000*, 1108–1112
and renal phosphatase, 307, 309
intake, 378–388, 578–579
See also Lungs; Respiration
adaptation for heavy exercise, 1212
and carbon dioxide inhalation, 713, 1250–1255
cerebral, 1248–1255
and fatty acid metabolism, 719–723
and hydrogen peroxide, 1831–1832
in liver disease, 1251
in organic dementia, 491–500
and palmitate, 732
and posture, 1210–1212
psychometric correlations, 496
and respiratory mechanics, 579, 589, 1346
tension, 380–388
transport, 379, 1020*
Oxyhemoglobin
and hydrogen peroxide, 1832–1833
and phenylhydrazine, 1822–1826
and potassium ferrocyanide, 1825–1829
Oxythiamine, in hypoxia, 998*
Oxytocin, 969*

P

Paget's disease, calcium and strontium metabolism, 885–903
Palmitate
esterification, 150–160, 731–734, 739
exercise clearance of albumin-bound, 216–220
transport, 983*, 1511–1515
Pancreas
in aminonucleoside nephrosis, 981*
glucagon levels, 1036*
insulin assays, 1074, 1078
and islet cell adenocarcinoma, 1166, 1168, 1174
and glomerular enzymatic activity, 982*
juice, after cholinergic blockade, 1000*
Pancytopenia, and plasma vitamin B_{12}, 1668, 1671
Pantothenic acid, 1005*
Papain
and blood clotting time, 1945–1946
and gamma globulin treatment, 986*, 1039*, 1934–1938
Para-aminohippuric acid
clearance, 974*
and antidiuresis, 1473–1474, 1477
and aortic constriction, 869
in hypertension, 396–404
and sodium excretion, 389–393, 396–404
and water excretion, 389–393
tubular excretory capacity, 389–393
after glycine, 1339, 1342
ureteral stop-flow method, 841–845
Paracolon bacilli, serum bactericidal effect, 76–80, 84–88
Paralysis
of esophagus, after di-isopropyl-fluorophosphate, 1746
of muscles, in potassium depletion, 689–691
and paralytic polio in Panama City, 1028*
Parathyroidectomy, and calcium and phosphorus homeostasis, 662–670
Penicillamine, 1322–1323, 1326, 1328
Penicillin
hemagglutination antibody, 995*
metabolite, 1328
and serum sedimentation rate, 1325
and staphylococcus strains, 1039*
transport across inflammatory membrane, 846–853
Penicillin G, 1323–1326, 1328
Pentothal, and bicarbonate, 1708, 1711–1712
Pepsin
pituitary extract Fraction H, 1023*
and streptokinase inhibitor, 1001*
Peptone
and gastric secretion, 835–836, 838
and triolein, 1036*
Peristalsis, esophageal, 1747–1751
Peritoneum
agar disc implantation, and penicillin penetration, 848–853
kidney explants, and blood pressure, 269–279
Phenolsulfonphthalein, excretion, in Fanconi syndrome, 1390
Phentolamine, and free fatty acids, 608
Phenylacetylglutamine, identification in blood, 987*
Phenylalanine
in catecholamine synthesis, 1733, 1929–1932
in erythrocytes, 1690–1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukemia, 1689–1691, 1693–1695
in plasma, 1634–1635, 1676, 1680, 1689
urinary excretion, 1677, 1681, 1686, 1697–1698
Phenylephrine, and vanillylmandelic acid excretion, 223, 225
Phenylhydrazine
hemoglobin precipitation, 1000*, 1820–1832
and plasma iron uptake, 1033*

2-Phenyl-1,3-indanedione, and serum β-lipoprotein levels, 1869–1872
Pheochromocytoma, 990*
See also Vanillylmandelic acid
Phosphatase, alkaline
in adult Fanconi syndrome, 1387
in cystine storage disease, 1387
dehydrogenase, in tubular diseases, 1386–1393
in endotoxin shock, 302–309
in ganglioneuroma, 1730
after growth hormone, 1225, 1230
in hypophosphatasia, 1387
ischemic effects, 1396
in kidney structures, 1372–1380
in lupus nephritis, 1394–1400
in nephrosis, 981*
glomerular, 1364–1371
and phlorhizin, 1392, 1393
and prednisolone, 1398
in proteinuria, 1370
Phosphate
compounds of erythrocytes during bank storage, 56–71
excretion, and acidity, 970*, 995*, 1516–1525
and calcium absorption, 1809–1812
and estrogen therapy, 900
in ganglioneuroma, 1730
and glucose, in placental insulin degradation, 119
intracellular inorganic and 2,3-diphosphoglycerate synthesis, 60
matrix acid of costal cartilage, 927
plasma concentration after Tris-(hydroxymethyl) aminomethane, 1035*
protein-binding in renal disease, 501–506
reabsorption, 1389
in adult Fanconi syndrome, 1390
in potassium deficiency, 1014*
in vitamin D-resistant rickets, 1807–1812
retention in azotemia, 503
and vitamin B_{12} absorption, 203–207
Phosphatide, prothromboplastic, 1950–1951
Phosphatidic acid, and triglyceride synthesis, 157
6 Phosphogluconate dehydrogenase
and adipose tissue lipogenesis, 997*
and glucose-6-phosphate dehydrogenase, 1010*
in liver glycogen disease, 998*
and thyroid-stimulating hormone, 986*
Phospholipids
in bile fistula, 1644, 1649
egg, and cobra venom, 1296
and epinephrine, 314–318
and fatty acids, 984*
in adenocarcinoma, 1186–1190
in diabetes, 1432
esterified, 154–155
in vegetarian, 1430, 1432, 1434
after growth hormone therapy, 1231
intestinal lipid fractionation, 737
in nephrosis, 457–458
phosphorus, diluted thromboplastin generation test, 1026*
in plasma, 1020*, 1427–1430
platelets, 345, 349
in serum, 1644, 1649
and desoxyribonucleic acid, 1025*
in hyperlipemia, 988*, 1778–1788
Phosphorus
in calf costal cartilage, 924–928
and creatinine clearance ratios, 664, 665
excretion, 886, 1016*
after sodium loading, 1553
in membrane hemoglobin, 3–6
metabolism
growth hormone effects, 1224–1237
in pseudo-hypoparathyroidism, 1015*
retention, in bone and muscle, 1233
transfer to adenosine diphosphate, 59
trichloroacetic acid-extractable of cartilage, 925
tubular reabsorption after parathyroidectomy, 663–665
urinary excretion after dihydrotachysterol, 1016*
Pitressin. *See* Vasopressin
Pituitary gland
adenoma, 1007*
and adrenocorticotropic hormone, 906, 982*, 1472–1479
and aldosterone secretion, 765–775, 981*
carbohydrate metabolism in diabetes, 991*
and cortisone, 1853–1858
Fraction H components, 1023*
and glucose metabolism, 992*
in adipose tissue, 1496
glycogen turnover, 991*
growth hormone, 125, 1006*, 1037*, 1223–1245, 1496
hexose-monophosphate shunt activity, 991*
and insulin response, 129, 991*
and mineralocorticoids 1859–1862
and nicotine, 1853–1858
phosphorylase activity, 991*
stimuli sensitivity and glucocorticoids, 1859–1863
tumors, and blood sugars, 1166, 1169, 1174
vasopressin release, 1853–1858
Placenta
and carbon dioxide transmission, 234–235
insulin degradation, 116–130
and lactic acid metabolism, 230, 234–235
Plasma
albumin concentration, 1034*
after storage, 1864–1867
alcohol concentrations, 805
aldosterone
and carotid constriction, 1331
and vena caval constriction, 766
amino acids, 993*, 1634, 1675–1687
ammonium, 332, 336–340
androsterone conjugates, 1586–1588
antidiuretic activity, 1539–1545
antigen, after heating, 701–704
bicarbonate, 1019*, 1036*, 1094–1097, 1105, 1518, 1552–1553, 1710–1713
calcium, 694
after strophanthidin, 1021*
carbon dioxide
in hydropenia, 688
in nephrocalcinosis, 694
tension, 335–336, 1710, 1713
and bicarbonate reabsorption, 1019*, 1707–1708
after Tris-(hydroxymethyl) aminomethane, 1035*
carbonic anhydrase activity, 1019*, 1552–1553
chloride, 1093–1095, 1518–1519
cholesterol, 315, 1288, 1292–1293, 1366, 1427
in diabetes, 1429–1430
in vegetarian, 1429
citrulline content, 1634
clearance
corticosterone, 326–327, 743–746, 751, 753
cortisol, 325, 327, 602–604, 751, 753
erythrocytes, labeled, 1148–1149
erythropoietic factor, 108
histamine, 678
indocyanine green, 594, 596
inulin carboxylic acid, 1004*
lipoproteins, 1784–1787
magnesium, 421–425
of radioiodide, 790–794, 975*
radioiron, 90, 104, 106, 1003*
sulfate, 1910–1911
sulfobromophthalein, 777–780, 1039*, 1133
thymidine, 912–913, 916, 917
thyroxine, 999*, 1591
triglycerides, 996*
vitamin B_{12}, 1312–1319, 1668–1673
coagulation, 431–433, 555, g130–g135
in hemophilia A carriers, 1619–1625
in liver glycogen disease, 1007*
recalcification tests, g130, g132
and staphylococci, 1013*
corticoids, electronic analog computer, 816–824
cortisol, 822
after 9α-fluorocortisol, 323
in liver disease, 327
production rate, and diurnal variation, 818–823
creatinine, and pelonephritis kidney, 871
cystine content, 1634
electrolytes after cesium, 172
after rubidium, 172
and erythrocytes, phospholipid exchange in spherocytosis, 1019*
expanders, 698–705, 1954–1959
browning reactions, 1954–1960
nonprotein, 1954–1958
potassium, 1954–1958
protein, 701–704, 1953–1961
sodium, 1954–1958
thermal stability estimation, 1954–1959
fatty acids, 984*, 1429
free, 215–220, 313, 441–446, 607–609, 717–723, 987*, 1513
glucose, 1035*
in renal disease, 1772–1774

Plasma (*cont'd*)
glutamine, 1634
glycine, 1634
hepatic flow, 1202
and sulfobromophthalein sodium removal rate, 239
17-hydroxycorticoids, 371, 1915–1917
and adrenal glands, 601, 604, 982*, 1040*
and adrenocorticotropic hormone, 604, 1102
in cancer, 1917–1922
and estrogens, 601–605, 1922–1924
and pituitary, 604
post-menopausal, 1915–1924
postpartum, 1922–1924
after surgery, 1920–1925
and transcortin cortisol binding, 603, 1915–1921
insulin concentration, 1157–1175
in acromegaly, 1166–1169, 1174
in cirrhosis, 1168
in diabetes, 1041*, 1164–1168, 1171, 1174
dilution effect, 1161–1163, 1171, 1173
after frozen storage, 1170, 1174
after glucose loading, 1167, 1171–1175
in hyperthyroidism, 1168
and islet cell tumor, 1173
after leucine feeding, 993*
iron levels, 103–107, 977*, 1033*
turnover, 109, 1006*
isoleucine content, 1634
lactate, 993*
leucine, 993*, 1634
lipids, 996*, 1424–1434
and epinephrine, 310–319
and fat meal after starvation, 441–446
in vegetarian, 1430, 1434
lipoproteins, 317, 1782–1788
lipase activity, 1783–1787
magnesium supersaturation, 983*
methionine, 1634
norepinephrine levels, 1038*
osmolality, 482–483, 694, 1065, 1303, 1305–1310
pH, 340, 988*, 1035*, 1954–1958
phenylalanine, 1634
phosphate, 503, 505, 993*, 1035*
phospholipids, 1427–1428
platelets, 1026*
aging process of stored, 970*
potassium, 103–105, 172, 688, 694, 993*, 1093–1095
at atrioventricular block, 1890–1891
after digitoxin, 1887–1892
in heart failure, 1464
in malignant hypertension, 1097–1098
in potassium depletion, 686, 1005*
shift to erythrocytes, 1013*
and ventricular arrhythmia, 1891–1892
proline, 1634
protein-binding, 699
of indocyanine, 595
of iodine in myxedema, 44
of phosphate, 504, 505
proteolytic activity, 431–433
prothrombin, 345
renal flow, 389–391, 873
in newborn infants, 1063
after nicotine, 1475
and oxytocin, 969*
stop-flow analysis, 843–845
resin-treated, 354, 355, 357
serine, 1634
sodium, 1093–1095
in heart failure, 1464
in hydropenia, 688
in nephrocalcinosis, 694
in potassium depletion, 686
post-anticholinergic, 1612, 1616
and propantheline, 1611–1614
after volume loading, 993*
splanchnic volume, 239
and collateral volumes, 1203–1207
steroid levels, 746
in liver disease, 322
after storage, 1864–1865
sulfobromophthalein concentration, 239, 777–780, 1140
in Dubin-Johnson syndrome, 1138
and hepatic parenchymal cell storage, 237
after sodium dehydrocholate, 1135–1137
taurine, 1634
threonine, 1634
thrombolytic activity, 426–434
after pyrogen, 428, 429
thromboplastin antecedent, 1947–1948
and Hageman factor, 1019*
and thrombosis, 262–265
thyroxine levels, 1120–1129
in children, 1592–1594
transcortin levels, 1920–1924
and cortisol, binding, 1915–1924
postpartum, 1922–1924
tritium activity after tritiated thymidine, 912–914
tyrosine, 1634
urate, 1004*
urea, 103–105, 686, 688, 694, 869, 1004*, 1093–1095, 1634, 1700
valine, 1634
volume, 977*
after chlorothiazide, 1278, 1280
after dextran, 1280
and water diuresis, 980*

Plasmin
coagulation, 1945–1951
formation, and fibrinolysis production, 1001*
and plasma thrombolytic activity, 430–433
streptokinase activation, 1030*

Platelet
amino acids, 1693
activating enzymes, 1765–1766
after brain thromboplastin infusion, 977*
after liver explants, 274
in polycythemia vera, 1723
protamine effects and heparin, 1016*
in renal failure, 1027*
serotonin concentrations, 1008*
in thrombocytopenic purpura, post-transfusion, 1029*
thromboplastic factors, 342–351
viability preservation, 970*

Pneumonia
hemorraghic, and fungus pyrogens, 1276
and myxedema, 49–51

Poliomyelitis
immunization dosage schedule, 970*
paralytic, 1028*

Polybrene, coagulation defect production, 1016*

Polycythemia
adenosine triphosphate, and pyrophosphatase exchange, 1765–1769
arylsulfatase values, 1035*
erythropoietine response, 1033*
hypervolemia, circulatory effects, 1722–1728
intracardiac pressures, 1726
and plasma thrombolytic activity, 429
vitamin B_{12} kinetics, 1667–1674

Polyoxyethylated nonylphenol, 1297

Polyoxyethylene lauryl ether, 1297

Polyoxyethylene sorbitan monooleate, and palmitate esterification, 153, 733–734, 738–739

Polysaccharide
costal cartilage fractionation, 1752, 1755, 1757
neutral, in aortic elastin residue, 1658

Posture
and cardiac output, 1020*, 1052–1060, 1348
and blood volume, 414–419, 1346–1352
and exercise, 1020*, 1060
and heart rate, 1055
and lungs, capillary blood flow, 795
and oxygen consumption, 1055
and plasma free fatty acids, 606–609
and pulmonary hemodynamics, 1346–1352
and respiratory mechanics, 144–148, 578, 588
and stroke volume, 1051–1061, 1210–1212

Potassium
and acetylcholine response in myasthenia gravis, 993*
and ascites treatment, serial changes, 977*
and atrioventricular node conduction after digitoxin, 1885–1893
balance
and growth hormone, 1224, 1226–1229
and serum sodium concentration, 1033*
and weight, 971*, 1228, 1231, 1235, 1237
in bile after taurocholate infusion, 164–169
in costal cartilage, 924–928
cellular content, 923–924
in spherocytosis, 1019*
chloride, 1890–1891
and serum calcium, 1890–1891
depletion, 172–175
after cesium loading, 172–173
after chlorothiazide, 1036*, 1277–1278

and desoxycorticosterone acetate feeding, 1014*
hyposthenuria, 684–692
and renal concentrating ability, 684–692
after sodium bicarbonate, 1036*
and tubular phosphate reabsorption, 1014*
and urinary osmolality, 687, 689–691
distal secretory site, stop-flow technique, 486
diuresis after acetazolamide, dosage effects, 1552–1553
excretion, 173, 1227
and dextrose, 256
in Fanconi syndrome, 1390
and mannitol, 256
after phosphate feeding, 995*
extra- to intracellular ratio, 1891–1892
and digitalis action, 1890–1891
fluoride and palmitate esterification, 153, 732
in hydropenia, 688
in hypertension, 880–884
intake, and sodium excretion after spironolactone, 984*
kidney concentration in proximal tubule of Necturus, 1015*
metabolism, after growth hormone, 1227, 1229–1237
in muscle, and cationic amino acids, 1005*
myocardial transfer and extracellular calcium concentration, 1020*
phosphate
and atrioventricular block after digitalization, 1885–1893
and serum calcium, 1890
in plasma expanders, 1954–1958
plasma levels. *See* Plasma
removal during gastrodialysis, 656–657
repletion, and pyelonephritis susceptibility, 28–33
retention, bone and muscle, 1233
secretion, and ureteral occlusion, 489–490
and sodium, 877–884, 1036*
myocardial exchange in respiratory acidosis, 1012*
stool content, 988*, 1227
wasting, and vitamin D, 985*

Prednisolone
and alkaline phosphatase, 1398, 1399
and antidiuretic response, 1853–1855
galvanometric deflections, 817
and lactic dehydrogenase, 1398, 1399
and nicotine antidiuresis, 1853–1858
and water diuresis, 1857–1858

Prednisone
and alkaline phosphatase, 1397, 1399
and lactic dehydrogenase, 1397, 1399
in plasma, 820
and serum electrolytes, 977*
and serum thyroxine-binding globulin, 999*

Pregnancy
carbohydrate metabolism, 116–130
corticosteroid metabolism, 604
diabetogenic effects, 116–130
eclampsia, 1529
estrogen urine-plasma ratios, 975*
hypertension, 1529
insulin metabolism, 116–130
labor induction and oxytocin, 969*
lactic acid metabolism, 226–235, 1527–1530
and plasma transcortin levels, 1920–1924
pre-eclampsia, 1529
proconvertin, and Stuart factor levels, 1015*
serum uric acid, 1529
and tetrahydroaldosterone excretion, 1100
toxemia, 1530
uric acid excretion, 1529–1530

Pregnane-3,11,20-triol, 368, 370, 371, 752

Pregnane-3,17,20-triol, 368–370, 373, 989*
urinary excretion, 535, 538, 906–907

Pregnenolone, 372
triphosphopyridine nucleotide inhibition of generation, 1010*

Premarin
and plasma 17-hydroxycorticosteroid levels, 1917–1924
and plasma transcortin levels, 1920–1924
cortisol binding, 1917–1924

Pressure
aortic, 933
and blood velocity, 971*
arterial, 374–375, 414–418, 827, 1058, 1278, 1878–1883
See also Hypertension; Hypotension
and acetyl strophanthidin, 932, 933, 939
and adrenalectomy, 932, 1097
in adrenogenital syndrome, 373
and aldosterone secretory rate, 1097
and angiotensin II, 1040*
and Arfonad, 961, 1046
and body position, 608, 1052, 1348–1351
after calcium infusion, 1021*
and cardiac hemodynamics, 1044
and carotid tension, 1017*, 1331
and chlorothiazide, 1028*, 1277–1280
and cortisone, 769
and desoxycorticosterone, 374–375
diastolic, 827, 1058, 1278, 1464, 1876–1883
after digitalis, 932, 939–940
in endotoxin shock, 1037*
and exercise, 414–418, 827, 830, 831, 1052–1060, 1210–1212, 1348
and ganglionic blockade, 1046
histamine responses, 678
in hypervolemia, 1046, 1723
heat acclimatization, 827
after hypophysectomy, 771
and isoproterenol, 1001*
kidney explanted to peritoneum, 269–279
and mecamylamine, 1028*
after mephentermine, 997*
and natriuresis, 883
after noxious stimuli, 1028*
in polycythemia vera, 1723, 1726
and rauwolfia, 1028*
and renal atrophy, 21–27
and renal explantation, 270
and saline infusion, 961
after sodium, 883, 961
after thyrocarotid arterial junction denervation, 1333
atrial, 825, 997*, 1464–1465
and stroke work, 1025*
capillary transmural, Starling hypothesis, 1350
caval constriction, 771, 1024*, 1335
and cortisone, 769
cerebral, after acetazolamide, 1255
esophageal, 586–590, 1747–1749
after di-isopropylfluorophosphate, 1747, 1749
intestinal
and propantheline, 1612–1613
and sodium absorption, 1611
intrasplenic, in splenomegaly, 1204, 1206
intrathoracic, and pulmonary air cysts, 1006*
lung elastic, and airway conductance, 582, 586–590
portal venous, 938, 939
pulmonary, 576–582, 1001*, 1031*, 1348
after carbon dioxide, 296–297
for forward acceleration, 1738–1743
pulsatile characteristics, 1626
pulmonary artery
after caval obstruction, 1024*
after fluid volume loading, 993*
and norepinephrine, 1348
and serotonin, 1034*
and trimethaphan, 1348
pulse, 974*, 1024*, 1038*
and aortic regurgitation, 1875–1876
after carotid constriction, 1335
by transseptal left heart catheterization, 1877–1883
and ventricular end-diastolic segment length, 1876–1878
Starling's law of heart, 974*
vena caval, 939–940
venous, 578, 771, 731, 939–940, 1040*
ventricular, 1464–1465, 1879–1883
and epinephrine, 1020*
and methoxamine, 1020*
wedged hepatic venous, 940, 1021*
and portal collateral blood flow, 1204

Proaccelerin, after thromboplastin infusion, 977*

Proconvertin
assay, 1015*, 1947–1951
in hypoproconvertinemia, 554–563

Progesterone, 372
and galactose metabolism, 178–184
and glucose-6-phosphate dehydrogenase, 1010*
hydroxylation products, 979*
in adrenogenital syndrome, 372–373

Progesterone (*cont'd*)
and respiration, 34–41
structural formula, 41
Proline
conversion to collagen hydroxyproline, 980*
in erythrocytes and pyrophosphate-adenosine triphosphate exchange 1763–1765
and glutamic acid metabolism, 1692
intracellular pools, 1002*
in leukemia, 1689–1691
in leukocytes, 1679–1680, 1693–1698
in plasma, 1634–1635, 1676, 1680, 1689
urinary excretion, 1677, 1681, 1686, 1697–1698
Propantheline, and gastrointestinal motility, 1617
Proprionamide and membrane permeability, 995*
Propylthiouracil, and thyroidal iodine uptake and clearance, 792, 1120–1129
Protamine
heparin neutralization, 1016*, 1780–1783
and lipolytic activity, 1285
Protein
and aminonucleoside, 981*, 1041*
Bence Jones, 1192–1200
of cervical mucus, 1358–1363
in costal cartilage, 927, 1752, 1755, 1757
and heat denaturation, 1194–1195, 1958–1960
and hydroxyapatite patterns in aortic residue, 1658–1666
intake, 1067
and behavior patterns, 760–762
in cystinuria, 1002*
in hydropenia, 1064
in newborn infants, 1062–1069
and osmolal clearances, 1064, 1067
in lung tissue, 13
in lymph fluids, 1921–1922
and membrane hemoglobin, 3
metabolism, 479, 565
in muscular dystrophy, 1180–1184
metal binding cofactor, 979*
-mineral ratio and fat-free body density, 628–629
moiety and magnesium binding sites, 982*
noncollagenous, and diphenylhydantoin, 1759–1762
in plasma, indocyanine green binding, 595
in plasma expanders, 698–705, 1954–1962
sedimentation characteristics, 1755
after serum albumin storage, 1838
in serum
in hyperlipemic siblings, 1778–1779
after sodium chloride-lactate solution, 882
synthesis
and growth hormone, 1002*
in intestinal epithelial cells, 1007*
in synovial fluid, 786, 788
transport, 982*
Proteinuria
in aminonucleoside nephrosis, 981*, 1366
in glomerulonephritis, 1003*
in hypertension, 1094–1095
and kidney enzyme activity, 982*, 1367, 1370
serum lipids and lipoprotein, 456
and tetrahydroaldosterone excretion, 1100
Prothrombin
and Aspergillin O, 1010*
after brain thromboplastin infusion, 977*
and diphenylhydantoin, 981*
and lipid effects, 347
in liver glycogen disease, 1007*
and proconvertin activity, 555, 559
protamine effects and heparin, 1016*
Quick test, 1943–1944
and thromboplastin, 1030*
Pulmonary
blood volume, 53, 54
and body position, 1345–1352
membrane diffusing capacity, 1348–1351
Pulmonary artery
and acetylcholine, 1031*
embolism, 1031*
occlusion, 1001*
and carbon monoxide concentration, 948
in polycythemia vera, 1726
pressure
See also Pressure, pulmonary artery
pressure-volume relationship, 576, 586
and relaxation, 1739–1743
transient prominence, 999*
Pulmonary valve stenosis, and cardiac myosin, 1464–1465
Purine
metabolites, and platelets after storage, 970*
in serum, in liver glycogen storage disease, 997*
synthesis, 449–452, 650
and 6-diazo-5-oxo-L-norleucine, 449–452
in uric acid synthesis, 448
Purpura, thrombocytopenic, and cerebrosides, 1547, 1549
Pyelonephritis
in adult Fanconi syndrome, 1390
and aortic constriction, 868–869
immunity role, 1024*
and plasma corticoid levels, 820
and renal artery constriction, 871
and renal concentrating ability, 865–870
and serum β-lipoprotein levels, 1869–1872
and streptococcal glomerulonephritis, 1003*
susceptibility
and hypotensive drugs, 1813–1817
after potassium depletion recovery, 28–33
Pyrazinamide, and tubercle bacilli, 1009*
Pyridine
hemochromagens, 1830–1831
nucleotide oxidation, 1041*
Pyridoxine, in alcoholism, 1005*
Pyrimidine
synthesis, in anemia, 17–19
Pyrophosphate, and adenosine-triphosphate in erythrocytes, 1763–1770
Pyruvate
degradation to lactic acid, 64
and lactic dehydrogenase assay, 1381
in nephrotic syndrome, 1042*, 1364–1370
oxidation, steroid inhibition, 1041*

Q

Quick test, 559, 1943–1944
Quinacrin, in rheumatic disease, 973*
Quinidine-albumin interaction, 978*

R

Raffinose, and insulin, 1008*
Rauwolfia, pressor response, 1028*
Regitine. *See* Phentolamine
Reserpine
atherosclerotic effects, 981*
in hypertension, 981*
and aldosterone excretion, 1093–1095
Respiration
carbon dioxide stimulation and progesterone, 37
circuit volume and cyclopropane uptake, 1794–1798
in cor pulmonale, 1012*
in emphysema, 34–41, 724, 727
energy cost of breathing, 47, 51, 586–590, 724–729, 1740
in hypercapnia, 39–40
in myxedema, 47, 51
and exercise, 1052
muscles, during, 54, 724–729
and progesterone, 34–41
pulmonary mechanics
and abdomen restriction, 575
in acceleration forward, 1737–1743
and air cysts, 1006*
and chest cage restriction, 573, 576
respiratory center sensitivity, 725–726
supine position, 1052
Respiratory quotient
in anemia, 379
and exercise, 379, 414–418
Respiratory rate
and acceleration forward, 1740
and acetylcholine infusion, 1031*
in anemia, 379, 382
and bronchoconstriction, 589, 590
and carbachol aerosol, 589
and chest restriction, 576
in myxedema, 47, 48
Respiratory tract
influenza virus infection, 1026*
obstructive disease and airway resistance, 584–591
Reticulocytes
in anemia, 1763
in Di Guglielmo syndrome, 15–19

and erythropoietic factor, 105, 107, 994*
in mature erythrocytes, ribonucleic acid turnover, 972*
after nephrectomy, 103, 105, 274
in polycythemia vera, 1763
and riboflavin therapy, 1004*
in spherocytosis, hereditary, 90

Rheumatic disease
antibody production, 784*, 995*, 1005*
cartilage destruction, 411
in congenital agammaglobulinemia, 987*
latex fixation test, 972*
serum-lipoprotein levels, 1869–1871
synovial fluid, 784
extracts and chondromucoprotein viscosity, 409
fructose-6-phosphate and glutamine transamidase, 1115

Rheumatoid factor, 996*, 1596–1597
in agammaglobulinemia, 987*
anti-thyroglobulin unrelated, 1260
gamma globulin, 478
hexose levels, 786, 787
inhibition and stabilization, 972*

Ribonucleic acid
and amino acid activating enzymes precipitation pH, 1763–1766
synthesis, 972*

Ribose, in histamine metabolism pathway, 676

Riboside, 680

Rickets
and cystine storage disease, 1390
vitamin D-resistant, and phosphate reabsorption, 1807–1812

Riedel's struma, 1033*

Rubidium, excretion, and intracellular pH, 172, 175

S

Salicylate
and glucosamine synthesis, 973*
and pancreatic venous insulin activity, 1028*

Saliva
enzymatic defects in orotic aciduria, 1029*
virus infection transmission, 1023*

Salivary gland, metabolism, after thyroid agents, 530

Sarcoidosis
lung diffusion
membrane diffusion component, 1407–1408, 1410
non-uniformity, 946–951
serum, leucine aminopeptidase, 672

Secretin
and bile flow, 164–169
and fecal radioactivity after triolein, 1036*

Sedoheptulose-7-phosphate, after erythrocyte storage, 62–70

Serine
in erythrocytes and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukemia, 1679–1680, 1689–1691, 1693–1698, 1700
phosphatidyl, and erythrocytes, 345–350
in plasma, 1634–1635, 1676, 1680, 1690, 1691
in uremia, 987*
urinary excretion, 1677, 1681, 1686, 1697–1698

Serotonin
and connective tissue, 1025*
and glucose oxidation, 986*
oxidation to 5-hydroxyindoleacetic acid, 1008*
and pulmonary arterial pressure, 1034*
urinary assay, 1015*
in ganglioneuroma, 1730

Serum
albumin, 118–130, 459, 463, 464, 701–704, 1362, 1772–1778
and acetylphenylhydrazine, 1824–1825
and chondromucoprotein viscosity, 407
cortisol binding, 1921–1925
in Cushing's syndrome, 1900–1908
in ganglioneuroma, 1730
and phenylhydrazine, 1824–1825
and plasma volume, 1902–1906
in portal collateral blood flow measurement, 1202–1207
and rheumatoid factor, 972*
storage, long-term, 1837–1840
and thyroxine, 1032*
alkaline phosphate, 1224–1225, 1230
in adult Fanconi syndrome, 1390
in bone disease, 886
in hyperparathyroidism, 894
in hypophosphatasia, 1389
in thyroid cancer, 894
alpha-globulin binding of papain protease, 1039*
amylopectin sulfate turbidity, 1865
anti-beef insulin, 1160–1163, 1170–1172
and glucose oxidation, 1495, 1496
antibodies, 701–704, 990*, 1006*, 1231, 1596
beef and human, cross reactivity, 1076
to DA virus, 998*
and erythrocyte destruction, 1040*, 1148–1150
to horse, and gamma globulin fractions, 986*
and insulin, 1070, 1072, 1161, 1173
liver extract components, 1602
reactivity, 1599
in lupus erythematosus, 1595, 1602–1604
and Mycobacterium tuberculosis, 985*
in nephrosis, 981*
nucleoprotein extract, 1596–1598
pyelonephritis, 1024*
thymus extract, 1599
thyroglobulin, 1259–1265, 1599
thyroid injury, 1033*
antigen-antibody precipitation, 701
to Bence Jones protein, 1197
bactericidal activity, 72–81, 355–359, 361, 1013*
species differences, 82, 355, 358, 362
bilirubin, 134–141, 1646
in hepatic dysfunction, 137–138, 140–141, 593, 594
after mannose infusions, 976*
retention, 1649
bovine, 125, 972*
bromide/chloride ratio, 283–284
calcium, 665–666, 887, 900–901
in adult Fanconi syndrome, 1390
in bone disease, 886
in hypopituitarism, 1226–1229
in Paget's disease, 892
after parathyroidectomy, 662–670
phosphate-losing tubular disease, 1389
in pseudo-hypoparathyroidism, 1016*
and sodium phosphate, 1890–1891
in tetany, 1038*
and vitamin D, 985*, 1808–1812
carbon dioxide, 29, 998*
after acetazolamide, 289–293
chloride
to bromide ratio, 282–287
and potassium nephropathy, 29
after sodium chloride-lactate, 882
cholesterol, 456, 464, 762, 886, 988*, 1649
and behavior patterns, 760–762
and desoxyribonucleic acids, 1025*
environmental influences, 760–762, 1022*, 1030*
esters and liver damage, 1642–1649
in glycogen storage disease, 997*
in hypercholesterolemia, 1870–1871
lung disease, 49
after MER-29, 1032*
in myxedema, 44, 49
in obesity, 49
and occupational influences, 1022*
to phospholipid ratio, 459
after pituitary extract Fraction H, 1023*
race differences, 1030*
and socioeconomic subgroups, 1030*
and starvation, 446
and stress, 317, 318
and thyroid substances, 526–532
cholinesterase, and esophageal motor disorder, 1745
clotting factors, 345, 762
thrombus formation, 262–265
and collagen synthesis, 980*
complement-fixing trachoma virus titer, 1000*
creatinine, in pregnancy, and lactate infusion, 1527
24-dehydrocholesterol accumulation, 1032*
in dysgammaglobulinemias, 1596
and Danilone, 1865–1869, 1871–1872
in hyperlipemic siblings, 1778–1779
and liver, 1562
lysolecithin, 1646
in nephrosis, 455–465
electrolytes in ascites, 977*
See also Specific electrolytes

Serum (*cont'd*)
ethanol precipitation of acid hydrolysates, 788
folic acid activity, 996*, 1008*
free fatty acids, 959–965, 1010*, 1023*
gamma globulin, 474, 1196, 1362 1602
in agammaglobulinemia, 987*
in brucella-infected rabbits, 990*
components, 473–480
in hyperimmunization, 990*
and liver cell nucleus, 1603
in myeloma, 565–572
and nucleoprotein extracts, 1603
globulin, 976*
in amyloidosis, 474–480
in multiple myeloma, 474–480
turbidity temperature, 1195
glucose, 786, 998*, 1506
heat-inactivated normal human and rheumatoid factor, 972*
hemolysins in leukemia, 975*
hexose, 786, 787
humoral factors in collagen synthesis, 980*
hydroxyproline, 980*, 1760
hyperbetaglobulinemia, 567–572
hyperglobulinemia, 474–480
hyperimmune, 990*
hyperlipemia, 1778–1780
hyperlipidemia, 988*
insulin, 1012*, 1070–1076, 1162–1163
placental degradation of, 118–130
insulin-like activity assay, 1499–1510
iron, 992*, 1763
ketones and blood glucose, 998*
lactate, 998*
lecithin concentration, 1643, 1646, 1649
leucine aminopeptidase, 671–675
lipids, 459–460, 988*, 1643, 1646, 1649, 1787–1788
and desoxyribonucleic acids, 1025*
after hypothalamic stimulation, 994*
and hypothalamus, 1967–1972
in liver disease, 1639–1650
in nephrosis, 455–465
after pituitary extract Fraction H, 1023*
sonic oscillation, 988*
and thromboplastin generation test, 1026*
lipolytic activity, 1283
lipo-polysaccharide, tolerance transfer, 1002*
lipoproteins, 464, 988*, 1001*, 1560, 1643, 1646, 1649, 1778–1780
β-, 1864–1873
in cardiovascular disease, 1865–1869
in cerebrovascular disease, 1869–1870
and liver disease, 1008*
metastatic, 675
lupus erythematosus, factors, 1596–1597, 1602
macroglobulin, 474–480, 1322, 1596
magnesium, 1226–1229
in pseudo-hypoparathyroidism, 1016*
in tetany, 1038*
mouse, lack of bactericidal activity, 358, 362
nonprotein nitrogen, 1390
in phosphate-losing tubular disease, 1389
osmolality, 636, 990*
and antidiuretic hormone, 259, 1473–1474
in diabetes insipidus, 1473
in hydropenia, 1063
and smoking, 1477
phosphatase, 1232
in hypopituitarism, 1226–1229
phosphate, 1232
in adult Fanconi syndrome, 1390
after calcium infusion in rickets, 1808–1812
in hypopituitarism, 1226–1229
in obesity, 1230
after phosphate feeding, 995*
phospholipids, 456–459, 464, 988*, 1023*, 1025*, 1646
and liver damage, 1642–1649
phosphorus, 1224–1225, 1808–1812
after ethylenediamine hydrogen trisodium acetate, 666–667
after parathyroidectomy, 664, 666
and phosphate reabsorption, 1807–1812
in pseudo-hypoparathyrodism, 1016*
after suprasterol, 1016*
potassium, 886, 978*, 1015*
in cystine storage disease, 1390
pH and hypokalemia, 657
and potassium nephropathy, 29
in respiratory acidosis, 1012*
protein, 975*, 976*, 1072, 1921–1924
in ganglioneuroma, 1730
and growth hormone therapy, 1224, 1230–1231
hexose-binding precipitation, 787–788
hypersensitivity delayed, 704
in hyperthyroidism, 983*
in lupus erythematosus, 1598
after methimazole, 1592
and DL-penicillamine, 1322
thyroxine binding, 526–532, 792, 983*
after estrogens, 1120–1129
prothrombin concentration, 345–350
pyrogen, transferable, 1274, 1275
pyruvate, 998*
rabbit, anti-rat red cell, and erythrocyte destruction, 1152–1153
rheumatoid factor, 478, 996*
sodium, 882–883, 978*
in gastrodialysis, 659
in hyponatremia, 1033*
and natriuresis, 883
and potassium nephropathy, 29
after water loading, 249
sphingomyelin, 1634, 1646
streptomycin concentrations, 851
strontium, 887, 892
thrombotic accelerator, 262–265, 981*
thyroxine binding, 1032*, 1126
pre-albumin, 999*
tubercle bacilli binding capacity, 985*
urate, 998*, 1527, 1529
and blood glucose, 998*
and 6-diazo-5-oxo-L-norleucine, 447
urea, 820
in toad, 636
viscosity, 1323–1325
vitamin B_{12} concentrations, 1315–1318, 1668–1669
zinc content, 1653–1655

Shock
anthrax and urine alkaline phosphatase, 308
electroconvulsive plasminogen activation, 1030*
endotoxin, 1037*
and renal phosphatase, 302–309

Sia test, 1323–1328

Sickle cell trait
in familial hyperlipemia, 1787–1788
hemoglobin C disease, 1895–1896, 1898–1899
hemoglobin S values, 1895–1896
and plasma thrombolytic activity, 429

Sino-atrial blocks, 1890–1891

Sjögren's syndrome, serum antithyroglobulin factors, 1260, 1263

Skin
and acclimatization to heat, 825
after Blastomyces dermatitidis, 1273
chloride/bromide ratios, 283–284
Cushing's syndrome, 1906–1907
and diphenylhydantoin, 1758–1762
hemagglutination reactions, 995*
homografts, 952–958
delayed hypersensitivity, 185–198
reactions to plasma preparations, 702
subpapillary venous system and heat loss, 832
tuberculin tests, Indian Hospital, 1005*

Smoking, 760–762, 973*
antidiuretic effect, 1475
and adrenal steroids, 1475, 1476
and coronary disease, 763

Sodium
absorption
gastrointestinal, 1607–1618
in loop of Henle, 872
and aldosterone secretion, 329, 765–767, 981*, 1095, 1097
amniotic fluid transfer, 229
balance, 1224–1229
and weight, 971*, 1228, 1231, 1235, 1237
benzoate as C^{14}-glycine trap, 1339
bicarbonate and carbonic acid formation, 1489
in bile, after taurocholate infusion, 164–169
bladder membrane permeability, 639

in calf costal cartilage, 924–928
chloride, 173, 255, 865–866, 1062–1067, 1519–1520
in hyperglycemia, 974*
lipase release inhibition, 1283
natriuretic response, 883
reabsorption, 485, 486, 488
in skin, 1760
transport from collecting ducts, 488–489
in costal cartilage, 925
dehydrocholate, and sulfobromophthalein removal, 1135–1136
deoxycholate, and lecithinase A, 1297–1301
depletion, 253–257
and electrolyte excretion, 256–257, 877
exchangeable, and ascites, 977*
excretion, 173, 389–393, 396–404, 687, 772, 865–866, 874, 883, 1095
after acetazolamide, 1555–1558
after ammonium, 173
and cardiac myosin, 1464–1465
after cesium, 173
and cortisol, 1474
and cortisone, 769, 1855–1858
and dextrose, 256
diurnal rhythm, 882–883
after glucocorticoids, 1853–1855
and growth hormone, 772, 1224, 1226–1229
hydration effects, 870
in hypercalcemia, 695
in hyperglycemia, 974*
in liver cirrhosis, 971*
and mannitol, 256, 867, 868, 1306–1307, 1555–1558
after rubidium, 173
after spironolactones, 984*
after thyrotropin, 772
after urea, 869, 1555–1558
and vasopressin, 867, 869
after volume loading, 993*
fluoride, cell-lipid uptake rate, 983*
hydroxide, and pituitary extract Fraction H, 1023*
intake, 256, 329, 765–767, 865–866, 877–884, 981*, 984*, 1062–1067, 1095–1097
loss, 977*, 984*
after chlorothiazide, 1277–1278
and mercaptomerin, 1306–1307, 1609, 1614–1618
metabolism, 1227–1237
in pancreatic juice, 1000*
phosphate
and atrioventricular conduction, 1890–1891
and phosphate excretion, 1517
and plasma potassium, 1890–1891
and serum calcium, 1890–1891
and titratable acid excretion, 1517–1520
in plasma. *See* Plasma, sodium
in plasma expanders, 1954–1958
plasma-urine ratio ureteral stop flow method, 485–489, 841–845
and potassium
deficiency, 173, 684, 687, 689–691, 1005*
reabsorption, 248, 403, 690–691, 991*
and antidiuretic hormone, 259
renal conservation, 1098
and renal function, 483–484, 865–870, 874, 1303–1310
in newborn, 1062–1069
in renal medullary and papillary tissue, 684–696
retention
of bone, 1233
and cortisone, 769, 1902–1906
and desoxycorticosterone, 1853, 1855–1856
and mineralocorticoid, 1859–1862
of muscle, 1233
after nicotine, 1853, 1855–1856
and plasma expanders, 1954–1958
in serum. *See* Serum, sodium
sulfate, and titratable acid excretion, 1519–1520
toad bladder permeability to, and vasopressin, 632
transport, 1607
during dialysis, 655
in loop of Henle, 1309
into medulla, 487, 872, 874
and medullary osmolality, 873
across renal tubular cells, 970*
and urine pH, 1516, 1523, 1524
Somatotropin. *See* Pituitary growth hormone
Spherocytosis, erythrocyte fragility, 89–101
and hemolysis, 1019*
life span, 979*
Sphingomyelin, 1020*
egg, and cobra venom, 1296
in erythrocytes, 345–350
in plasma lipids, 1430
in liver disease, 1642–1649
in platelets, 345
Sphingosine, synthesis in Gaucher's disease, 1546
Spleen
alkaline phosphatase assay in hypophosphatasia, 1389
blood flow, 1201
cerebroside content, 1547
contraction after endotoxin injection, 307
and erythrocytes, 99–100
sequestration, 1148–1153
explanted, no protection against hypertension, 271, 272
extracts, and chondromucoprotein viscosity, 407
fatty infiltration, 1785–1787
fungi multiplication, 1439
and hemolytic disease, 980*
hexose pools, 1549
infarcts after serotonin, 1026*
and portal collateral blood flow, 1203–1207
radioiron clearance, 91, 94, 104–106
after renal explantation, 274
Sprue, idiopathic, and wheat gluten, 1023*
Squalene, and cholesterol, 643–644, 648–651
Staphylococci
fever after intravenous injection, 969*
phage patterns and lyses, 1038*
serum destruction, 1013*
Starling's law of heart, 974*, 976*, 1043–1050, 1208, 1212, 1874–1884
Stearic acid, gastrointestinal esterification, 150–160
Steroids
adrenocortical, 329, 741, 754, 755, 816, 1040*, 1478, 1922–1924
and albumin catabolism, 1906–1907
in bacteremia, 303–304
binding after estrogen therapy, 1922–1924
in liver disease, 320–331
and neurohypophyseal function, 1853–1855, 1859–1862
patterns in monozygotic triplets, 620–625
and vasopressin release, 1851–1863
cortisol-like in Addison's disease, 1857–1858
and estrogens, 604
glucuronide formation, by kidney tissues, 978*, 1584–1589
metabolism, in cirrhosis, 329
and pyruvate oxidation, 1041*
radiochemical purity, critique of methods for study, 551
urinary excretion, 367–377
in congenital adrenal hyperplasia, 906–907
of phenylhydrazine-reacting, 325
in virilizing testis tumor, 535, 538
Stilbestrol
and plasma 17-hydroxycorticosteroids, 601–605, 1917–1920, 1922–1924
and plasma transcortin, 1920–1924
cortisol binding, 1917–1920, 1922–1925
Stool. *See* Feces
Streptococcus
and glomerulonephritis, acute, 1003*
Group A, 1018*
Streptokinase
antibody to, and gamma globulin 7S fractions, 986*
esterase induction, 1030*
inhibitor, 1001*
Streptomycin
implantation in peritoneal cavity, 851–853
and staphylococcus strains, 1039*
Stress
emotional and plasma thrombolytic activity, 428–429
gravitational, 1533–1537
and 3-methoxy-4-hydroxymandelic acid excretion, 1534–1538
orthostatic, 607–609
and serum cholesterol levels, 317, 318, 1022*
surgical
and plasma transcortin, 1915–1925
thermal burn
and adrenal medullary insufficiency, 1927–1932

Strontium, and calcium metabolism, 885–903
Strophanthidin
and blood velocity, 971*
and plasma calcium concentration, 1021*
Stuart factor, 555, 1015*
tests, 559
cephalin-modified, 1947–1948
and thrombosis, 262–265
Sucrose, toad bladder permeability, 632
Sulfate
cartilage content, 921
and new bone salt deposition, 927
and diuretic response, after meralluride, 991*
ethereal, in sulfobromophthalein compounds, 1217
metabolism, arylsulfatase activity in cells, 1035*
tubular reabsorption, 1909–1913
and urine, titratable acid excretion, 970*, 1519–1520
Sulfhemoglobin, 1820–1829, 1831–1832
Sulfobromophthalein
absorption, 1137
biliary excretion and transport, 237, 243–247, 1013*, 1039*, 1131–1144
conjugate structure, 1222
and glutathione, 978*, 1214–1222, 1570–1577
hydroxamic acid formation, 1217
ninhydrin-positive fractions, 1222, 1571–1573
thioether linkage, 1218–1221
and dehydrocholate, 1135–1137
hepatic storage and excretion, 236–247, 1138–1143, 1653
and indocyanine green, 596–599, 1040*
metabolites, 1013*
plasma clearance, 236–247
reabsorption, 1137
toxicity, 1139–1140
Sulfonylureas, insulin-secreting potencies, 1027*
Sulfur
binding in sulfobromophthalein conjugates, 1218, 1576–1577
in costal cartilage, 925–926
glutathione uptake, and bile sulfobromophthalein conjugates, 1575
protein-bound and thiourea, 1009*
Suprasterol in pseudo-hypoparathyroidism, 1016*
Surgery
in cancer, plasma proteins shift, 1924–1925
and plasma 17-hydroxycorticosteroids, 1920–1921, 1924–1925
transcortin cortisol binding, after, 1920–1921, 1924–1926
Sympathectomy
and aldosterone secretion, 1093–1095
and left ventricular function, 976*
in malignant hypertension, 1097
Synovial fluid
extract, and chondomucoprotein viscosity, 406–407
and serum exchange, selective, 788
Syrosingopine, and pyelonephritis susceptibility, 1815–1817

T

Taurine
in leukemia, 1679–1680, 1690–1695
and palmitate esterification, 733
in plasma, 1634–1635
urinary excretion, 1677, 1681, 1686, 1697–1698
Taurocholate
and bile, 161–170, 1039*
and fatty acid esterification, 154–155, 731
and glucose transport, 735, 738
and indocyanine green, 1040*
and palmitate esterification, 733–734, 738, 739
Temperature
See also Fever; hypothermia
acclimatization to heat, 825–833
and alkaline phosphatase assay in kidney, 1373
and amino acids, in cells and plasma, 1679–1681
of arms, and exercise, 416
and Bence Jones protein denaturation, 1194–1199
and bishydroxycoumarin, 981*
body
krypton solubility, 1082–1083
and progesterone, 38
and coagulation factors, 1950–1951
and donor cell antibody transfer, 1011*
and fungi culture growth, 1266–1267, 1274
gel formation, 1324
and hemoglobin precipitation, 1824–1826, 1831–1832
phenylhydrazine-like drugs, action of, 1826–1829
of incubation
and diisopropylfluorophosphate-labeled granulocytes, 1483
urine hydrolysis test, 988*
and lactic dehydrogenase, 1381
and lecithinase A stability, 1298
leukocyte extract, and chondromucoprotein viscosity, 407, 410
and methemoglobin production from hemoglobin, 1824–1826, 1831–1832
of placental fractions, and insulin degradation, 120, 124–125
and plasma thrombolytic activity, 430
room, and ammonium diffusion, 337
and serum albumin storage, 1838–1840
and solute transfers in gastrodialysis, 655
synovial extract, and chondromucoprotein viscosity, 407
Testis
interstitial cell virilizing tumor, 534–553
Testosterone
and amino acids in leukocytes, 1693
and glucose-6-phosphate dehydrogenase, 1010*
and plasma 17-hydroxycorticosteroids, 1917–1920, 1922–1924
in testicular tumor, 540–550
and transcortin cortisol binding, 1917–1920, 1922–1924
Tetracycline, and staphylococcus strains, 1039*
Tetrahydrocorticosterone
turnover rate after adrenocorticotropic hormone, 749
urinary excretion, 748, 753
after corticosterone, 326, 752
Tetrahydrocortisol
metabolism in liver disease, 323, 327
and transcortin cortisol binding, 1921–1925
urinary concentration
after corticosterone, 752
urinary excretion, 748
in adrenogenital syndrome, 367–369, 373, 906–907
after cortisol infusion, 324
in virilizing testis tumor, 538
Tetrahydrocortisone
metabolism in liver disease, 323–327
and plasma, albumin binding, 1921–1922
17-hydroxycorticosteroids after estrogen therapy, 602–605
and transcortin cortisol binding, 1921–1925
urinary excretion, 748, 906–907
in adrenogenital syndrome, 368–369
in virilizing testis tumor, 538
Tetrahydro-11-dehydrocorticosterone
turnover rate, 749
urinary excretion, 368–369, 748
3,5,3′,5′-Tetraiodothyropropionic acid, metabolic effects, 523–533
Thalassemia minor, 1896–1897, 1898–1899
Thiamine
blood levels, in alcoholism, 1005*
in Wernicke's disease, 1038*
Thimerosal, and virus hemagglutinating activity, 1017*
Thiomerin, and water balance, 257
Thiourea
in thyroid tissue, disulfide bond cleavage, 1009*
toad bladder permeability and vasopressin, 632, 633
Threonine
and blood glucose concentration, 993*
in erythrocytes, 1690, 1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukocytes, 1679, 1680, 1693–1695
in plasma, 1634–1635, 1676, 1680
in leukemia, 1689–1691
in uremia, deproteinized plasma, 987*
urinary excretion of, 1677, 1681, 1685, 1686, 1697–1698
Thrombocytopenia
after liver explants, 274
platelet viability index, 970*
post-transfusion immunology, 1028*
Thrombocytosis, in liver glycogen disease, 1008*
Thromboembolic disease, 262–265

Thromboplastin
generation, 1026*
and Aspergillin O, 1010*
protamine effects on, 1016*
and intravascular clotting, 977*
lecithin, 347
phosphatidyl ethanolamine, 347
phosphatidyl serine, 347
plasma antecedent deficiencies, Hageman factor activation of, 1019*
plasma clotting, 1947–1948
reticuloendothelial clearance, 1030*
total extract, 347
Thrombosis
bishydroxycoumarin, *in vivo* inhibition, 981*
cerebral, 1869–1870
and plasma thrombolytic activity, 429
retinal artery, in hypertension, 1094–1097
serum-induced, 262–265
and serum β-lipoprotein levels, 1869–1870
Thrombus
Aspergillin O lytic effect, 1010*
specific coagulation factors of serum, 262–265
Thymidine
half-times, 917
intracellular uptake in tumors, 973*
kinase activity in regenerating rat liver, after, 997*
metabolism, 909–918
turnover, 1003*
Thymidylate
hydrolysis to thymidine in gut absorption, 916–917
synthesis, and 5-fluorouracil, 996*
Thyroid gland
and calcium, and strontium metabolism, 885–903
fluorescence microscopy, 1033*
function, 45, 49, 54
and plasma iodine concentration after estrogen therapy, 1124
and thyroxine uptake by ion exchange resins, 1032*
glucose uptake and thyroid stimulating hormone, 986*
nonthyroxine iodide release, 975*
protein-binding defects, Berson test, 790–794
radioiodide uptake, 790–794
after thyroactive substances, 530
serum anti-thyroglobulin activity, 1260, 1264
therapy, 1119
in hypopituitarism, 1226–1229
Thyronine, 523–533
Thyrotoxicosis
and calcium metabolism, 886, 889, 901
retention, 893–894
corticosterone metabolism, 745
glucose tolerance test, 1166, 1169
nitrogen metabolism, 886
phosphorus metabolism, 886
pulmonary diffusing capacity and exercise, 1406, 1410
strontium metabolism, 886
Thyrotropin
and insulin, placental degradation, 125
plasma clearance, 792
and sodium retention, 772
and venous pressure, 772
Thyroxine, 523–533
cellular degradation, 1126
clearance, 999*, 1120–1129
distribution volume, 983*, 1120–1124, 1592–1594
after estrogen, 999*, 1119–1130
extrathyroidal pool, 1592–1594
fecal excretion, 1122, 1124, 1127
half-life, 1590, 1592–1594
in hyperthyroidism, 983*
metabolism, 523–533, 999*, 1119–1130, 1590–1594
in myxedema, 983*
and oxygen consumption, 531–532
in serum, 1032*
and cholesterol levels, 529–530
thyroid uptake block, 530
turnover, 999*, 1120–1129, 1592–1594
uptake, and thyroid function, 1032*
Tissue
adipose, fatty acids, 435–439, 608, 961–964, 1007*
and glucose metabolism, 976*, 1494–1496
insulin-like activity measurement, 1487–1496, 1499–1510
lipogenesis, 997*
and mannose metabolism, 976*
nitrogen content and wet weight, 1490, 1491
dry lean constituents in controlled weight loss, 971*
free fatty acid uptake and negative arteriovenous differences of total, 1511–1515
fungus census and cortisone, 1435–1441
lipolytic activity, 1282–1287
mast cells, 1017*
necrosis of homograft and 6-mercaptopurine, 955–957
peripheral, indocyanine green uptake, 596–599
Tocopherol, and pyruvate oxidation, 1041*
Tolbutamide
and pancreatic venous insulin, 1028*
and plasma insulin concentration, 1041*
Trachoma, virus isolation in United States, 1000*
Transcortin, 1913–1926
binding capacity
after estrogens, 602–603, 1917–1920, 1922–1926
and plasma 17-hydroxycorticosteroids, 1920–1921, 1922–1924
cortisol binding, 1915–1925
and adrenocorticotropic hormone, 1921, 1924–1925
9α-fluorocortisol, 1910, 1924–1925
in lymph, 1921–1922
and plasma 17-hydroxycorticosteroids, 1915–1917
post-menopausal, 1922–1924
postpartum, 1918–1920, 1922–1924
after surgery, 1920–1921, 1924–1925
and testosterone, 1917–1920, 1922–1924
serum albumin binding, 1921–1922
Transferrin, avidity for iron, 979*
Transmanganin, 979*
Transplantation
kidney, 266–281
and 6-mercaptopurine, 952–957
sensitivity transfer, 185–198
2,4,6-Triethyleneimino-s-triazine, in leukemia, 1691–1694
3α, 17α, 21-Trihydroxy-pregnane-20-one, 906
3,5,3′-Triiodothyroacetic acid, metabolic effects, 523–533
3,5,3′-Triiodothyronine
in hypopituitarism, 1226–1229
calcium and ethylenediamine hydrogen trisodium acetate infusions, 666–667
in lung disease, 49
in myxedema, 45, 49, 54
in obesity, 49
and oxygen consumption, 531–532
3,5,3′-Triiodothyropropionic acid, metabolic effects, 523–533
Trimethaphan
and blood volume, hypervolemia effect on central, 1045–1046
cardiovascular response, 1049
pressor responses after dextran and chlorothiazide, 1278–1280
and pulmonary capillary bed body position responses, 1346–1351
and serum free fatty acid levels, 959–965
Triphosphopyridine nucleotide
and dehydroisoandrosterone, 1010*
and enzyme glucose-6-phosphate dehydrogenase, 1819–1820
in fatty acid synthesis in liver, 114
glomerular, in nephrosis, 1364–1370
and pregnenolone, 1010*
Triplets, monozygotic, steroid patterns in, 620–625
Tris-(hydroxymethyl) aminomethane, hypoglycemic effect, 1035*
Trit. *See* 3,5,3′-triiodothyronine
Tritium
digoxin-labeled, 1578–1583
water, 1099
amniotic fluid transfer, 229
exchangeable, 1798–1799
Triton, and cholesterol synthesis in liver, 1566
Trypsin
and blood clotting, 1942–1951
chondromucoprotein viscosity and soya bean inhibitor, 406
erythrocyte treatment and serum hemolysis capacity, 1041*
and leukocyte transfer factor, 186
and papain binding by serum proteins, 1039*
pituitary extract, Fraction H, 1023*
and streptokinase inhibitor, 1001*
synergistic reaction, 1945–1951
Tryptophan
with adenosine triphosphate, 1763–1765

Tryptophan (*cont'd*)
amino-acid-dependent exchange, 1766–1768
and glucose oxidation, 986*
in leukemia, 1679–1680, 1690–1695
in plasma, 1676, 1680, 1681
expanders, 699
urinary excretion, 1677, 1681, 1685, 1686, 1697–1698
Tuberculosis, 985*
tuberculins, 1009*
avian, Battey and human cross-reactivity, 1005*
d-Tubocurare, and bicarbonate excretion, 1711–1712
Tumors
deoxyribonucleic acid synthesis, 997*
mouse polyoma virus, 1023*
thymomas, erythroid hyperplasia in hemochromatosis, 1006
Turner's syndrome, chromosomal constitution, 1024*
Typhoid, bacilli, humoral inactivation, 352–363
Tyrosine
in catecholamine synthesis, 1733
epinephrine precursor, 1929–1932
erythrocytes, 1690–1691
and pyrophosphate-adenosine triphosphate exchange, 1763–1765
in leukemia, 1689–1698
in leukocytes, 1679–1680, 1693–1695
in plasma, 1634–1635, 1676, 1680, 1691
urinary excretion, 1677, 1681, 1685, 1686, 1697–1698

U

Ulcer
duodenal, 834–839
gastric, after serotonin, 1026*
Urea
action as urinary solute in infants, 1067–1068
amniotic fluid exchange, 228
blood pressure after loading, 990*
clearance
in adult Fanconi syndrome, 1390
in hypertension, 1094
cortical nephron permeability, 1004*
and dietary intake, 1062–1099
diuresis, 869
and after acetazolamide, 1555, 1557, 1558
excretion, 1066
fluid-plasma ratios after infusion, 1004*
and membrane permeability, 630–641, 995*
and monoamine oxidase activity of mitochondria, 990*
plasma levels. *See* Plasma
reabsorption, 636, 640
and renal concentrating mechanism, 1303–1310
in newborn infants, 1062–1069
in renal papilla and medulla, 687–696, 1004*
and vitamin D intoxication, 693–696
retention, 1101
urinary excretion, 1063, 1066, 1677, 1681, 1686, 1697–1698
Uremia
and arterial blood pressure, 990*
in ascites therapy, 978*
deproteinized plasma amino acids, conjugated compounds, 987*
gastrodialysis treatment, 658–660
hemodialysis, 658, 1027*
histamine metabolism in, 676–682
nonprotein nitrogen removal as index, 657
and peritoneal lavage, 109
and plasma corticoid levels, 820
and renal phosphatase, 303, 304
terminal, and aldosterone secretion, 1095, 1102
Ureter
catheterization and renal hemodynamics, 292–293
occlusion, 103, 841
and renal function, 402–403, 484–485, 488
Uric acid
synthesis, and 6-diazo-5-oxo-L-norleucine, 447–454
urinary excretion, 449, 1004*
in adult Fanconi syndrome, 1390
in pregnancy, and lactic acid, 1526–1532
Uridine diphosphoacetylglucosamine, 1114
Uridine diphosphogalactose, 182
Uridine diphosphogalactose-4-epimerase, 999*
Uridine diphosphogalactose-5-epimerase, 999*
Uridine diphosphoglucose, 182
Urine
aldosterone, 329, 772, 971*, 989*
alpha-ketolic steroid metabolites, 372, 752
amino acids, 1675–1705
after chlorambucil, 1699
in cystinuria
after leucine, 993*
in leukemia, 1688–1705
β-amino isobutyric acid, 1699
ammonium, 694–696
after acetazolamide, 288–293
after aortic constriction, 867, 869
bicarbonate, 173, 1019*
and acetazolamide analog, 1552
after sodium chloride treatment, 173
bile pigment pattern, 134
calcium, 694–696, 886, 887, 891, 900–901, 1390
in Fanconi syndrome, 1390, 1635–1637
after growth hormone, 1225, 1230
in obesity, 1230
catechol amines, 834–839
in ganglioneuroma, 1734
chloride, 984*, 1093–1095
concentration
after acetazolamide, 288–293
after ammonium, 686, 688, 694–696
analog CL-8490, 1552, 1555–1558
in cirrhosis, 249–250
and collecting duct permeability, 872
glomerular filtration rate and solute excretion effects, 866
hemoglobin, stop flow technique, 843, 845
in hydropenia, 688
hyposthenuria in potassium depletion, 684–692
in renal disease, 864–875
and tubular reabsorption or secretion activity, 840
after urea loading, 1066, 1555–1558
and vasa recta blood flow, 873
corticoids, 322, 329
corticosterone metabolites, 752
creatinine, 843–845, 1555, 1557, 1558
cysteine, in Fanconi syndrome, 1635–1637
cystine, 1003*, 1635–1637
digoxin metabolites, 1580, 1581
dihydrodeoxyhydrocortisone, 368–369
dopamine, 1733–1734
epinephrine, 221–226
after burn stress, 1928–1932
and centrifugal acceleration, 1533–1538
after histamine, 835
after insulin, 835–836, 838
after peptone, 835
flow, 253, 1711
after acetazolamide, 1555, 1557, 1558
in adult Fanconi syndrome, 1390
and antidiuretic hormone, 1473–1474
and catechol excretion, 837
in diabetes insipidus, 1473
and diuretic agents, 1303–1310
See also Diuresis
in endotoxin shock, 1037*
environmental factors, 837–838
after gastrodialysis, 659
after glucose, 872
and hexamethonium infusion, 980*
in hydration, 991*, 1068
during hydropenia, 1067
in infants, with low protein feeding, 1067
after isotonic sodium chloride-lactate infusion, 877–884
and oxytocin, 969*
and renal arterial compression, 867
and renal concentrating mechanisms, 389–404, 1063
and smoking, 1477, 1853
in sodium chloride diuresis, 483–486
and sodium intake, 877–884
and total solute excretion, 258
after urea, 869, 872, 1555, 1557, 1558
and ureteral occlusion, 483 484
and venous congestion of extremities, 1477
after volume loading, 483–484, 993*
and water diuresis, 250–261
formiminoglutamic acid, 1008*
globulins, 1195
glucose, 1387, 1388
gonadotropins, in hypopituitarism, 1226–1229

glycosuria, 1772–1774
histamine metabolites, 676–682
homovanillic acid, 1734
hormones, and behavior patterns, 761, 763
hydrogen ions after phosphate feeding, 995*
17-hydroxycorticosteroids, 1224–1229
after estrogens, 602, 604
5-hydroxyindoleacetic acid, and α-methyl-3,4-dihydroxy-DL-phenylalanine, 1015*
in hypertension, 223–226, 396–404, 989*, 1093, 1102, 1530
hypertonic to plasma, 1067
incontinence, after di-isopropylfluorophosphate, 1745
inulin, 482–483, 843–845, 1555–1558
iodoacetate-treated, 1636
17-ketosteroids, 322, 329, 1102
in congenital adrenal hyperplasia, 906–907
in hypopituitarism, 1226–1229
magnesium, 421–425, 1038*
in pseudo-hypoparathyroidism, 1016*
after suprasterol, 1016*
3-methoxy-4-hydroxymandelic acid, 1734
in carcinoid syndrome, 223
and centrifugal tolerance acceleration, 1533–1538
in pheochromocytoma, 221–226, 990*
mouse polyoma virus infection transmission, 1023*
nitrogen, 886
after dihydrotachysterol II, 1016*
norepinephrine, 221–226, 835–838, 1533–1538, 1734, 1928–1932
after insulin, 835–836, 838
orotic acid excretion, 19, 1029*
osmolality, 636, 686, 867, 868, 872, 974*, 1065, 1305–1310
and aortic constriction, 867–869
in diabetes insipidus, 980*
hydration effects, 870, 991*, 1068
in hypercalcemia, 1042*
in nephrocalcinosis, 694
and nicotine antidiuresis, 1853
in potassium depletion, 689–691
and renal arterial constriction, 867–869
of separate kidneys, 389–391, 396–404
stop flow technique, 484
and urea, 686, 869, 1067
and ureteral occlusion, 483–484
and vasopressin, 867–869
and vitamin D, 695
after water loading, 249, 483–484
oxalate, 1339
pH, 1711
after acetazolamide, 288–293, 1713
and acidosis, 174
and anions, penetration, 970*, 1516–1525
for cell differentiation urine hydrolysis test, 988*
after cesium, 173
after chloride, 1516
after corticosterone, 747
after ferrocyanide, 1516
in potassium depletion, 173
after rubidium, 173–174
after sodium chloride, 1518, 1519
after sodium phosphate, 1517–1520
after sulfate, 1516, 1519–1520
after thiocyanate, 1516
and titratable acid excretion, 1516
phospho-ethanolamine, in hypophosphatasia, 1389
phosphorus, 886
and growth hormone, 1224
in pseudo-hypoparathyroidism, 1016*
after suprasterol, 1016*
potassium, 175, 688, 694–969, 1093–1095, 1227
in potassium depletion, 172
pregnanetriol, 905–906, 989*
proconvertin, after injections, 555
sodium, 389–391, 396–404, 686, 688, 690, 694–696, 843–845, 874, 971*, 974*, 1093–1095, 1098, 1306–1307
in adrenal insufficiency, 1227
and aldosterone production, 1096, 1105
after spirolactones, 984*
specific gravity after antidiuretic hormone, 1544, 1545
steroids, 322, 324
in congenital adrenal hyperplasia, 364–377
after 2-methyl-1,2-*bis*(3-pyridyl)-propanone, 905–906
in virilizing testis tumor, 538
strontium, 887, 891, 901
thymidine metabolites, 915, 916
total solute, 389–391, 396–404, 694–696, 1066
urea, 688, 694–696, 1004*
and Pitressin, 869
of toad, 636
uric acid, 447, 869
and 6-diazo-5-oxo-L-norleucine, 449, 451
in pregnancy, 1530
urgency, diurnal, and behavior patterns, 760–762
vanillylmandelic acid. *See* urine, 3-methoxy,4-hydroxymandelic acid
viruria, 1037*

Urobilinogen, fecal
constitutional hepatic dysfunction, 138, 140–141
in heart failure, 977*

Urokinase
and plasma thrombolytic activity, 427, 430–433
reaction with plasminogen, 1001*
and streptokinase inhibitor, 1001*

Urolithiasis, calcium oxalate, 1337

Uronic acid, and gold sodium thiomalate, 1117

V

Vaccines
Salmonella, 359–360, 1029*
streptococci, Type 12, 1018*

Vagus nerves
and aldosterone secretion, 1334–1335
and cardiac output, 976*
stimulation, and heart rates, 1025*

L-Valine
and blood glucose concentration, 993*
in erythrocytes, and pyrophosphate-adenosine triphosphate exchange, 1763–1765
and hemoglobin synthesis, 1109–1112
in leukemia, 1679–1680, 1689–1698
in plasma, 1634–1635, 1680, 1689
urinary excretion, 1677, 1681, 1686, 1697–1698

Vanillylmandelic acid, excretion, in pheochromocytoma, 221–226, 990*

Vascular system
after acetazolamide, 288–293
after aortic stenosis, 25
cerebrovascular accidents, and synovial fluid, nondialyzable hexose, 788
dynamics, and caval block, 1023*
and exercise in hot environment, 825–833
and ganglionic blockade, 1345–1352
hypertensive disease, 1022*
adrenal aldosterone secretion, 1091–1106
peripheral, 831, 414–418, 1022*
and digitalis, 930–942
portal, 1021*, 1201–1207
mediastinal-pulmonary connections, 1848–1849
pressure-flow relations, 1034*
pulmonary, 1022*, 1031*, 1348–1351
carbon dioxide effects, 295–301
reflex venodilatation, 1048
and renal atrophy, 25
resistance, 296–301, 414–418, 1022*
and acetylcholine infusion, 1031*
and acetylstrophanthidin, 932
and body position, 1348–1351
and isoproterenol, 1001*
and serotonin, 1034*
and amine oxidase inhibitor simultaneously, 1026*
splanchnic, 776–781, 940
albumin clearance, 1201
splenic, 1145
vasomotor activity, 1350–1351, 1422

Vasoconstriction
and brachial artery flow pattern, 1422
after chlorothiazide, 1278
after endotoxin injection, 305–309
splanchnic, after vasopressin, 1021*

Vasodilitation
after Arfonad, 1048
coronary and myocardial oxygen consumption, 1011*
in hot environment, with exercise, 832
after renal vasoconstriction, 307
and serotonin and amine oxidase inhibitor simultaneously, 1026*

Vasopressin
and adrenocortical steroids, 1853–1856
and aortic constriction, 868
arginine in toad bladder, 1026*

Vasopressin (*cont'd*)
in cirrhosis, 255, 257, 1021*
in cystine storage disease, 1390
and glucocorticoids, 1853–1855
hemodynamic changes, 1021*
hydration effects, 870, 871
in hypopituitarism, 1226–1229
neurohypophyseal release, 1851–1863
and cortisone, 1853–1855
and fluorocortisol, 1859–1862
and hypertonic saline, 1857
hypothalamic control, 1859–1863
and nicotine, 1853–1855, 1857–1862
and pain, 1857
and osmotic diuresis in hypercalcemia, 1042*
and oxytocin, 969*
and permeability, 487, 489, 995*, 1027*
toad bladder, to urea, 633
in renal disease, 865–871
and tritium clearance, 1027*
tubular response in diabetes insipidus, 980*
and turtle bladder water efflux, 974*
and urine volume, 1033*
and water diuresis, 255, 257, 1477, 1478
and water intoxication, 1033*
Vena cava
and aldosterone secretion, 766, 770–774, 1333–1334
blockade and circulatory dynamics, 1023*
in heart failure, 1464–1466
and plasma adrenocorticotropic hormone concentrations, 1539–1544
pressures after acetylstrophanthidin, 939
and sodium retention, 772
after thyrocarotid arterial junction denervation, 1334–1335
Venesection, and pyrophosphate-adenosine triphosphatase exchange, 1766–1769
Venom, cobra and egg phospholipids, 1296
Ventilation
and acetylcholine, 1031*
and airway resistance, 589, 727
alveolar, 54, 1031*, 1083
and chest strapping, 578
ethyl ether elimination test, 1014*
gas distribution, 52, 1081
in anemia, 378–388
after anhydrohydroxyprogesterone, 36
in bronchitis, industrial, 588–590
and carbon dioxide, 298–300, 726–727
and carbon monoxide diffusing capacity, non-uniformity in two lungs, 795–801
in cor pulmonale and diuresis, spontaneous, 1012*
dead space, and pulmonary embolization, 1031*
after 1,2 dehydroprogesterone, 36
in emphysema, 725–727, 1080–1090
and exercise, 379–388, 414–418, 1404
and forward acceleration, 1740
and hyperventilation, 1405, 1410–1411
lung resistance and age, 589, 590
in myxedema, 42–55
and nitrogen release, 580–582
and 19 nor-ethinyl-testosterone, 40
after progesterone, 35–36
and aspirin, 33, 39, 40
and pulmonary diffusing capacity, non-uniformity, 795–801, 946–951
Ventricle
and altitude exposure, 999*
atrophy, right and left, 1465
contraction, 1020*, 1878–1882
Starling's law of heart, 974*
diastolic pressure, and cardiac output in hypoxia, 998*
end-diastolic segment length and pressure, 974*, 1874–1883
failure, 1011*
and pulmonary emphysema, 1002*
filling pressure, 1024*
and heat acclimatization, 831
function after heart denervations, 976*
and plasma potassium levels, 1891–1892
after acetylstrophanthidin, 1890
stroke volume in polycythemia vera, 1725–1727
stroke work
and cardiac hemodynamics, 1044, 1048
and exercise, 414–418
in hypertension, 1022*
in hypervolemia, 1047, 1048
after transfusion and ganglionic blockade, 1049
Virilism
congenital adrenal, 364–377, 907
testicular tumor, 534–553
Viruses
Coxsackie, 1017*, 1037*
DA, 998*
ECHO, 1017*, 1037*
enteroviruses, 1017*, 1037*
erythrocytes and host cell interaction, 1017*
in infectious hepatitis, 998*
influenza, 1026*
mumps, viruria, 1037*
poliovirus, Type 2, 1028*
polyoma, infections foci of mouse, 1023*
trachoma, in United States, 1000*
Vitamin
B_{12}
absorption, 199–214, 1023*, 1671
in anemia, 17–18, 1763
binding of, added, 1318, 1319
metabolism, 1672
in myeloproliferative disorders, 1667–1674
plasma clearance, 1312–1319
in polycythemia vera, 1763
and pyrimidine metabolism, 17–19
in solid tumors, 1667–1674
turnover, 1672, 1673
uptake and ethylenediaminetetraacetate, 203–207
urinary excretion, 1315–1318, 1671
D
and calcium transport, 1025*
and hypercalcemia, 693, 985*
and potassium conservation impairment, 985*
and urinary osmolality, 695, 985*
D_2, 1035*
and fecal calcium excretion, 1016*
and diet, in auditory hallucinosis, 1038*
Von Gierke's disease. *See* Liver, glycogen storage disease

W

Water
absorption, 971*
in Asiatic cholera, 988*
aerosol, and airway resistance, 588–590
back-diffusion from collecting ducts, 690, 696, 872
bladder membrane permeability, 639
of toad, and vasopressin, 632
body, 627
and ascites, treatment serial changes, 977*
in controlled weight loss, 971*
in osteosclerosis, 628–629
and total body fat calculation, 627, 1798–1803
after urea loading, 990*
clearance
and antidiuretic hormone, 1473–1474
in diabetes insipidus, 980*, 1473
in hypercalcemia, 1042*
and oxytocin, 969*
and smoking, 1477
and sodium intake, 877–884
and total solute excretion, 258
and venous congestion of extremities, 1477
concentration, 1473–1475
of costochondral junction, 927–928
in hydropenia, 688, 1064
and insulin, 1008*
in newborn infants, 1062–1069
and protein intake, 1062–1069
renal, 687–688
after vitamin D, 694–704
deprivation, and urinary osmolality in pyelonephritis, 871
dermal, after diphenylhydantoin, 1762
diuresis, 482, 980*, 1552–1559
in Addison's disease, 1855–1856, 1859–1862
and antidiuretic hormone, 871, 1068, 1473
in cirrhosis, 248
and cortisol, 980*, 1473–1475
and glucocorticoids, 1853–1856, 1862–1863
and glucose, 1477
in hydrated man, 991*
and nicotine, 1853–1855
and unreabsorbable solute, 253
and urinary osmolality after vitamin D, 985*

and venous congestion of lower extremities, 1476
excretion, 1552–1553
after acetazolamide, 1714
after acetozolamide analog (CL 8490), 1552–1559
and adrenal steroids, 1851–1853
after chlorothiazide, diurnal pattern, 980*
after fluid volume loading, 993*
in hyperglycemia, 974*
by separate kidneys, 389–404
and sodium, 660, 1553
intoxication and hyponatremia, 1033*
intracellular content, 1042*, 1714
and intramitochondrial pH, 1022*
reabsorption, 487, 1065, 1067
reabsorption after diuretics, 1303, 1859–1862
removal during gastrodialysis, 657
retention and cortisone, 1902–1906
saving, in animal, by urea reabsorption, 640
transport, 487–489, 995*, 1004*
in turtle bladder, 974*

Weber-Rendu-Osler's disease, arteriovenous shunts, 1846–1847, 1848–1849

Weight
and bishydroxycoumarin, 981*
and body composition, 626, 971*, 1798–1803
change, and cyclopropane absorption, 1794–1796
after chlorothiazide, 1277–1278
controlled loss, 971*
and digitoxin, 1887–1890
and di-isopropylfluorophosphate, 1746
and growth hormone, 1224, 1226–1229, 1231, 1235, 1237
after heparin, 1780–1782
after nephrectomy, 268, 272
in plasma radioiodide clearance, 790
in polycythemia vera, 1723–1724, 1727
in potassium depletion, 686
and sulfobromophthalein transport, 1137–1138
total body fat, 1791–1792

Wernicke-Korsakoff syndrome, nutritional factor, 1037*

Wyamine. *See* Mephentermine

X

X-ray
of spleen, and leukocyte amino acids, 1693
therapy, in leukemia, 1691–1693, 1697

Xylose, dietary intake, cataract development and progesterone, 181–182

Z

Zinc
in blood cells in liver disease, 1651–1656
chloride, and chondromucoprotein viscosity, 407
insulin-bound, 979*
sulfate, and placental insulin degradation, 125

Zymosan and serum bactericidal action, 355

THE JOURNAL

OF

CLINICAL INVESTIGATION

VOLUME 39
(JANUARY TO JUNE)

1960

PUBLISHED BY
THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, INC.

PHILIP K. BONDY, *Editor-in-Chief*

Associate Editors

FRANKLIN H. EPSTEIN

ALLAN V. N. GOODYER

EDITORIAL COMMITTEE

ROBERT W. BERLINER
SOLOMON A. BERSON
GEORGE L. CURRAN
LEWIS DEXTER
I. S. EDELMAN
CLEMENT A. FINCH
ALFRED P. FISHMAN
ROBERT A. GOOD
JOHN B. HICKAM
FRANZ J. INGELFINGER
HENRY G. KUNKEL
MACLYN MCCARTY
ARNOLD S. RELMAN
JOHN V. TAGGART
KENNETH L. ZIERLER

CONTENTS

NUMBER 1, JANUARY 1960

Relation of Hemoglobin to the Red Cell Membrane. HELEN M. ANDERSON AND JOSEPH C. TURNER 1

Studies on the Collagen and Elastin Content of the Human Lung. JOHN A. PIERCE AND JOE B. HOCOTT 8

Pyrimidine Metabolism in Man. III. Studies on Leukocytes and Erythrocytes in Pernicious Anemia. LLOYD H. SMITH, JR. AND FAITH A. BAKER 15

Reversibility of Renal Atrophy Caused by Unilateral Reduction of Renal Blood Supply. T. OMAE AND G. M. C. MASSON 21

Susceptibility of Rats to Experimental Pyelonephritis Following Recovery From Potassium Depletion. JAMES W. WOODS, LOUIS G. WELT, WALTER HOLLANDER, JR. AND MARGARET NEWTON 28

The Effect of Progesterone on the Respiration of Patients with Emphysema and Hypercapnia. JOHN M. TYLER 34

The Pulmonary Abnormalities in Myxedema. WILLIAM R. WILSON AND GEORGE N. BEDELL 42

Changes in the Phosphate Compounds of the Human Red Blood Cell During Blood Bank Storage. GRANT R. BARTLETT AND HARRY N. BARNET 56

Phosphate Compounds of the Rabbit Red Blood Cell During Storage in Acid Citrate Dextrose (ACD) and ACD-Inosine. GRANT R. BARTLETT AND A. WILLIAM SHAFER 62

Effect of Inosine on the Post-Transfusion Survival of Stored Rabbit Erythrocytes. A. WILLIAM SHAFER AND GRANT R. BARTLETT 69

A Study of the Relationship of the Normal Bactericidal Activity of Human Serum to Bacterial Infection. ROBERT J. ROANTREE AND LOWELL A. RANTZ 72

The Survival of Strains of Enteric Bacilli in the Blood Stream as Related to Their Sensitivity to the Bactericidal Effect of Serum. ROBERT J. ROANTREE AND NICHOLAS C. PAPPAS ... 82

Alterations in Osmotic and Mechanical Fragility Related to *In Vivo* Erythrocyte Aging and Splenic Sequestration in Hereditary Spherocytosis. ROBERT C. GRIGGS, RUSSELL WEISMAN, JR. AND JOHN W. HARRIS 89

The Role of the Kidney in Erythropoiesis. JEAN-PIERRE NAETS 102

Synthesis of Cholesterol and Fatty Acids in Fractions of Peripheral Nerve. ANN H. HUGHES AND SVEN G. ELIASSON 111

Carbohydrate Metabolism in Pregnancy. I. The Metabolism of Insulin by Human Placental Tissue. NORBERT FREINKEL AND CHARLES J. GOODNER 116

Bile Pigments of Jaundice. HARRY N. HOFFMAN, II, FRED F. WHITCOMB, JR., HUGH R. BUTT AND JESSE L. BOLLMAN 132

Effect of Deep and Quiet Breathing on Pulmonary Compliance in Man. BENJAMIN G. FERRIS, JR. AND DAVID S. POLLARD 143

The Esterification of Palmitate-l-C^{14} by Homogenates of Intestinal Mucosa. ANTHONY M. DAWSON AND KURT J. ISSELBACHER 150

Determinants of the Flow and Composition of Bile in the Unanesthetized Dog During Constant Infusions of Sodium Taurocholate. HENRY O. WHEELER AND OSWALDO L. RAMOS 161

Acid Excretion in Rubidium- and Cesium-Substituted Rats. PHILIP W. HALL, III AND ARNOLD S. RELMAN 171

Progesterone Effects on Galactose Metabolism in Prepubertal Patients with Congenital Galactosemia and in Rats Maintained on High Galactose Diets. LEROY A. PESCH, STANTON SEGAL AND YALE J. TOPPER 178

Transfer of Delayed Hypersensitivity to Skin Homografts with Leukocyte Extracts in Man. H. S. Lawrence, F. T. Rapaport, J. M. Converse and W. S. Tillett 185
Sequential Mechanisms in the Enhanced Absorption of Vitamin B_{12} by Intrinsic Factor in the Rat. Bernard A. Cooper and William B. Castle 199
The Effect of Exercise on the Concentration and Turnover of Plasma Nonesterified Fatty Acids. S. J. Friedberg, W. R. Harlan, Jr., D. L. Trout and E. H. Estes, Jr 215
The Diagnosis of Pheochromocytoma by Determination of Urinary 3-Methoxy, 4-Hydroxymandelic Acid. Stanley E. Gitlow, Milton Mendlowitz, Sarah Khassis, Gerald Cohen and Joanne Sha 221

Number 2, February 1960

The Distribution and Metabolism of C^{14}-Labeled Lactic Acid and Bicarbonate in Pregnant Primates. Emanuel A. Friedman, Mary Jane Gray, Maurice Grynfogel, Donald L. Hutchinson, William Thomas Kelley and Albert A. Plentl 227
Hepatic Storage and Excretion of Sulfobromophthalein Sodium in the Dog. Henry O. Wheeler, Robert M. Epstein, Roscoe R. Robinson and Eric S. Snell 236
An Explanation for and Experimental Correction of the Abnormal Water Diuresis in Cirrhosis. Harold P. Schedl and Frederic C. Bartter 248
The Role of Human Coagulation Factors in Serum-Induced Thrombosis. Stanford Wessler and Stanley M. Reimer 262
Renal Autoexplantatation and Protection Against Renoprival Hypertensive Cardiovascular Disease and Hemolysis. E. E. Muirhead, J. A. Stirman and F. Jones 266
The Distribution of Bromide and Chloride in the Body. Stanley Hellerstein, Carolyn Kaiser, Daniel DeS. Darrow and Daniel C. Darrow 282
The Kidney as a Source of Blood Ammonia in Patients with Liver Disease: The Effect of Acetazolamide. Edward E. Owen, Malcolm P. Tyor, John F. Flanagan and J. Norman Berry 288
The Effect of Carbon Dioxide on the Pulmonary Circulation. F. Manfredi and H. O. Sieker 295
Diminution in Renal Alkaline Phosphatase in Endotoxin Shock. Wesley W. Spink and Mary Jean Landeryou 302
The Essential Role of the Adrenal Cortex in the Response of Plasma Free Fatty Acids, Cholesterol, and Phospholipids to Epinephrine Injection. Eleazar Shafrir and Daniel Steinberg 310
Adrenocortical Steroid Metabolism and Adrenal Cortical Function in Liver Disease. Ralph E. Peterson 320
The Existence of Ammonia in Blood *In Vivo* with Observations on the Significance of the NH_4^+-NH_3 System. Philip A. Bromberg, Eugene D. Robin and Claude E. Forkner, Jr. 332
Thromboplastic Factors in Platelets and Red Blood Cells: Observations on Their Chemical Nature and Function in *In Vitro* Coagulation. Stanley B. Troup, Claude F. Reed, Guido V. Marinetti and Scott N. Swisher 342
Inactivation of Endotoxin by a Humoral Component. VI. Two Separate Systems Required for Viable and Killed *Salmonella typhosa*. Maurice Landy, Robert-John Trapani and Fred S. Rosen 352
Characterization of Urinary Steroids in Adrenal Hyperplasia: Isolation of Metabolites of Cortisol, Compound S, and Desoxycorticosterone from a Normotensive Patient with Adrenogential Syndrome. Hortense M. Gandy, E. Henry Keutmann and Anthony J. Izzo 364
Cardiopulmonary Physiological Responses to Heavy Exercise in Patients with Anemia. Brian J. Sproule, Jere H. Mitchell and William F. Miller 378

Renal Function in the Separate Kidneys of Man. I. Hemodynamics and Excretion of Solute and Water in Normal Subjects. William H. Hulet, David S. Baldwin, Albert W. Biggs, Ervin A. Gombos and Herbert Chasis 389
Renal Function in the Separate Kidneys of Man. II. Hemodynamics and Excretion of Solute and Water in Essential Hypertension. David S. Baldwin, William H. Hulet, Albert W. Biggs, Ervin A. Gombos and Herbert Chasis 395
Effect of Leukocyte and Synovial Membrane Extracts on Cartilage Mucoprotein. Morris Ziff, H. Joel Gribetz and Joseph Lospalluto 405
The Effects of Exercise on Central Blood Volume in Man. Eugene Braunwald and Eugene R. Kelly 413
Magnesium Turnover in the Human Studied with Mg^{28}. Lawrence Silver, James S. Robertson and Lewis K. Dahl 420
Studies on the Thrombolytic Activity of Human Plasma. William D. Sawyer, Anthony P. Fletcher, Norma Alkjaersig and Sol Sherry 426
Effect of Glucose and Insulin on the Esterification of Fatty Acids by Isolated Adipose Tissue. M. S. Raben and C. H. Hollenberg 435
Announcement of Meetings 265

Number 3, March 1960

Effect of Previous Starvation on the Response of Plasma Lipids and Free Fatty Acids to a Fat Meal. Margaret J. Albrink and Robert S. Neuwirth 441
Suppression of Uric Acid Synthesis in the Gouty Human by the Use of 6-Diazo-5-oxo-L-norleucine. Arthur I. Grayzel, J. E. Seegmiller and Ethel Love 447
Serum Lipid and Lipoprotein Alterations in Nephrosis. James H. Baxter, Howard C. Goodman and Richard J. Havel 455
Evaluation of the Slope-Volume Method as an Index of Pulmonary Blood Volume. Yang Wang, John T. Shepherd and Robert J. Marshall 466
Chromatographic Properties of Gamma Globulin: Behavior of Serum Gamma Macroglobulins. Joseph Lospalluto, Julio Chegoriansky, Arthur Lewis and Morris Ziff 473
A Study of Distal Renal Tubular Functions by a Modified Stop Flow Technique. John R. Jaenike and Robert W. Berliner 481
Bilateral Studies of Cerebral Oxygen Uptake in Young and Aged Normal Subjects and in Patients with Organic Dementia. N. A. Lassen, I. Feinberg and M. H. Lane 491
Protein-Binding of Inorganic Phosphate in Plasma of Normal Subjects and Patients with Renal Disease. Mackenzie Walser 501
The Physiological Significance of the Secretion of Endogenous Insulin into the Portal Circulation. III. Evidence for a Direct Immediate Effect of Insulin on the Balance of Glucose Across the Liver. Leonard L. Madison, Burton Combes, Reuben Adams and William Strickland 507
The Metabolic Effects of the Acetic and Propionic Acid Analogs of Thyroxine and Triiodothyronine. S. Richardson Hill, Jr., S. B. Barker, Jean H. McNeil, John O. Tingley and Lester L. Hibbett 523
Clinical, Morphological and Biochemical Studies of a Virilizing Tumor in the Testis. Kenneth Savard, Ralph I. Dorfman, Billy Baggett, Linda L. Fielding, Lewis L. Engel, Harry T. McPherson, Leonard M. Lister, David S. Johnson, Edwin C. Hamblen and Frank L. Engel 534
Disappearance Rate of Concentrated Proconvertin Extracts in Congenital and Acquired Hypoproconvertinemia. M. Silvija Hoag, Paul M. Aggeler and Alfred H. Fowell 554
Announcement of Meetings 454

NUMBER 4, APRIL 1960

Turnover of Labeled Normal Gamma Globulin in Multiple Myeloma. STUART W. LIPPINCOTT, SAMUEL KORMAN, CONRAD FONG, ELMER STICKLEY, WILLIAM WOLINS AND WALTER L. HUGHES 565
Some Effects of Restriction of Chest Cage Expansion on Pulmonary Function in Man: An Experimental Study. COLIN G. CARO, JOHN BUTLER AND ARTHUR B. DUBOIS 573
Physiological Factors Affecting Airway Resistance in Normal Subjects and in Patients with Obstructive Respiratory Disease. JOHN BUTLER, COLIN G. CARO, RAPHAEL ALCALA AND ARTHUR B. DUBOIS 584
Indocyanine Green: Observations on its Physical Properties, Plasma Decay, and Hepatic Extraction. GILBERT R. CHERRICK, SAMUEL W. STEIN, CARROLL M. LEEVY AND CHARLES S. DAVIDSON 592
Studies on the Mechanism of the Plasma 17-Hydroxycorticosteroid Elevation Induced in Man by Estrogens. ELEANOR Z. WALLACE AND ANNE C. CARTER 601
Free Fatty Acid Mobilization by Neuroadrenergic Stimulation in Man. JAMES T. HAMLIN, III, ROGER B. HICKLER AND ROBERT G. HOSKINS 606
Hypocatalasemia: A New Genetic Carrier State. SHIGEO TAKAHARA, HOWARD B. HAMILTON, JAMES V. NEEL, THOMAS Y. KOBARA, YOSHIO OGURA AND EDWIN T. NISHIMURA 610
Study of the Genetic and Extra-Genetic Determinants of Alpha-Ketosteroid Production in Man. ATTALLAH KAPPAS AND T. F. GALLAGHER 620
Estimation of the Constancy of Density of the Fat-Free Body. EDWARD J. WERDEIN AND LAURENCE H. KYLE 626
The Effect of Neurohypophyseal Hormones on the Permeability of the Toad Bladder to Urea. ROY H. MAFFLY, RICHARD M. HAYS, EZRA LAMDIN AND ALEXANDER LEAF 630
Studies on the Site of the Feedback Control of Cholesterol Synthesis. MARVIN D. SIPERSTEIN AND M. JOANNE GUEST 642
Gastrodialysis in the Treatment of Acute Renal Failure. THOMAS A. MARR, JAMES M. BURNELL AND BELDING H. SCRIBNER 653
Calcium and Phosphorus Homeostasis in the Parathyroidectomized Dog; Evaluation by Means of Ethylenediamine Tetraacetate and Calcium Tolerance Tests. PETER H. SANDERSON, FOSTER MARSHALL, II AND RICHARD E. WILSON 662
Localization of Leucine Aminopeptidase in Serum and Body Fluids by Starch Gel Electrophoresis. O. DHODANAND KOWLESSAR, LORRAINE J. HAEFFNER AND MARVIN H. SLEISENGER 671
Histamine Metabolism in Human Disease. GILDON N. BEALL AND PAUL P. VANARSDEL, JR. 676
On the Mechanism of Impairment of Renal Concentrating Ability in Potassium Deficiency. ANDRZEJ MANITIUS, HOWARD LEVITIN, DAVID BECK AND FRANKLIN H. EPSTEIN 684
On the Mechanism of Impairment of Renal Concentrating Ability in Hypercalcemia. ANDRZEJ MANITIUS, HOWARD LEVITIN, DAVID BECK AND FRANKLIN H. EPSTEIN 693
Immunological Studies with Plasma Expanders Derived from Human Plasma. PAUL H. MAURER AND D. SUBRAHMANYAM 698
Announcement of Meetings 572
Program of the Fifty-Second Annual Meeting of the American Society for Clinical Investigation to be held in Atlantic City, N. J., May 2, 1960 ..... facing page 565

NUMBER 5, MAY 1960

James L. Gamble (Obituary). CHARLES A. JANEWAY i
A Method for the Continuous Measurement of Cerebral Blood Flow in Man by Means of Radioactive Krypton (Kr^{79}). BENJAMIN M. LEWIS, LOUIS SOKOLOFF, RICHARD L. WECHSLER, W. BUDD WENTZ AND SEYMOUR S. KETY 707

Myocardial Metabolism of Fatty Acids. FRED B. BALLARD, WILLIAM H. DANFORTH, SIEGFRIED NAEGLE AND RICHARD J. BING 717
The Respiratory Response to Carbon Dioxide in Health and in Emphysema. D. BRODOVSKY, J. A. MACDONELL AND R. M. CHERNIACK 724
Studies on Lipid Metabolism in the Small Intestine with Observations on the Role of Bile Salts. ANTHONY M. DAWSON AND KURT J. ISSELBACHER 730
The Metabolism of Corticosterone in Man. RALPH E. PETERSON AND CHARLES E. PIERCE .. 741
Excretion of Catecholamines, 17-Ketosteroids, 17-Hydroxycorticoids, and 5-Hydroxyindole in Men Exhibiting a Particular Behavior Pattern (A) Associated with High Incidence of Clinical Coronary Artery Disease. MEYER FRIEDMAN, SHIRLEY ST. GEORGE, SANFORD O. BYERS AND RAY H. ROSENMAN 758
The Role of the Anterior Pituitary in the Control of Aldosterone Secretion in Experimental Secondary Hyperaldosteronism. JAMES O. DAVIS, NICHOLAS A. YANKOPOULOS, FEROL LIEBERMAN, JOHN HOLMAN AND ROBERT C. BAHN 765
Effect of Intravenous Infusions of Ethyl Alcohol on Estimated Hepatic Blood Flow in Man. HANS CASTENFORS, ERIC HULTMAN AND BERTIL JOSEPHSON 776
Nondialyzable Hexose of Human Synovial Fluid. JOHN SANDSON AND DAVID HAMERMAN ... 782
Abbreviation of Berson Technic for Estimation of Thyroidal Clearance of Plasma Radioiodide: Use of Berson Test to Recognize Thyroidal Protein-Binding Defects. CHARLES A. OWEN, JR., RALPH S. MCCANTS AND WILLIAM M. MCCONAHEY 790
Non-Uniform Pulmonary Diffusion as Demonstrated by the Carbon Monoxide Equilibration Technique: Mathematical Considerations. BENJAMIN BURROWS, ALBERT H. NIDEN, PAUL V. HARPER, JR. AND WILLIAM R. BARCLAY 795
The Dialysance of Ethanol and Methanol: A Proposed Method for the Treatment of Massive Intoxication by Ethyl or Methyl Alcohol. JULIEN MARC-AURELE AND GEORGE E. SCHREINER 802

NUMBER 6, JUNE 1960

Studies on Intestinal Cholesterol Absorption in the Human. BENGT BORGSTRÖM 809
Analysis by Means of an Analog Computer of Plasma Corticoid Values During Andrenocorticotropic Hormone Infusion. P. DE MOOR, W. DE BACKER, A. HENDRIKX, M. HINNEKENS AND A. DE BOCK 816
Responses of the Veins and Arterioles of the Forearm to Walking During Acclimatization to Heat in Man. J. EDWIN WOOD AND DAVID E. BASS 825
Catechol Amine Excretion by Duodenal Ulcer Patients. WILLIAM R. WADDELL, GEORGE D. ZUIDEMA AND GENE M. SMITH 834
The Demonstration and Localization of Renal Tubular Reabsorption of Hemoglobin by Stop Flow Analysis. WILLOUGHBY LATHEM, BERNARD B. DAVIS, PAUL H. ZWEIG AND ROBERT DEW 840
Delivery of Antimicrobial Drugs Across Inflammatory Membrane in Rabbits. ROBERT MCCUNE 846
Experience with the Chromic Oxide Method of Fecal Marking in Metabolic Balance Investigations on Humans. L. G. WHITBY AND DAPHNE LANG 854
The Influence of Glomerular Filtration Rate, Solute Excretion and Hydration on the Concentrating Mechanism of the Experimentally Diseased Kidney in the Dog. NEAL S. BRICKER, S. WESLEY KIME, JR., PETER A. F. MORRIN AND TADEUSZ ORLOWSKI 864
The Response to the Administration of an Isotonic Sodium Chloride-Lactate Solution in Patients with Essential Hypertension. SOLOMON PAPPER, JOSEPH L. BELSKY AND KENNETH H. BLEIFER 876

Strontium and Calcium Metabolism in Metabolic Bone Diseases. ELIAS C. DOW AND JOHN B. STANBURY 885
Further Evidence of a Relative Lack of C-21 Hydroxylation in Congenital Adrenal Hyperplasia. ANDREW G. FRANTZ, DONALD A. HOLUB AND JOSEPH W. JAILER 904
The Metabolism and Fate of Tritiated Thymidine in Man. JOSEPH R. RUBINI, EUGENE P. CRONKITE, VICTOR P. BOND AND T. M. FLIEDNER 909
A Profile of Electrolytes in the Cartilaginous Plate of Growing Ribs. D. S. HOWELL, E. DELCHAMPS, W. RIEMER AND I. KIEM 919
Studies on Digitalis. I. Direct Effects on Peripheral Vascular Resistance. JOHN ROSS, JR., JOHN A. WALDHAUSEN AND EUGENE BRAUNWALD 930
Studies on Digitalis. II. Extracardiac Effects on Venous Return and on the Capacity of the Peripheral Vascular Bed. JOHN ROSS, JR., EUGENE BRAUNWALD AND JOHN A. WALDHAUSEN 937
Non-Uniform Pulmonary Diffusion as Demonstrated by the Carbon Monoxide Equilibration Technique: Experimental Results in Man. BENJAMIN BURROWS, ALBERT H. NIDEN, CHARLES MITTMAN, ROBERT C. TALLEY AND WILLIAM R. BARCLAY 943
The Effects of 6-Mercaptopurine on Homograft Reactions. ROBERT SCHWARTZ AND WILLIAM DAMESHEK 952
The Effect of Autonomic Ganglionic Blockade upon Serum Free Fatty Acid Levels in Man. MORTON D. BOGDONOFF, ARNOLD M. WEISSLER AND FRANK L. MERRITT 959
Proceedings of the Fifty-Second Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N. J., May 2, 1960 966

THE JOURNAL

OF

CLINICAL INVESTIGATION

VOLUME 39

(JULY TO DECEMBER)

1960

PUBLISHED BY

THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, INC.

PHILIP K. BONDY, *Editor-in-Chief*

Associate Editors

FRANKLIN H. EPSTEIN
ALLAN V. N. GOODYER

EDITORIAL COMMITTEE

ROBERT W. BERLINER
SOLOMON A. BERSON
GEORGE L. CURRAN
LEWIS DEXTER
I. S. EDELMAN
CLEMENT A. FINCH
ALFRED P. FISHMAN
ROBERT A. GOOD
JOHN B. HICKAM
FRANZ J. INGELFINGER
HENRY G. KUNKEL
MACLYN MCCARTY
ARNOLD S. RELMAN
JOHN V. TAGGART
KENNETH L. ZIERLER

CONTENTS

NUMBER 7, JULY 1960

Studies on Starling's Law of the Heart. I. The Circulatory Response to Acute Hypervolemia and its Modification by Ganglionic Blockade. ROBERT L. FRYE AND EUGENE BRAUNWALD 1043

The Effect of Changes in Posture and of Graded Exercise on Stroke Volume in Man. YANG WANG, ROBERT J. MARSHALL AND JOHN T. SHEPHERD 1051

Renal Concentrating Mechanisms in Newborn Infants. Effect of Dietary Protein and Water Content, Role of Urea, and Responsiveness to Antidiuretic Hormone. C. M. EDELMANN, JR., H. L. BARNETT AND V. TROUPKOU 1062

An Immunochemical Assay of Total Extractable Insulin in Man. GEROLD M. GRODSKY AND PETER H. FORSHAM 1070

Studies of the Ventilation-Perfusion Relationships in the Lungs of Subjects with Chronic Pulmonary Emphysema, Following a Single Intravenous Injection of Radioactive Krypton (KR^{85}). I. Presentation and Validation of a Theoretical Model. H. P. GURTNER, W. A. BRISCOE AND A. COURNAND 1080

Aldosterone Secretion and Primary and Malignant Hypertension. JOHN H. LARAGH, STANLEY ULICK, VLODZIMIERZ JANUSZEWICZ, QUENTIN B. DEMING, WILLIAM G. KELLY AND SEYMOUR LIEBERMAN 1091

Factors Influencing Relative Rates of Synthesis of Adult and Fetal Hemoglobin *In Vitro*. DAVID W. ALLEN AND JAMES H. JANDL 1107

Metabolism of Mucopolysaccharides in Connective Tissue. II. Synthesis of Glucosamine-6-Phosphate. ALFRED JAY BOLLET AND ALLEN SHUSTER 1114

The Effect of Estrogens upon the Peripheral Metabolism of Thyroxine. J. THOMAS DOWLING, NORBERT FREINKEL AND SIDNEY H. INGBAR 1119

Biliary Transport and Hepatic Storage of Sulfobromophthalein Sodium in the Unanesthetized Dog, in Normal Man, and in Patients with Hepatic Disease. HENRY O. WHEELER, JAY I. MELTZER AND STANLEY E. BRADLEY 1131

The Destruction of Red Cells by Antibodies in Man. III. Quantitative Factors Influencing the Patterns of Hemolysis *In Vivo*. JAMES H. JANDL AND MANUEL E. KAPLAN 1145

Immunoassay of Endogenous Plasma Insulin in Man. ROSALYN S. YALOW AND SOLOMON A. BERSON 1157

The Relation of Diaphorase of Human Erythrocytes to Inheritance of Methemoglobinemia. E. M. SCOTT 1176

Abnormalities of Muscle Protein Metabolism in Mice with Muscular Dystrophy. JACQUES KRUH, JEAN-CLAUDE DREYFUS, GEORGES SCHAPIRA AND GEORGE O. GEY, JR. 1180

The Fatty Acid Composition of Human Thoracic Duct Lymph Lipids. ROLF BLOMSTRAND AND OLLE DAHLBÄCK 1185

Detection in Normal Urine of Protein Resembling Bence Jones Protein. G. T. STEVENSON .. 1192

NUMBER 8, AUGUST 1960

Measurement of Blood Flow in the Collateral Vessels of the Portal Vein; Preliminary Results of a New Method. F. L. IBER, D. N. S. KERR, W. DÖLLE AND S. SHERLOCK 1201

Behavior of Stroke Volume at Rest and During Exercise in Human Beings. CARLETON B. CHAPMAN, JOSEPH N. FISHER AND BRIAN J. SPROULE 1208

Conjugation of Sulfobromophthalein Sodium with Glutathione in Thioether Linkage by the Rat. BURTON COMBES AND GENEVA SUE STAKELUM 1214

Effects of Human Growth Hormone in Man. PHILIP H. HENNEMAN, ANNE P. FORBES, MARC MOLDAWER, ELEANOR F. DEMPSEY AND EVELYN L. CARROLL 1223
Effects of Human Growth Hormone on Levels of Blood and Urinary Carbohydrate and Fat Metabolites in Man. DOROTHY H. HENNEMAN AND PHILIP H. HENNEMAN 1239
The Toxic Effects of Carbon Dioxide and Acetazolamide in Hepatic Encephalopathy. JEROME B. POSNER AND FRED PLUM 1246
Characterization of Anti-Thyroglobulin Factors in Human Serum. JOHN L. FAHEY AND HOWARD C. GOODMAN 1259
Fever from Pathogenic Fungi. A. I. BRAUDE, J. MCCONNELL AND H. DOUGLAS 1266
Mechanism of the Altered Blood Pressure Responsiveness Produced by Chlorothiazide. EDWARD D. FREIS, ANNEMARIE WANKO, HAROLD W. SCHNAPER AND EDWARD D. FROHLICH 1277
The Effect of Fasting on the Lipoprotein Lipase Activity of Rat Heart and Diaphragm. C. H. HOLLENBERG 1282
Direct Measurement of Cholesterol Absorption via the Thoracic Duct in Man. LEON HELLMAN, E. L. FRAZELL AND R. S. ROSENFELD 1288
A Lecithinase A in Duodenal Contents of Man. WILLIAM C. VOGEL AND LESLIE ZIEVE 1295
Studies on the Renal Concentrating Mechanism. V. Effect of Diuretic Agents. WILLIAM Y. W. AU AND LAWRENCE G. RAISZ 1302
The Plasma Disappearance of Intravenously Administered Cobalt^{58} Vitamin B_{12}. CHARLES A. HALL 1312
The Effect of Some Mercaptanes upon a Macrocryogelglobulin; Modifications Induced by Cysteamine, Penicillamine and Penicillin. STEPHAN E. RITZMANN, SOLON L. COLEMAN AND WILLIAM C. LEVIN 1320
Increase in Aldosterone Secretion by Carotid Artery Constriction in the Dog and Its Prevention by Thyrocarotid Arterial Junction Denervation. FREDERIC C. BARTTER, IVOR H. MILLS AMD DONALD S. GANN 1330
The Biosynthesis and Turnover of Oxalate in Normal and Hyperoxaluric Subjects. T. DAVID ELDER AND JAMES B. WYNGAARDEN 1337

NUMBER 9, SEPTEMBER 1960

The Effects of Body Position, Ganglionic Blockade and Norepinephrine on the Pulmonary Capillary Bed. BENJAMIN M. LEWIS, WILLIAM T. MCELROY, ERNEST J. HAYFORD-WELSING AND L. CARL SAMBERG 1345
The Local Exudative Cellular Response in Leukemia. PASQUALE E. PERILLIE AND STUART C. FINCH 1353
Composition and Properties of Human Cervical Mucus. I. Electrophoretic Separation and Identification of Proteins. KAMRAN MOGHISSI, OTTO W. NEUHAUS AND CHARLES S. STEVENSON 1358
Enzymatic Activity of the Isolated Glomerulus in Normal and Nephrotic Rats. ULRICH C. DUBACH AND LILLIAN RECANT 1364
Quantitative Histochemistry of the Nephron. II. Alkaline Phosphatase Activity in Man and Other Species. SJOERD L. BONTING, VICTOR E. POLLAK, ROBERT C. MUEHRCKE AND ROBERT M. KARK 1372
Quantitative Histochemistry of the Nephron. III. Lactic Dehydrogenase Activity in Man and Other Species. SJOERD L. BONTING, VICTOR E. POLLAK, ROBERT C. MUEHRCKE AND ROBERT M. KARK 1381
Quantitative Histochemistry of the Nephron. IV. Alkaline Phosphatase and Lactic Dehydrogenase Activities in Renal Tubular Diseases. VICTOR E. POLLAK, SJOERD L. BONTING, ROBERT C. MUEHRCKE AND ROBERT M. KARK 1386

Quantitative Histochemistry of the Nephron. V. Alkaline Phosphatase and Lactic Dehydrogenase Activities in Lupus Nephritis. VICTOR E. POLLAK, SJOERD L. BONTING, ROBERT C. MUEHRCKE AND ROBERT M. KARK 1394
Variations in the Pulmonary Capillary Blood Volume and Membrane Diffusion Component in Health and Disease. D. V. BATES, C. J. VARVIS, R. E. DONEVAN AND R. V. CHRISTIE 1401
Arterial Blood Flow Patterns in Human Subjects and their Effect on Indicator Dilution Curves from Various Arterial Sites. RAMON L. LANGE, CARLISLE SMITH AND HANS H. HECHT .. 1413
Gas Chromatographic Analysis of the Fatty Acid Composition of the Plasma Lipids in Normal and Diabetic Subjects. BO HALLGREN, STINA STENHAGEN, ALVAR SVANBORG AND LARS SVENNERHOLM 1424
The Influence of Cortisone on Experimental Fungus Infections in Mice. DONALD B. LOURIA, NANCY FALLON AND HARRY G. BROWNE 1435
Relationship between Rh_0 (*D*) Genotype and Quantity of I^{131} Anti-Rh_0 (*D*) Bound to Red Cells. S. P. MASOUREDIS 1450
Chemical Characterization of Cardiac Myosin from Normal Dogs and from Dogs with Chronic Congestive Heart Failure. JAMES O. DAVIS, WILLIAM R. CARROLL, MARY TRAPASSO AND NICHOLAS A. YANKOPOULOS 1463
Mechanisms of Impaired Water Excretion in Adrenal and Pituitary Insufficiency. II. Interrelationships of Adrenal Cortical Steroids and Antidiuretic Hormone in Normal Subjects and in Diabetes Insipidus. CHARLES R. KLEEMAN, JERRY KOPLOWITZ, MORTON H. MAXWELL, RALPH CUTLER AND J. THOMAS DOWLING 1472
Leukokinetic Studies. II. A Method for Labeling Granulocytes *In Vitro* with Radioactive Diisopropylfluorophosphate (DFP^{32}). A. M. MAUER, J. W. ATHENS, HELEN ASHENBRUCKER, G. E. CARTWRIGHT AND M. M. WINTROBE 1481
Measurement of Small Quantities of Insulin-Like Activity Using Rat Adipose Tissue. I. A Proposed Procedure. ALBERT E. RENOLD, DONALD B. MARTIN, YVES M. DAGENAIS, JURGEN STEINKE, RITA J. NICKERSON AND MINDEL C. SHEPS 1487
Measurement of Small Quantities of Insulin-Like Activity Using Rat Adipose Tissue. II. Evaluation of Performance. MINDEL C. SHEPS, RITA J. NICKERSON, YVES M. DAGENAIS, JURGEN STEINKE, DONALD B. MARTIN AND ALBERT E. RENOLD 1499

NUMBER 10, OCTOBER 1960

The Characteristics of the Peripheral Transport of C^{14}-Labeled Palmitic Acid. S. J. FRIEDBERG, R. F. KLEIN, D. L. TROUT, M. D. BOGDONOFF AND E. H. ESTES, JR. 1511
The Influence of Anion Penetrating Ability on Urinary Acidification and the Excretion of Titratable Acid. NORMAN BANK AND WILLIAM B. SCHWARTZ 1516
The Role of Lactic Acid in the Reduced Excretion of Uric Acid in Toxemia of Pregnancy. JOSEPH S. HANDLER 1526
Urinary Output of Adrenaline, Noradrenaline, and 3-Methoxy-4-Hydroxymandelic Acid Following Centrifugation and Anticipation of Centrifugation. MCC. GOODALL AND M. L. BERMAN 1533
Plasma Antidiuretic Activity and Free Water Clearance Following Osmoreceptor and Neurohypophyseal Stimulation in Human Subjects. ROBERT A. BARATZ, ANDREW DOIG AND IRVING J. ADATTO 1539
Cerebroside Synthesis in Gaucher's Disease. EBERHARD G. TRAMS AND ROSCOE O. BRADY .. 1546
The Diuretic Effects of Large Doses of Acetazolamide and an Analog Lacking Carbonic Anhydrase Inhibiting Activity. ARNOLD S. RELMAN, RICHARD PORTER, JAMES F. TOBIAS AND WILLIAM B. SCHWARTZ 1551
Studies on the Synthesis and Secretion of Serum Lipoproteins by Rat Liver Slices. CHARLES M. RADDING AND DANIEL STEINBERG 1560

The Intrahepatic Conjunction of Sulfobromophthalein and Glutathione in the Dog. NORMAN B. JAVITT, HENRY O. WHEELER, KATHARINE J. BAKER, OSWALDO L. RAMOS AND STANLEY E. BRADLEY 1570
Studies of Tritium-Labeled Digoxin: Tissue, Blood and Urine Determinations. LUIS F. GONZALEZ AND ENNIS C. LAYNE 1578
The *In Vivo* Glucuronide Conjugation of Radioactive Etiocholanolone and Androsterone by the Dog Kidney. GEORGE L. COHN AND MICHAEL HUME 1584
Rates of I^{131}-Labeled Thyroxine Metabolism in Euthyroid Children. HESKEL M. HADDAD .. 1590
Serum Factors in Lupus Erythematosus and Other Diseases Reacting with Cell Nuclei and Nucleoprotein Extracts: Electrophoretic, Ultracentrifugal and Chromatographic Studies. HOWARD C. GOODMAN, JOHN L. FAHEY AND RICHARD A. MALMGREN 1595

NUMBER 11, NOVEMBER 1960

Absorption of Radioactive Sodium from the Intestinal Tract of Man. I. Effect of Intestinal Motility. II. Effect of an Organomercurial. VICTOR W. GROISSER AND JOHN T. FARRAR 1607
Anti-Hemophilic Globulin Levels in Carriers of Hemophilia A. SAMUEL I. RAPAPORT, MARY JANE PATCH AND FREDERICK J. MOORE 1619
The Pulsatile Nature of the Pulmonary Capillary Blood Flow. MARIO RIGATTO AND ALFRED P. FISHMAN 1626
The Concentrations of Cysteine and Cystine in Human Blood Plasma. M. PRINCE BRIGHAM, WILLIAM H. STEIN AND STANFORD MOORE 1633
The Lipid Composition of Serum in Patients with Liver Disease. GERALD B. PHILLIPS 1639
Zinc in Human Blood Cells: Normal Values and Abnormalities Associated with Liver Disease. ROBERT E. FREDRICKS, KOUICHI R. TANAKA AND WILLIAM N. VALENTINE 1651
X-ray Diffraction Studies of Human Aortic Elastin Residues. GERALD WEISSMANN AND SIGMUND WEISSMANN 1657
$Co^{58}B_{12}$ Absorption, Plasma Transport and Excretion in Patients with Myeloproliferative Disorders, Solid Tumors and Non-neoplastic Diseases. I. BERNARD WEINSTEIN AND DONALD M. WATKIN 1667
Studies of Unbound Amino Acid Distributions in Plasma, Erythrocytes, Leukocytes and Urine of Normal Human Subjects. RAPIER H. MCMENAMY, CHARLES C. LUND, GERALD J. NEVILLE AND DONALD F. H. WALLACH 1675
Unbound Amino Acid Concentrations in Plasma, Erythrocytes, Leukocytes and Urine of Patients with Leukemia. RAPIER H. MCMENAMY, CHARLES C. LUND AND DONALD F. H. WALLACH 1688
The Role of Plasma CO_2 Tension and Carbonic Anhydrase Activity in the Renal Reabsorption of Bicarbonate. FLOYD C. RECTOR, JR., DONALD W. SELDIN, ALBERT D. ROBERTS, JR. AND JERRY S. SMITH 1706
Circulatory Effects of Chronic Hypervolemia in Polycythemia Vera. LEONARD A. COBB, ROBERT J. KRAMER AND CLEMENT A. FINCH 1722
Catecholamine Metabolism in a Functional Neural Tumor. ROBERT E. GREENBERG AND LYTT I. GARDNER 1729
Respiratory Mechanics During Forward Acceleration. JOHN F. WATSON, NEIL S. CHERNIACK AND FRED W. ZECHMAN 1737
Esophageal Aperistalsis and Achalasia Produced in Dogs by Prolonged Cholinesterase Inhibition. LAURAN D. HARRIS, W. D. ASHWORTH AND FRANZ J. INGELFINGER 1744
Proteinpolysaccharides of Human Costal Cartilage. BLANCHE JOHNSON AND MAXWELL SCHUBERT 1752
The Effect of Sodium Dilantin Administration upon the Chemistry of the Skin. J. C. HOUCK, R. A. JACOB AND G. D. MAENGWYN-DAVIES 1758

NUMBER 12, DECEMBER 1960

Amino Acid Activating Enzymes in Red Blood Cells of Normal, Anemic and Polycythemic Subjects. G. IZAK, T. WILNER AND J. MAGER 1763
Observations on the Functional Homogeneity of the Nephron Population in the Chronically Diseased Kidney of the Dog. NEAL S. BRICKER, TADEUSZ ORLOWSKI, S. WESLEY KIME, JR. AND PETER A. F. MORRIN 1771
Idiopathic Hyperlipemia: Metabolic Studies in an Affected Family. RICHARD J. HAVEL AND ROBERT S. GORDON, JR. 1777
Determination of Total Body Fat by Absorption of an Inert Gas; Measurements and Results in Normal Human Subjects. GERSON T. LESSER, WILLIAM PERL AND J. MURRAY STEELE 1791
Vitamin D-Resistant Rickets: The Effect of Calcium Infusion on Phosphate Reabsorption. MORTON H. FIELD AND ERIC REISS 1807
Susceptibility to Experimental Pyelonephritis when Hormonal Hypertension is Prevented by Hypotensive Drugs. JAMES W. WOODS 1813
Oxidative Hemolysis and Precipitation of Hemoglobin. I. Heinz Body Anemias as an Acceleration of Red Cell Aging. JAMES H. JANDL, LOUISE K. ENGLE AND DAVID W. ALLEN 1818
Effects of Long-Term Storage on Human Serum Albumin. I. Chromatographic and Ultracentrifugal Aspects. J. S. FINLAYSON, RICHARD T. SUCHINSKY AND ANN L. DAYTON ... 1837
Estimation of Pulmonary Arteriovenous Shunt-Flow using Intravenous Injections of T-1824 Dye and Kr^{85}. H. W. FRITTS, JR., A. HARDEWIG, D. F. ROCHESTER, J. DURAND AND A. COURNAND 1841
Adrenal Steroid Inhibition of Vasopressin Release from the Neurohypophysis of Normal Subjects and Patients with Addison's Disease. JOSEPH F. DINGMAN AND RENE H. DESPOINTES 1851
Serum *B*-Lipoprotein Levels in Health and Disease, as Determined by the Nephelometric Method with Amylopectin Sulfate as Reagent. PETER BERNFELD, C. D. BONNER AND B. J. BERKELEY 1864
Studies on Starling's Law of the Heart. III. Observations in Patients with Mitral Stenosis and Atrial Fibrillation on the Relationships Between Left Ventricular End-Diastolic Segment Length, Filling Pressure, and the Characteristics of Ventricular Contraction. EUGENE BRAUNWALD, ROBERT L. FRYE, MAURICE M. AYGEN AND JOSEPH W. GILBERT, JR. 1874
Enhancement of Potassium-Induced Atrioventricular Block by Toxic Doses of Digitalis Drugs. CHARLES FISCH, B. L. MARTZ AND FRED H. PRIEBE 1885
Electrophoretic Components of the Hemoglobin of Red Cell Membranes. FREDERICK A. KLIPSTEIN AND HELEN M. RANNEY 1894
The Effect of Cushing's Syndrome upon Serum Albumin Metabolism. KENNETH STERLING .. 1900
Renal Mechanisms for the Excretion of Inorganic Sulfate in Man. E. LOVELL BECKER, HENRY O. HEINEMANN, KIETSU IGARASHI, JURG E. HODLER AND HERBERT GERSHBERG 1909
Transcortin: A Corticosteroid-Binding Protein of Plasma. III. The Effects of Various Steroids. AVERY A. SANDBERG, W. ROY SLAUNWHITE, JR. AND ANNE C. CARTER 1914
Adrenal Medullary Insufficiency in Severe Thermal Burn. McC. GOODALL AND B. W. HAYNES, JR. 1927
Structural Units of Human 7S Gamma Globulin. EDWARD C. FRANKLIN 1933
Enzymes and Blood Clotting. I. Trypsin as an Accessory Factor. JOHN H. FERGUSON, ELLA GRAY WILSON, SOTIRIOS G. IATRIDIS, HERMAN A. RIERSON AND BETTY R. JOHNSTON ... 1942
A Study of Eight Heated Plasma Protein Preparations. RICHARD T. SUCHINSKY 1953
Effect of Chronic Hypothalamic Stimulation upon Cholesterol-Induced Atherosclerosis in the Rabbit. C. G. GUNN, MEYER FRIEDMAN AND SANFORD O. BYERS 1963
Author Index to Volume 39 1973
Subject Index to Volume 39 1994

THE JOURNAL

OF

CLINICAL INVESTIGATION

VOLUME 39

1960

PUBLISHED BY

THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, INC.